Regulation of endothelial nitric oxide synthase by phosphorylation by Mohamed, Annisuddin
Regulation of Endothelial Nitric Oxide 
Synthase by Phosphorylation  
 
 
 
 
Dissertation 
zur Erlangung des Doktorgrades 
der Naturwissenschaften 
 
 
 
vorgelegt beim Fachbereich 15 
Biologie und Informatik-Wissenschaften 
der Johann Wolfgang Goethe- Universität 
in Frankfurt am Main 
 
 
 
Von 
Annisuddin Mohamed 
aus Bangalore, India. 
 
 
Frankfurt am Main 2005 
 
 
 
  
  I
Vom Fachbereich Biologie und Informatik der Johann Wolfgang Goethe-Universität  
als Dissertation angenommen.  
 
 
 
 
 
Dekan: Prof. Dr. Osiewacz  
 
Gutachter: Prof. Dr. I. Fleming  
 
Datum der Disputation: 22, Dezember 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Eidesstattliche Erklärung 
  I
Eidesstattliche Erklärung  
 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Dissertation selbständig  
und nur mit den angegebenen Hilfsmitteln angefertigt habe. 
 
 
Frankfurt am Main, den 03, August 2005  
 
 
Annisuddin Mohamed 
 
 
 
 
 
 
 
 
 Acknowledgements 
  II
Acknowledgements 
 
As I start to write this acknowledgement many names cross my mind, people who have 
helped me in their own ways towards the achievement of this milestone. Not all of them 
might find a mention here, but your contribution will always be remembered and appreciated.  
 
First, I would like to express my deepest gratitude to my parents Mr. Mohamed Rafiuddin and 
Mrs. Azra Nasreen. They have been a constant source of encouragement and strength through 
out my academic and non-academic life. 
 
I would like to express my respectful gratitude to Prof. Dr. Rudi Busse for providing me with 
an opportunity to spend over three fruitful years in the very stimulating environment of the 
Department of Cardiovascular Physiology. I am grateful for the continuous support I received 
from him.  
 
My special thanks go to Prof. Karl-Dieter Entian for accepting to be my external supervisor. 
 
I am indebted in more than one way to my supervisor Prof. Ingrid Fleming. She has been a 
continuous source of inspiration, an excellent guide and over all a good friend who always 
helped me in seeing light at the end of the tunnel, the latest being with my marriage. Words 
would fall short in expressing my gratitude to her for her continuous support and 
encouragement towards the successful completion of this thesis, not to forget the pain she 
took in the correction of this thesis. Her focussed and critical direction contributed to the 
development of my own understanding on science. 
 
During the course of my work, many people in the laboratory have contributed in their own 
way to my work providing me with technical and emotional support. I would like to sincerely 
thank Isabel Winter, Mechtild Piepenbrock and Tanja-Maria Mareczek for their excellent 
technical support and friendship.  
 
When you don’t have your family you must have good friends. When I moved to Frankfurt 
new friends made the distance from home and the difficulties of life much easier to deal with. 
Being away from India was made less traumatic by people like PD. Dr. Ralf Brandes, who 
took the trouble of initiating and arranging lab outings which made the difficulties of life Acknowledgements 
  III
much easier. My thanks also go to him for introducing me to confocal microscopy and radical 
measurements, not to mention his help in fixing the many and varied problems with my 
computer.  
 
My special thanks to Dr. Beate Fisslthaler for her kind support and critical comments during 
the course of this work. Not to forget Dr. Rudiger Popp, Madhu, Mariano, Voahangy, Pravir, 
Annemarieke, Benjamin, Elke, Anke, Timo and all the others for their friendship and the 
stimulating (and at times) funny discussions we had together. 
 
I would like to acknowledge the contributions of Dr. Andrei L Kleschyov and Dr. Klaus 
Zwicker for introducing me to NO spin trapping and ESR spectroscopy. 
 
Lastly, I would like to mention my fellow “KITTENS”- my siblings, Ameenuddin, 
Abraruddin, Tabassum, Taranum, Saba and Farha for their love and encouragement which 
always kept me going. 
 Table of Contents 
  IV
Table of Contents 
1  Introduction.......................................................................................................................1 
1.1  Role of endothelium in maintaining the tone of vasculature......................................1 
1.2  Endothelium-derived vasoactive factors.....................................................................2 
1.3  Importance of NO as a normal regulator of blood pressure......................................2 
1.4  Endothelial dysfunction in cardiovascular disease....................................................2 
1.5  Nitric oxide .................................................................................................................4 
1.6  Nitric oxide synthases.................................................................................................5 
1.6.1  Mechanism of NO biosynthesis..........................................................................7 
1.6.2  Substrate and cofactor requirement ....................................................................9 
1.7  Regulation of eNOS ..................................................................................................10 
1.7.1 Intracellular  localisation ...................................................................................10 
1.7.2 Regulation  by  eNOS-associated proteins .........................................................12 
1.7.3 Regulation  by  phosphorylation.........................................................................19 
1.7.4  NOS reductase domain regulatory elements.....................................................26 
1.8  NOS uncoupling........................................................................................................27 
1.9  Free radicals in the cardiovascular system..............................................................28 
1.9.1  Superoxide anion radical (O2
-)..........................................................................28 
1.9.2 Peroxynitrite......................................................................................................28 
1.10  Measurement of NO..................................................................................................30 
2  Aim...................................................................................................................................32 
3  Materials and methods:..................................................................................................33 
3.1  Bacterial transformation...........................................................................................33 
3.1.1  Preparation of competent cells by KCM method..............................................33 
3.1.2 Transformation..................................................................................................33 
3.2  Isolation of nucleic acids..........................................................................................33 
3.2.1  Mini plasmid DNA preparation by alkaline lysis method................................33 
3.2.2  Maxi plasmid DNA preparation .......................................................................34 Table of Contents 
  V
3.2.3  DNA extraction from agarose gels ...................................................................34 
3.2.4 RNA  isolation...................................................................................................34 
3.2.5  Purification of DNA by phenol chloroform isoamyl alcohol extraction and 
ethanol precipitation .........................................................................................................35 
3.3  Manipulation of nucleic acids...................................................................................35 
3.3.1 Restriction  digestion.........................................................................................35 
3.3.2  Dephosphorylation of linearised double-stranded DNA ..................................35 
3.3.3  Large fragment of the E.coli DNA polymerase I (Klenow fragment):.............36 
3.3.4 DNA  ligation.....................................................................................................36 
3.3.5 Site  directed  mutagenesis..................................................................................36 
3.3.6 Sequencing  of  DNA..........................................................................................37 
3.4  Detection of nucleic acids.........................................................................................37 
3.4.1  Colony hybridisation using a 
32P-radiolabelled probe......................................37 
3.4.2  Southern blot hybridisation...............................................................................38 
3.4.3  Northern blotting and hybridisation..................................................................38 
3.5  Cell culture and adenoviral methods........................................................................39 
3.5.1  Generation of eNOS adenoviruses....................................................................39 
3.5.2  Culturing of cells ..............................................................................................40 
3.5.3  Transfection with calcium choloride ................................................................40 
3.5.4  Adenoviral infection of COS-7 cells ................................................................41 
3.5.5  Adenoviral infection of human umbilical vein endothelial cells......................41 
3.5.6 Ox-LDL  treatment ............................................................................................41 
3.5.7 Stimulation  with  bradykinin .............................................................................41 
3.6  Immunohistochemistry..............................................................................................41 
3.7  Methods with protein................................................................................................42 
3.7.1 Isolation  of  protein............................................................................................42 
3.7.2 Sodium-dodecyl-sulfate  polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blotting................................................................................................................42 
3.7.3  Low temperature- polyacrylamide gel electrophoresis (LT-PAGE) ................43 
3.7.4 Immunoprecipitation.........................................................................................43 
3.7.5 Reproducing  Western  blots...............................................................................44 
3.8  Assays of eNOS activity, NO and O2
- detection........................................................44 
3.8.1 Citrulline  assay: ................................................................................................44 Table of Contents 
  VI
3.9  Measurement of nitric oxide using Fe(DETC)2 by electron spin resonance 
spectroscopy..........................................................................................................................46 
3.9.1  Measurement in cells:.......................................................................................46 
3.10  Measurement of superoxide anion (O2
-)...................................................................47 
3.10.1 Chemiluminescence..........................................................................................47 
3.10.2  Electron spin resonance (ESR) spectroscopy ...................................................47 
3.11  Statistical analysis....................................................................................................48 
4  Results..............................................................................................................................49 
4.1  Effects of mimicking phosphorylation at specific serine residues of eNOS..............49 
4.1.1  Effect of Ser
114 or Ser
633 mutations
 on eNOS catalytic activity and Ca²
+-CaM 
dependence........................................................................................................................49 
4.1.2  Effect of shear stress and bradykinin on the phosphorylation of eNOS...........51 
4.1.3  Effect of the mutation of eNOS on NO production in intact COS-7 cells as 
measured by ESR spectroscopy........................................................................................52 
4.1.4  Effect of specific mutation on eNOS dimer formation.....................................54 
4.1.5  Effect of eNOS inhibitors, an NO
.
 donor and radicals on eNOS dimer stability
 56 
4.1.6  Effect of specific eNOS mutation on its intracellular localisation ...................57 
4.1.7  Effect of specific mutation on superoxide anion (O2
-) production by eNOS ...59 
4.2  Effect of ox-LDL on eNOS uncoupling.....................................................................62 
4.2.1  Time course of the LDL-induced changes in eNOS phosphorylation..............64 
4.3  The role of tyrosine phosphorylation in the regulation of eNOS activity.................70 
5  Discussion ........................................................................................................................80 
6  Summary..........................................................................................................................93 
7  Zusammenfassung ..........................................................................................................96 
Curriculum Vitae..................................................................................................................124 
 Introduction 
  1
1  Introduction 
Nitric oxide (NO), synthesized by the endothelial nitric oxide synthase (eNOS), is a major 
endothelium-derived factor that regulates the vascular tone. Its multiple roles include the 
regulation of vasomotion (Palmer et al., 1987), cell adhesion to the endothelium (Kubes et al., 
1991; Lefer et al., 1999), platelet aggregation (Radomski et al., 1991; Wolf et al., 1997) and 
vascular smooth muscle cell proliferation (Rudic et al., 1998). At first glance, this list 
suggests that NO is a crucial factor in the prevention of cardiovascular damage such as that 
seen in atherosclerosis, ischemia/repurfusion injury, thrombosis and hypertension. Indeed, the 
loss of endothelium-derived NO that underlies “endothelial dysfunction” is now thought to be 
a major cause of such pathological conditions which emphasizes the need to understand the 
mechanisms that regulate eNOS expression and activity.  
1.1  Role of endothelium in maintaining the tone of vasculature. 
The endothelium is a monolayer of polygonal flat epithelial cells (0.2-0.3 µm thick) that 
extends continuously over the luminal surface of the entire vasculature and could be 
considered as the largest endocrine organ within the human body. In different regions, the 
structural features vary with specificity. In brain, endothelial cell junctions are mainly tight 
while an intracellular cleft is wide open in liver to facilitate protein transport. The endothelial 
cells of the glomerulus have small oval windows called fenestrae so that small molecules, 
such as glucose and urea, can be filtered readily (Ostendorf et al., 1999). 
The biological functions of endothelium are numerous and vary according to the size and 
distribution of the blood vessel that it lines. The endothelium serves and participates in highly 
active metabolic and regulatory function including control of primary hemostasis, platelet and 
leukocyte interactions with the vessel wall, clot deposition, clot lysis and selective phagocytic 
activity (Luscher, 2001). Also, it interacts with the lipoprotein metabolism and presentation of 
histocompatibility antigens. A plethora of bioactive molecules are produced by the 
endothelium (Garcia-Cardena et al., 2001) that can be mutually antagonistic. Many protein 
growth factors, matrix supporting proteins and vasoactive substances are produced by the 
endothelium, highlighting the fact that the functions of the vascular endothelium are dynamic 
rather than fixed. Immune complexes, lipids, angioplasty, germs, hypertension, shear stress, 
hypoxia, acidosis, smoking, aging, diabetes mellitus and surgery inflict injury to the 
endothelium causes its activation.  Introduction 
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1.2  Endothelium-derived vasoactive factors 
In 1980 Furchgott and Zawadzki reported the existence of a non-prostanoid endothelium-
derived relaxing factor (EDRF) (Furchgott & Zawadzki, 1980). The term EDRF was coined 
to account for the finding that upon stimulation with acetylcholine the endothelium releases a 
relaxing factor. In 1987 pharmacological and chemical evidence indicated that EDRF is 
identical to, or closely related to, NO (Ignarro et al., 1987). At the same time it was found that 
the EDRF/NO released by endothelial cells is a potent inhibitor of platelet aggregation and 
adhesion to the vascular wall. The effect was found to be mediated by the stimulation of 
soluble guanylyl cyclase in the platelets (Busse et al., 1987; Palmer et al., 1987). While NO is 
the predominant vasodilator, acting through the stimulation of the soluble guanylate cyclase 
in the smooth muscle cells, other substances are also important. Prostacyclin, similar to NO, is 
a potent vasodilator (Moncada & Vane, 1980; Moncada & Vane, 1981). The endothelium-
derived hyperpolarizing factor (EDHF), another diffusible factor, was found to cause 
endothelium-dependent relaxation via a mechanism related to the hyperpolarization of smooth 
muscle cells (Busse et al., 1987). On the other hand, several endothelium-derived prostanoids, 
such as thromboxane A2, cause vasoconstriction and promote platelet aggregation. 
Endothelin-1 is a peptide produced by endothelial cells with powerful vasoconstriction 
property. The endothelium-derived free radical superoxide (O2
-) promotes vasoconstriction by 
scavenging NO (Fig. 1). 
1.3  Importance of NO as a normal regulator of blood pressure  
Substances of non-endothelial origin such as angiotensin and norepinephrine, were previously 
considered to be the major determinants of vascular tone. However, physiological studies 
using inhibitors of NO synthase (NOS) have indicated a primary role for endothelium-derived 
NO in regulating vascular tone. Intravenous administration of NOS inhibitors, such as mono-
methyl arginine, to animals (Aisaka et al., 1989; Rees et al., 1989; Whittle et al., 1989) or 
humans (Vallance et al., 1989a; Vallance et al., 1989b) provokes a rapid and marked increase 
in vascular resistance. In fact, NOS inhibitors cause a more notable increase in blood pressure 
than do drugs that influence the action of norepinephrine or angiotensin.  
1.4  Endothelial dysfunction in cardiovascular disease 
The endothelium contributes to cardiovascular homeostasis in health and disease (Luscher & 
Noll, 1995; Rubanyi, 1991). Due to its location at the interface between vessel wall and 
circulating blood, this cell layer is the primary target for mechanical forces and cardiovascular 
risk factors. Impairment of endothelial function occurs before structural changes such as Introduction 
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intimal hyperplasia or lipid deposition. Therefore, endothelial dysfunction is an upstream 
event in the pathophysiology of cardiovascular disease. Endothelial dysfunction is 
characterized by attenuated endothelium-dependent vascular responses, and decreased 
expression or activity of eNOS. Also there is an enhanced expression of a number of pro-
inflammatory proteins. There are several different mechanisms contributing to endothelial 
dysfunction, including NO scavenging by O2
- and eNOS uncoupling; a state of eNOS where 
the transfer of electrons is no longer coupled to NO formation. O2
- is generated within 
atheromatous plaques by vascular smooth muscle cells, endothelial cells, neutrophils or 
macrophages. The potential source of O2
- includes NADPH oxidase, xanthine oxidase and 
interestingly enough, eNOS that has been uncoupled. Uncoupling of eNOS occurs under 
conditions of substrate (L-arginine) depletion (Xia et al., 1996) and limitation of the essential 
co-factor tetrahydrobiopterin (H4B) (Xia et al., 1998).  
 
Figure 1. Products of the endothelium and their effect. Vasoactive products from the endothelium act 
both in the lumen of the blood vessel and the vascular smooth muscle cells. In the lumen they are 
responsible for hemostasis by releasing pro- or anti-thrombotic factors and inflammation. In the 
vascular wall they stimulate vascular growth, influence vascular permeability and maintain vascular 
tone.  
 Introduction 
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Alterations in the production and/or availability of NO are accepted as a major factor in the 
development of cardiovascular disease (Warnholtz et al., 2004), such as atherosclerosis 
(Kawashima, 2004), hypercholesterolemia (Stehbens, 2001), ischemia/repurfusion injury 
(Szocs, 2004), thrombosis (Voetsch et al., 2004) and hypertension (Lassegue & Griendling, 
2004). The understanding of the molecular, biochemical and cellular mechanisms that 
regulate eNOS activity and the chemistry behind NO and its adducts is therefore essential for 
identifying and developing new approaches for the treatment of endothelial dysfunction. 
1.5  Nitric oxide 
Nitric oxide is a small diatomic gaseous molecule with an unpaired electron, which makes it a 
free radical with a fairly short half-life. The hydrophobic nature of NO together with a small 
molecule size enables it to diffuse rapidly across cell membranes and depending upon the 
conditions, it is able to diffuse distances of more that several hundred microns. These 
properties make NO uniquely suitable as both an intra- and intercellular messenger. The 
unpaired electron of NO
 
makes the molecule a potent reducing substance which reacts readily 
with biological targets such as heme groups, sulfhydryl groups, iron and zinc clusters, which 
in turn mediate its biological effects. Such a diverse range of potential targets for NO explains 
its importance as a regulatory molecule. 
Effectors of NO 
Once NO is produced by the endothelium, it can regulate several aspects of the vascular 
function. Its primary “receptor” is the soluble guanylyl cyclase (sGC), but it can also initiate 
nitrosation reactions with iron-sulphur-centred proteins or proteins with reactive thiols (S-
nitrosylation). Nitrosylation of caspase-3 and caspase-8 inactivates the proteins, leading to 
inhibition of apoptosis (Stamler et al., 2001). 
In the vascular system, NO- dependent relaxation of vascular smooth muscle is predominantly 
sGC- and protein kinase G- (PKG) dependent, whereas the anti-proliferative actions and ion 
channel modulation of NO can occur via PKG or via nitrosation reactions (Feil et al., 2003; 
Matalon et al., 2003; Miranda et al., 2003). 
NO has the capacity to interact with a variety of enzymes, thereby altering their function and 
influencing inflammatory (and other) reactions. For example, NO can inhibit many iron-
containing enzyme functions, including mitochondrial electron transfer (Beckman & 
Koppenol, 1996), which may contribute to the tumoricidal activity of macrophages. In 
micromolar concentrations, NO can reversibly inhibit cytochrome P-450 (Palacios-Callender 
et al., 2004). NO has also been shown to interact with cycclooxygenase, another heme-Introduction 
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containing enzyme, resulting in an increase in its activity (Salvemini et al., 1993). NO has 
been shown to inhibit inducible NOS (iNOS) expression (Cirino et al., 1996), as NOS is also 
a heme-containing enzyme, it is possible that NO may interact with the enzyme(s) that 
generate it. S-nitrosylation of the eNOS is associated with enzyme monomerisation and 
decreased enzyme activity (Ravi et al., 2004).  
At micromolar concentrations, NO can inhibit ribonucleotide reductase, an enzyme critical for 
the synthesis of DNA precursors (Beckman & Koppenol, 1996; Moncada & Higgs, 1995). It 
can also inhibit transcriptional events by inhibiting the transcription factor NF-kB 
(Katsuyama et al., 1998). This has been suggested to be an important mechanism underlying 
the anti-inflammatory actions of some NO-releasing drugs (Fiorucci et al., 2002). 
Because of these powerful functions, the production of this pivotal mediator is tightly 
regulated and there is ample literature to show that too little or too much NO production 
contributes to numerous human diseases and disorders. Decreased NO generation in the penis, 
for example, results in impotence. On the other hand, many other diseases and conditions 
such as intradialytic hypotension, hemorrhagic shock, tissue rejection, rheumatoid arthritis, 
and diabetes are associated with the overproduction of NO by activated immunocompetent 
cells. 
1.6  Nitric oxide synthases 
Nitric oxide is produced by a family of homodimeric NO synthases (NOS), which catalyse the 
conversion of L-arginine to NO and L-citrulline. To date, three genetically distinct
  NOS 
isoforms have been identified, neuronal NOS (nNOS, NOS-I) originally isolated from 
cerebellum (Bredt & Snyder, 1990), inducible NOS (iNOS, NOS-II) from macrophages (Xie 
et al., 1992), and endothelial NOS (eNOS, NOS-III) from endothelial cells (Pollock et al., 
1991). All of the NOS isoforms share an overall 50% amino acid sequence
 homology and 
have similar co-factor requirements. Each NOS monomer
 contains an N-terminal oxygenase 
domain with a binding site for
 the substrate L-arginine, H4B, Ca
2+/calmodulin (CaM), and 
Zn
2+, as well as a C-terminal reductase domain with
 one binding site each for flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN),
  and reduced form of nicotinamide 
adenine dinucleotide phosphate (NADPH) as electron donor. The reductase domain 
terminates in a C-terminal tail, which contains an autoinhibitory sequence. Both the reductase 
and oxygenase domain are linked by a short CaM-binding domain. In order to synthesize NO 
the electrons flow from the reductase domain of one monomer to the oxygenase domain of the Introduction 
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other (Fig. 2), a phenomenon called “domain swapping” (Panda et al., 2001; Siddhanta et al., 
1998; Siddhanta et al., 1996). 
Figure 2. Domain structure of the human eNOS, nNOS and iNOS isoforms. The PDZ, oxygenase 
and reductase domains are denoted by solid structures and the amino acid residue number at the 
start/end of each domain is shown. The myristoylation (Myr) G2 and palmitoylation (Palm) C15 and 
C26 sites on eNOS are shown, as is the location of the zinc-ligating cysteines (Zn). The autoinhibitory 
loops (red) within the FMN regions and the carboxyl end of nNOS and eNOS are also shown and the 
dimer interface in the oxygenase domain is indicated by grey bars. Abbreviations: PDZ, Post Synaptic 
Density protein -95 discs large/ZO-1 homology domain; Arg, arginine; H4B, tetrahydrobiopterin; 
CaM, calmodulin; FMN, flavin mononucleotide; FAD, flavine- adenine dinucleotide; NADPH, 
nicotinamide adenine dinucleotide phosphate; Zn, zinc. 
 
Only nNOS and eNOS are constitutively expressed predominantly in neurons and skeletal 
muscle or endothelial cells,
 respectively. Both the isforms are activated by agonist-induced 
elevation of the
 intracellular free Ca
2+ concentration with subsequent binding of Ca
2+/CaM to 
NOS (Venema et al., 1996a), and hence are also referred to as calcium- dependent NOS 
enzymes. The constitutive isoforms also differ form iNOS in having an auto-inhibitory insert 
in FMN binding site in the reductase domain. In contrast, iNOS is regulated predominantly
 at 
the transcriptional level by endotoxins and cytokines in macrophages, hepatocytes, and 
vascular smooth muscle cells (Nathan, 1997), and binds CaM with high affinity rendering it 
active at the Ca
2+ level of a resting cell (Ruan et al., 1996) (Fig. 3A).  
Additional regulatory mechanisms which have been proposed to regulate NOS include, 
protein-protein interactions, subcellular localisation of the enzymes, acylation, changes in L-
arginine availability which is determined by arginase activity, phosphorylation (Fleming & 
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Busse, 2003; Michel & Feron, 1997), and enzyme monomerisation (Bommel et al., 1998; Reif 
et al., 1999).  
 
Figure 3. Activation of NOS and biosynthesis pathway of nitric oxide (NO) from L-arginine. (A) 
Conversion of L-arginine to L-citrulline by the NOS isoforms eNOS, nNOS and iNOS. eNOS and 
nNOS are constitutively expressed, are Ca
2+ dependent and activation is receptor-mediated, while 
iNOS is cytokine-inducible and is Ca
2+ independent. (B) eNOS catalyzes a 5 electron oxidation of 
guanidino nitrogen of  L-arginine to L-citrulline and NO·. N
ω-Hydroxy-L-arginine is formed as an 
intermediate that is tightly bound to the enzyme. The reaction consumes 2 mol of O2 and 1.5 mol of 
reduced nicotinamine adenine dinucleotide phosphate (NADPH) per mole of NO· formed and 
requiring calcium (Ca), calmodulin (CaM) and tetrahydrobiopterin (H4B) as co-factors. 
Abbreviations: VEGF, vascular endothelial growth factor; S1P, spingosine-1-phosphate; IL-1, 
interleukin-1; gIFN, interferon-gamma; TNF, tumour necrosis factor; and LPS, lipopolysaccharide. 
 
1.6.1  Mechanism of NO biosynthesis 
NOS hydroxylates a guanidino nitrogen of L-arginine and then oxidizes the N
ω-hydroxy-L-
arginine intermediate (NOHA) to NO and L-citrulline (Fig. 3B). The NOS reductase 
(flavoprotein) domain first provides an electron (derived from NADPH) to the ferric heme in 
the oxygenase domain (Fig. 4). This is the slowest step of the biosynthetic reaction, and 
enables formation of a ferric heme-superoxy species (S I) in the L-arginine or NOHA 
reactions (Wei et al., 2003c). Species I (S I) is not reactive toward L-arginine but may (Huang 
et al., 2001) or may not (Wei et al., 2003c) be reactive toward NOHA. Species I can receive 
an electron from H4B (Wei et al., 2003b) or from the flavoprotein domain when H4B is absent 
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(Rusche  et al., 1998). The electron transfer from H4B is the second, slowest step in the 
biosynthetic reaction and its kinetics are influenced by surrounding protein residues and by 
the pterin structure itself (Wang et al., 2002; Wei et al., 2003b). Timely electron transfer from 
H4B prevents O2
- release (Fig. 4). The heme-peroxo species (S II) has only been observed in 
NOS at cryogenic temperatures (Davydov et al., 2002) and may become protonated and lose 
water to form a heme iron-oxo species (S III) (Fig. 4) that either hydroxylates L-arginine or 
may react directly with NOHA (Fig. 3). Importantly, the first product observed of NOS 
catalysis is a ferric heme-NO complex and not free NO (Negrerie et al., 1999; Scheele et al., 
1999; Wei et al., 2003c) (Fig. 4) as practically all NO binds to NOS ferric heme before 
exiting the enzyme. The reductase domain then reduces the ferric heme-NO complex to 
ferrous heme-NO species resulting in a slow release of NO. 
 
Figure 4. Mechanism for NO biosynthesis. Mechanism of oxygen activation by the NOS heme and 
NO synthesis. The ferric heme first receives an electron from the FMN hydroquinone (FMNH2) that is 
located in the NOS flavoprotein domain. This enables dioxygen to bind, forming the ferric-superoxy 
species (S I). This species then receives an electron from tetrahydrobiopterin (H4B) to generate heme 
peroxo (S II) and perferryl (S III) species that are thought to react with L-arginine (1 reaction) or 
NOHA (2nd reaction) to generate NO. Modified from Stuehr et al J Biol Chem 2004; 279:36167-
36170. 
 
After NO biosynthesis two different cycles compete: NO dissociation from the ferric heme 
(dissociation constant; kd) is required for a “productive cycle” that releases NO and is 
essential for NOS bioactivity. Conversely, reduction of the ferric heme-NO complex 
(reduction constant; kr’) channels the enzyme into a “futile cycle” that ultimately generates 
nitrate in place of NO. NOS futile cycling is also influenced by the rate at which O2 reacts 
with the ferrous heme-NO species (kox in Fig. 5). Together, the productive and futile cycles 
S I S II S III S I S II S IIIIntroduction 
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create a global kinetic mechanism for NOS catalysis. A NOS must also control partitioning 
between both cycles by balancing heme reduction (kr, kr’) and NO dissociation (kd) if it is to 
release the NO that it makes. For example, the specific activities of the three mammalian 
NOSs are of rank order iNOS > nNOS > eNOS, with nNOS activity being four times that of 
eNOS. But if one considers their actual rates of NO biosynthesis (the speed at which each 
NOS makes one NO) it is clear that nNOS is at least twice as fast as iNOS and about 30 times 
faster than eNOS (Stuehr et al., 2004). This discrepancy is explained by the global kinetic 
model and the different enzyme distribution pattern of each of NOS in the steady state 
(Santolini et al., 2001). 
 
Figure.5. Global kinetic model for NOS. Ferric enzyme reduction (kr) is rate-limiting for the 
biosynthetic reactions (central linear portion). kcat1 and kcat2 are the conversion rates of the FeIIO2 
species to products in the L-arginine and NOHA reactions, respectively. The ferric heme-NO product 
complex (FeIIINO) can either release NO (kd) or become reduced (kr’) to a ferrous heme-NO complex 
(FeIINO) which reacts with O2 (kox) to regenerate ferric enzyme. Modified from Stuehr et al J Biol 
Chem 2004;279:36167-36170. 
 
1.6.2  Substrate and cofactor requirement 
All NOS enzymes require NADPH, FAD, FMN and H4B as cofactors and L-arginine as 
substrate. Deficiency of L-arginine and H4B has be reported for conditions of 
hypercholesterolemia, atherosclerosis and diabetes (Busse & Fleming, 1996; Stroes et al., 
1997). 
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H4B 
Tetrahydrobiopterin is a critical co-factor of NOS. It acts as a redox factor and also helps in 
the dimerisation of eNOS. H4B deficiency leads to eNOS uncoupling, and H4B 
supplementation restores endothelial function. During NO biosynthesis the delivery of the 
second electron to the heme has to be rapid enough for the enzyme to generate the heme-oxy 
species that will react with Arg or NOHA before auto-oxidation of ferric-superoxy species I 
occurs. NOS solves this dilemma by utilizing H4B as a source of the second electron. H4B 
delivers the second electron about 3 to 30 times faster than can the NOS reductase domain, 
and this difference is sufficient to minimise O2
- release from the heme and so enable coupled 
oxygen activation (Wang et al., 2002; Wei et al., 2003a). H4B exhibits a range of allosteric 
and structural effects, presumably resulting from binding of the pterin in the dimer interface 
in close proximity to the heme and substrate binding site (Crane et al., 1998; Raman et al., 
1998). 
1.7  Regulation of eNOS 
Since eNOS is constitutively expressed its activity is regulated by complex post-translational 
modifications, protein-protein interactions, subcellular localisation, changes in substrate 
availability which is determined by arginase activity, phosphorylation (Fleming & Busse, 
2003; Michel & Feron, 1997), and enzyme monomerisation (Bommel et al., 1998; Reif et al., 
1999). 
1.7.1  Intracellular localisation  
Myristoylation and palmitoylation 
Of the three NOS isoforms, only eNOS is both myristoylated and palmitoylated. eNOS is co-
translationally and irreversibly myristoylated at the N-terminal glycine residue Gly
2, when the 
methionine corresponding to the translational initiation codon is removed by a specific 
aminopeptidase, exposing glycine at the N-terminus. The mutation of Gly
2 to Ala converts 
eNOS from a membrane- associated to a cytosolic enzyme (Pollock et al., 1992; Sessa et al., 
1993), without affecting the activity of the enzyme. Myristoylation may not be the only 
mechanism responsible for the membrane attachment of eNOS. Indeed, many myristoylated 
proteins are cytosolic (Towler et al., 1988). Purified wild-type eNOS binds to pure anionic 
phospholipid vesicles but not to neutral phospholipid vesicles, demonstrating that eNOS 
attachment to lipid bilayers requires electrostatic as well as hydrophobic interactions. 
Palmitoylation occurs post-translationally and reversibly at cysteine residues Cys
15 and Cys
26 
(Prabhakar et al., 2000). Dual acylation of eNOS is required for efficient localisation to the Introduction 
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plasmalemmal caveolae of endothelial cells (Garcia-Cardena et al., 1996b). It has been 
suggested that palmitoylation is dynamically regulated by agonists such as bradykinin (Feron 
et al., 1998). This is highly controversial as mutational studies to disrupt palmitoylation on 
eNOS did not significantly alter its membrane association. Additionally, [
3H] palmitic acid 
was not incorporated into nonmyristoylated mutant eNOS, suggesting that myristoylation is 
necessary for subsequent palmitoylation of the enzyme (Liu et al., 1995). The available 
literature imply that palmitoylation does not play a major role in membrane association of 
eNOS.  
The localisation of eNOS is well studied and described but controversy on the importance of 
changes of intracellular localisation still exists. eNOS is localised by virtue of its 
myristoylation and palmitoylation in the plasma membranes (Hecker et al., 1994), caveolae 
(Garcia-Cardena et al., 1996b; Liu et al., 1996a), the perinuclear Golgi apparatus (Liu et al., 
1997; O'Brien et al., 1995; Sessa et al., 1995), and there are even some reports of eNOS in the 
nucleus (Feng et al., 1999; Giordano et al., 2002; McNaughton et al., 2002). The 
immunostaining of native endothelial cells reveals predominant association with the plasma 
membrane and the Golgi apparatus (Fulton et al., 2002). eNOS is also reported to shuttle 
between these two pools and although this was initially attributed to a rapid depalmitoylation 
of the enzyme (Robinson et al., 1995), the exact mechanism(s) involved still remain to be 
clarified (Liu et al., 1995). A fast translocation of eNOS from the vicinity of caveolin to other 
cell compartments in response to acute agonist stimulation has however been reported by 
several groups (Prabhakar et al., 1998; Reiner et al., 2001; Robinson et al., 1995) and may be 
mediated by a dynamin-dependent process (Chatterjee et al., 2003). Certainly, movement 
away from plasma membrane-bound signalling molecules may regulate NO output and the 
“mislocalisation” of eNOS has been suggested to contribute to the vascular complications 
associated with angiotensin II-induced hypertension (Gerzanich et al., 2003). In which 
fraction eNOS is active in unstimulated cells and can account for the basal production of NO 
is also controversial, since the eNOS in caveolae is thought to be mostly inactive and 
disruption of the Golgi apparatus in rabbit carotid arteries failed to affect NO-mediated 
relaxation (Bauersachs et al., 1997). Attenuating the association of eNOS with the plasma 
membrane by the disruption of caveolae using β-cyclodextrin, ox-LDL (Blair et al., 1999; 
Feron  et al., 1999) or cyclosporin A (Lungu et al., 2004) are all reported to affect the 
intracellular localisation of eNOS. However, these changes are generally associated with a 
decrease rather than an increase in NO production. It follows that any change in intracellular 
localisation of eNOS will be associated with changes in the eNOS signalling complex and Introduction 
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while caveolin-1 can associate with eNOS in caveolae, the two proteins are localised to 
distinct perinuclear compartments (Govers et al., 2002b). Endothelial cells treated with 
nocodazole, a microtubule-depolymerising drug scattered the Golgi complex and caveolin-1 
was found in vesicles at the periphery of the cell, while eNOS is localised at large structures 
near the nucleus suggesting that eNOS activity is not regulated by caveolin-1 in the Golgi 
complex (Govers et al., 2002b). Recent studies to determine the intracellular site, which 
contains an active and agonist-stimulatable pool of eNOS, targeted eNOS to specific 
intracellular compartments. eNOS constructs that targeted to the plasma membrane were 
found to be constitutively active, phosphorylated and to respond to changes in Ca
2+ but were 
largely unresponsive to activation by the kinase Akt, while eNOS in the Golgi complex was 
less sensitive to Ca
2+ but sensitive to Akt-dependent phosphorylation (Fulton et al., 2004). 
These and other observations suggest that the intracellular localisation of eNOS determines its 
sensitivity to changes in intracellular Ca
2+ levels as well as its susceptibility to 
phosphorylation by different kinases (Gonzalez et al., 2002). 
1.7.2  Regulation by eNOS-associated proteins 
It has been clear for quite a few years that eNOS is part of a protein complex with caveolin-1, 
CaM and heat shock protein 90 (Hsp90) and that the composition of the “eNOS signalosome” 
has profound effects on the intracellular localisation and activity of eNOS. Several of the 
eNOS associated proteins are kinases or phosphatases, which reflects the importance of 
phosphorylation in the regulation of eNOS activity.  
Negative regulatory associated proteins  
Caveolin 
Caveolae are flask-shaped invaginations of the plasma membrane occupying up to 30% of 
cell surface in capillaries (Garcia-Cardena et al., 1996b), but considerably less in cultured 
endothelial cells. They harbour a variety of signalling molecules such as the bradykinin 2 (B2) 
receptor, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) receptors, 
mitogen-activated protein (MAP) kinases, Src family non-receptor tyrosine kinases, G 
proteins, PKC, cationic arginine transporter-1; class B, type I scavenger receptor for high-
density lipoprotein, H-Ras, Ca
2+ ATPases and inositol 1,4,5 triphosphate-dependent Ca
2+ 
channels, among others (Lisanti et al., 1994; Liu et al., 1996b; Parton, 1996). The chief 
structural components of caveolae are cholesterol and structural proteins, such as the 
caveolins (caveolin-1, -2 and -3). Caveolin-1 is abundant in endothelial cells and its hairpin 
structure can be attributed to the inclusion of a 33-residue membrane-spanning region Introduction 
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between the N- and C-terminal cytosolic domains. The scaffolding domain, a component of 
the C-terminal membrane proximal segment, (amino acids 61-101) is responsible for the 
presence of a number of signal proteins in caveolae. The incubation of eNOS with peptides 
derived from the scaffolding domains of caveolin-1 and -3 inhibits its enzymatic activity, an 
effect not observed following site-directed mutagenesis of the predicted caveolin binding 
motif (Garcia-Cardena et al., 1997). A similar modulation of eNOS activity by this peptide 
has also been demonstrated in vivo and a chimeric peptide with a cellular internalisation 
sequence fused to the caveolin-1 scaffolding domain has been shown to selectively inhibit 
acetylcholine-induced, NO-mediated relaxation (Bucci et al., 2000). That the association of 
eNOS with caveolins (Garcia-Cardena et al., 1997) inhibits its activity can also account for 
the reports that the basal activity of eNOS is enhanced in mice deficient in either caveolin-1 
or caveolin-3 (Drab et al., 2001; Razani et al., 2001). 
G protein-coupled receptors  
Multiple G protein-coupled receptors resident in caveolae have been reported to contribute to 
the eNOS-membrane complex and regulate eNOS
 activity. The intracellular domain (ID) of 
G-protein coupled receptors, such as ID4 of the bradykinin 2 (B2), the angiotensin II R1 and 
the endothelin-1 ETB receptors can negatively regulate eNOS activity (Golser et al., 2000; Ju 
et al., 1998; Marrero et al., 1999). Co-immunoprecipitation and
 in vitro binding assays have 
indicated that the bradykinin
 B2 receptor, via its COOH-terminal ID4 (amino acids 310–329),
 
interacts with eNOS in a ligand- and Ca
2+-dependent manner. On the basis of this evidence it 
was suggested that in the resting state, the receptor docks with eNOS in the caveolar
 
membrane and participates in its inactivation. Stimulation of
 endothelial cells with bradykinin 
or Ca
2+ ionophore would then trigger
  dissociation of the eNOS-B2 receptor complex and 
activate eNOS (Ju et al., 1998). The sites of binding to eNOS and the
 mechanisms by which 
the bradykinin B2 receptor and caveolin-1
 inhibit eNOS are suggested to be distinct (Ju et al., 
1998). Phosphorylation of serine or tyrosine residues in the eNOS-interacting region of
 the 
bradykinin B2 receptor decreases the binding affinity of
 the receptor domain for the eNOS 
enzyme and relieves eNOS inhibition (Marrero et al., 1999; Venema et al., 1996b). 
Furthermore, bradykinin-induced tyrosine phosphorylation of
 the bradykinin B2 receptor in 
cultured endothelial cells appears
  to promote a transient dissociation of eNOS from the 
receptor,
 accompanied by a transient increase in NO production. Mechanistically, the ID4 
peptide has been shown to affect NOS catalysis by interference with the electron transfer from 
the flavins in the reductase domain to the heme in the oxygenase domain (Golser et al., 2000; 
Marrero et al., 1999). Indeed, G protein-coupled receptors have been suggested to participate Introduction 
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in the complex regulation of eNOS activity in endothelial
 cells and that these interactions are 
regulated by receptor
 phosphorylation (Marrero et al., 1999). 
Despite the claims of an interaction between eNOS and G protein-coupled receptors, perhaps 
the data need to be reassessed in more in vivo oriented models. Certainly, the bradykinin B2 
receptor, which has been the focus of much of this work, is not normally found in caveolae. 
However, the bradykinin B2 receptor is sequestered into the caveolae in response to cell 
stimulation and leads to receptor desensitisation (Benzing et al., 1999; Lamb et al., 2001). 
Moreover, there are vast differences in the characteristics of caveolae in native and primary 
cultures of endothelial cells. Since much of the work on the eNOS signalosome and caveolae 
has been obtained using multiple-passaged cells and overexpressing systems, it seems clear 
that some of the “physical interactions” reported in the literature actually reflect artefacts 
associated with in vitro models. 
Positive regulatory associating proteins  
Calmodulin  
Calmodulin (CaM) is an ubiquitous, Ca
2+-binding protein and was the first protein shown to 
be involved in eNOS regulation (Busse & Mülsch, 1990; Forstermann et al., 1991). 
Mechanistically, CaM binding to a 32 residue CaM binding motif can displace an adjacent 
autoinhibitory loop (Salerno et al., 1997) located in the FMN domain on eNOS leading to 
conformational changes (Daff et al., 2001; Siddhanta et al., 1996), thus facilitating NADPH-
dependent electron flux from the reductase domain of the protein through to the terminal 
electron acceptor heme in the oxygenase domain (Abu-Soud et al., 1994). The association of 
CaM with the CaM-binding domain within eNOS is determined by multiple molecular 
interactions (Knudsen et al., 2003; Salerno et al., 1997) as well as by the 
phosphorylation/dephosphorylation of Thr
495 (Aoyagi et al., 2003; Fleming et al., 2001). 
However, other modifications such as the binding of Hsp90 and the phosphorylation of Ser
1177 
have also been reported to affect the association of the two proteins (Gratton et al., 2000). 
More recently the phosphorylation of CaM by the kinase CK2 was found to attenuate its 
ability to activate eNOS (Greif et al., 2004). Deletion of CaM binding domain converts eNOS 
from a membrane-bound to a cytosolic protein when the enzyme is expressed in Sf9 cells 
(Venema et al., 1995). 
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Heat shock protein 90 (Hsp90)  
Hsp90 is a highly abundant cytosolic protein known to serve as a molecular chaperone and is 
responsible for the folding of proteins such as steroid
  receptors and cell cycle-dependent 
kinases (Caplan, 1999). Hsp90 is involved in the folding of nNOS and is reported to 
determine the insertion of heme into the immature protein (Billecke et al., 2002). In addition 
to this function, Hsp90 can also act as an integral part of numerous signal transduction
 
cascades by virtue of its function as a scaffolding molecule.  
Hsp90 can associate with eNOS in resting endothelial cells and endothelial cell stimulation 
with vascular
 endothelial growth factor (VEGF), histamine, fluid shear stress,
 and estrogen all 
enhance the interaction between Hsp90 and eNOS at the same time as increasing NO 
production (Garcia-Cardena et al., 1998; Russell et al., 2000). The association of Hsp90 with 
eNOS appears to be determined by the agonist-stimulated tyrosine phosphorylation of Hsp90 
(Harris et al., 2000), but it is not clear whether this modification is also required for the 
recruitment of other proteins to the signalosome. Most of the kinases shown to phosphorylate 
eNOS on serine or threonine residues physically associate with the enzyme, either directly or 
via binding to Hsp90 (Fontana et al., 2002). Hsp90 also interacts with other chaperones and 
the Hsp90 co-factor; carboxyl terminus of Hsp70-interacting protein (CHIP), is reported to be 
part of the eNOS complex and to play a role in determining its intracellular localisation (Jiang 
et al., 2003). An enhanced association of eNOS and Hsp90 is thought to underlie adiponectin-
induced protection against angiotensin II- (Lin et al., 2004) and glucose-induced apoptosis 
(Lin et al., 2005) while an impaired association of eNOS with Hsp90 has been associated with 
various forms of hypertension (Murata et al., 2002; Shah et al., 1999). 
Soluble guanylyl cyclase (sGC) 
 The soluble guanylyl cyclase is the primary intracellular receptor for NO and was, until 
relatively recently, assumed to be a cytosolic enzyme. It now appears that a small proportion 
of the “soluble” guanylyl cyclase can become membrane-associated in a stimulus-dependent 
manner (Zabel et al., 1999). This translocation would bring eNOS and the sGC closer 
together, thereby increasing the effectiveness of NO signaling and reducing the possibility of 
inactivation of NO by intracellular O2
-. Not all the groups that have addressed this aspect of 
NO signaling have found any evidence suggesting a direct association between the eNOS and 
the sGC, however, the β subunit of sGC has been reported to associate with Hsp90 after 
agonist stimulation and therefore form part of the eNOS signalosome (Venema et al., 2003) 
(Fig. 6).  Introduction 
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The list of eNOS-associated proteins is continually increasing, with recent additions being 
polymerised actin (Su et al., 2003), platelet endothelial cell adhesion molecule 1 (PECAM-1) 
(Govers et al., 2002a) and the voltage-dependent anion channel 1, VDAC1 or porin (Sun & 
Liao, 2002). 
 
Figure 6. Protein interaction of eNOS at caveolae. Myristoylation and palmitoylation of eNOS target 
it to the plasma membrane of caveolae. Interaction with caveolin inhibits eNOS activity where as 
stimulation promotes recruitment of Hsp90, Akt, dynamin, porin and Ca2+/CaM to eNOS increasing 
its activity. The interaction with CHIP, NOSTRIN and NOSIP seems to decrease the enzyme activity, 
while association of sGC has been reported to increase the effectiveness of NO signalling. 
Abbreviation: Hsp90, heat shock protein 90; Akt, protein kinase B; Dyn, dynamin; CaM, calmodulin; 
CHIP, carboxyl terminus of Hsp70-interacting protein; NOSTRIN, eNOS traffic inducer; NOSIP, 
eNOS interacting protein and sGC, soluble guanylyl cyclase.  
 
Interactions between caveolin, CaM, and Hsp90.  
CaM has been proposed to be exclusively responsible for the dissociation of eNOS from 
caveolin. Immunoprecipitation studies demonstrated the presence of eNOS, caveolin-1, and 
Hsp90 in the same complex (Gratton et al., 2000). Moreover, the addition of exogenous CaM 
weakly displaced caveolin from CaM. Interestingly, the binding of caveolin-1 to eNOS was 
displaced by the caveolin-1 scaffolding domain peptide, but not by Ca
2+-activated CaM, 
demonstrating that CaM cannot physically disrupt the eNOS-caveolin-1 complex in vitro. 
Reconstitution of the heterotrimeric complex in vitro showed eNOS interaction with both 
Hsp90 and caveolin-1, but the latter proteins did not interact with each other, demonstrating Introduction 
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that eNOS was the bridge holding the complex together. However, Hsp90, per se, did not 
influence the eNOS/caveolin-1 interaction but facilitated the ability of CaM to displace 
caveolin-1 from eNOS. It has been proposed that perhaps the “recruitment or activation” of 
Hsp90 and CaM to eNOS results in weak physical displacement of eNOS from caveolin-1, 
but the complex remains in caveolae; or Hsp90 and Ca
2+-activated CaM coexist with eNOS 
bound to caveolin-1, and a slight change in eNOS conformation in the absence of bulk 
translocation away from caveolin-1, allows for efficient stimulus-response coupling (Fulton et 
al., 2001). 
NOS trafficking 
Proper cellular localisation of eNOS is critical
  for optimal coupling of extracellular 
stimulation with NO production (Sakoda et al., 1995; Sessa et al., 1995). It has been 
suggested that redistribution of eNOS is one of the events flowing its activation. However, 
demonstrations that NO production is a more rapid process than enzyme relocation suggest 
that intracellular eNOS traffic plays a role in termination rather than initiating NO release. To 
ensure that eNOS is at the right place at the right time, there have to be protein-protein 
interactions that could help in the relocation of eNOS. Some of the proteins which have come 
to light and which can alter the intracellular compartmentalisation of eNOS are dynamin-2, 
NOSIP, NOSTRIN, and CHIP. 
Dynamin-2 
Dynamin-2 belongs to the family of large GTPases and is believed to be involved in vesicle 
formation, receptor-mediated endocytosis, and the internalisation of caveolae and vesicle 
trafficking in and out of the Golgi. Dynamin-2 has been shown by confocal microscopy to 
colocalise with eNOS in the plasma membrane and Golgi membranes of endothelial cells and 
to bind eNOS directly, both in vivo and in vitro (Cao et al., 2001). Specifically dynamin-2 
associates with the reductase domain of eNOS resulting in an increased flow of electrons from 
FAD to FMN, thereby increasing the enzyme activity (Cao et al., 2003; Cao et al., 2001). 
Interfering with the activity of dynamin-2 appears to deplete eNOS from caveolae (Chatterjee 
et al., 2003) in response to stimuli such as braykinin. In its function as a motor protein 
dynamin-2 has been hypothesised to shuttle eNOS between caveolae and the Golgi. However, 
it remains to be determined whether the dynamin-2-associated changes in the subcellular 
localisation or its direct binding to the eNOS protein exert the most pronounced effects on 
enzyme activity. 
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NOSIP 
NOSIP (eNOS interacting protein) is a 34-kDa protein, and is one of the more recent 
additions to the eNOS signalosome. Cotransfection of NOSIP in cells
 expressing eNOS has 
two major consequences, i.e., the displacement
 of eNOS from the plasma membrane and its 
relocation to intracellular
 compartments, and a decrease in eNOS activity (Dedio et al., 2001). 
The interaction between NOSIP and eNOS has been shown both in vitro and in vivo, and 
through deletion analysis, NOSIP was shown to bind eNOS between amino acids 366 and 
486. Stimulation of cells with calcium ionophore does not change the association of NOSIP 
and eNOS; however, a peptide derived from the scaffolding domain of caveolin (82–101) is 
able to displace eNOS from NOSIP. NOSIP does not affect eNOS activity assays in vitro but, 
when coexpressed in CHO cells, is reported to reduce ionomycin-stimulated NO release 
(Nedvetsky et al., 2002). NOSIP and eNOS are reported to be coexpressed in distinct cell 
types of the
 lung and the trachea, suggesting a functional role for NOSIP
 in regulating NO 
synthesis and delivery in the airway system (Konig et al., 2005). However physiological 
evidence for the interaction between eNOS and NOSIP is lacking. 
NOSTRIN 
NOSTRIN (eNOS traffic inducer), overexpressed in CHO cells, binds to eNOS (also 
overexpressed) and results in the relocation of eNOS from the plasma membrane and Golgi 
membranes to vesicle-like structures distributed throughout the cytosol (Zimmermann et al., 
2002). The translocation of eNOS, thereby strongly attenuates eNOS-dependent NO 
production. Inhibition of NO production in NOSTRIN- overexpressing cells may be the 
consequence of this redistribution of eNOS. Together with NOSIP, NOSTRIN seems to be a 
promising candidate for regulating the intracellular trafficking of eNOS and perhaps other 
proteins in the plasma membrane.  
CHIP 
CHIP (carboxyl
 terminus of Hsp70-interacting protein), a molecular chaperone remodels the 
Hsp90 heterocomplex (Connell et al., 2001) and causes protein degradation
 of some Hsp90 
substrates through the ubiquitin-protein isopeptide
  ligase activity of CHIP. In contrast, in 
transiently transfected COS cells, CHIP was found to incorporate
  into the eNOS·Hsp90 
complex and specifically decrease
  soluble eNOS levels. CHIP elicited the partitioning of 
eNOS to
 the detergent- insoluble cell compartment and impaired trafficking through the
 Golgi 
apparatus, which is otherwise required for trafficking of eNOS to the plasmalemma
  and Introduction 
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subsequent activation (Jiang et al., 2003). Taken together, it seems that CHIP may be a 
negative regulator of eNOS activity.  
1.7.3  Regulation by phosphorylation 
Phosphorylation is one of the post-translational mechanisms employed by the cellular 
machinery to regulate the activity of its enzymes. As eNOS is constitutively expressed, 
phosphorylation plays an important role in regulating the activity of the enzyme. eNOS can be 
phosphorylated on serine, threonine and tyrosine residues (Boo & Jo, 2003; Fleming et al., 
1998; Fleming & Busse, 2003) (Fig. 7A), leading to eNOS activation or inactivation. There 
are numerous putative phosphorylation sites, but the most extensively studied eNOS residues; 
the phospho-status of which determines enzyme activity are a serine residue (human eNOS 
sequence: Ser
1177; bovine sequence Ser
1179) in the reductase domain, which positively 
regulates NO production, and a threonine residue (human eNOS sequence: Thr
495; bovine 
sequence Thr
497) within the CaM-binding domain (Fig. 8). The various kinases reported to be 
involved in the phosphorylation of eNOS following cell activation by different stimuli are 
shown in figure 9.  
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Figure 7. Effect of fluid shear stress on serine, threonine and tyrosine phosphorylation of eNOS. 
(A) eNOS was immunoprecipated from ³²P-labelled porcine aortic endothelial cells either maintained 
under static condition or exposed to shear stress (12 dynes cm-², for 2 and 5 min), and subjected to 
two dimensional phospho amino acid analysis. (B) Densitometric analysis of phosphoserine, P-S; 
phosphothreonine, P-T; and phosphotyrosine P-Y with respect to control. Pi, inorganic phosphate 
(from Fisslthaler et al, Acta Physiol Scand.2000; 168: 81– 88).  
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Figure 8. Scheme showing eNOS (human sequence) ligand binding domain and potentially 
phosphorylable amino acids. Phosphorylation of the serine residues, Ser
1177 and Ser
633 in the 
reductase domain positively regulate enzymatic activity, while phosphorylation at threonine Thr
495, in 
the Ca/CaM binding domain and Ser
114 near the Zn
2+ binding domain lead to a decrease in NO 
production.  
 
Ser
1177  
The C-terminal reductase domain of eNOS terminates in a α-helix which contains a terminal 
Ser
1177. In unstimulated, cultured endothelial cells, Ser
1177 is not phosphorylated but is rapidly 
phosphorylated upon agonist stimulation with compounds such as bradykinin (Fleming et al., 
2001), estrogen (Haynes et al., 2000), VEGF (Fulton et al., 1999; Michell et al., 2001) or 
insulin (Kim et al., 2001) and mechanical stimuli such as fluid shear stress (Boo & Jo, 2003; 
Dimmeler et al., 1999; Fissithaler et al., 2000; Gallis et al., 1999). The phosphorylation of 
eNOS Ser
1177 enhances the activity of the enzyme and alters its Ca
2+ sensitivity to increase 
NO production 2- to 3-fold above basal levels, an effect that can be attributed to an increase in 
the flux of electrons through the reductase domain (McCabe et al., 2000). Mutation of this 
residue to a phosphomimetic aspartate (Dimmeler et al., 1999) or deletion of 27 amino acids 
containing Ser
1177 at the C-terminal tail (Lane & Gross, 2002) renders the mutant eNOS active 
at resting levels of intracellular Ca
2+.  
Oxygenase Domain Reductase Domain
S633
T495
S1177
1202
G2
C15
C26
S114
C184
E361
H4B /Heme/ Arg
1
Autoinhibitory inserts
NADPH binding domain
FAD binding domain
Contact domain
Hinge reigon
FMN binding domain
Zinc binding site
Calmodulin binding domain
G2           Myristoylation site
C15/C26  Palmitoylation sites
C184       Heme binding
E361       Participates in arginine
binding
Oxygenase Domain Reductase Domain
S633
T495
S1177
1202
G2
C15
C26
S114
C184
E361
H4B /Heme/ Arg
1
Oxygenase Domain Reductase Domain
S633
S633
T495
T495
S1177
S1177
1202
G2
C15
C26 G2
C15
C15
C26
S114
S114
C184
E361
H4B /Heme/ Arg
1
Autoinhibitory inserts
NADPH binding domain
FAD binding domain
Contact domain
Hinge reigon
FMN binding domain
Zinc binding site
Calmodulin binding domain
G2           Myristoylation site
C15/C26  Palmitoylation sites
C184       Heme binding
E361       Participates in arginine
binding
Autoinhibitory inserts
NADPH binding domain
FAD binding domain
Contact domain
Hinge reigon
FMN binding domain
Zinc binding site
Calmodulin binding domain
G2           Myristoylation site
C15/C26  Palmitoylation sites
C184       Heme binding
E361       Participates in arginine
binding
Autoinhibitory inserts
NADPH binding domain
FAD binding domain
Contact domain
Hinge reigon
FMN binding domain
Zinc binding site
Calmodulin binding domain
G2           Myristoylation site
C15/C26  Palmitoylation sites
C184       Heme binding
E361       Participates in arginine
bindingIntroduction 
  21
 
 Figure 9. Kinases involved in the phosphorylation of known amino acid residues influencing eNOS 
activity. Physiological stimuli such as VEGF, S1P, estrogen, bradykinin and fluid shear stress can 
activate various signalling pathways leading to the activation of eNOS. Ser
1177 is known to be 
phosphorylated by Akt, PKA, CaMKII, ERK1/2, PKG and AMPK, Ser
615 by Akt and Ser
633 by PKA. 
Phosphorylation on Thr
495 and Ser
114 is mediated by PKC. Abbreviations: VEGF, vascular endothelial 
growth factor; S1P, sphingosine 1-phosphate; PKA, protein kinase A; Akt, protein kinase B; CaMKII, 
CaM kinaseII; PKC, protein kinase C; AMPK, AMP activated protein kinase; PKG, cGMP-dependent 
protein kinase; ERK1/2; extracellular signal-regulated kinase 1/2. 
 
Based on the stimuli applied, various kinases are involved in the phosphorylation of Ser
1177. 
For example, while shear stress elicits the phosphorylation of Ser
1177 by activating Akt and 
PKA, insulin, estrogen and VEGF mainly phosphorylate eNOS in endothelial cells via Akt. 
The bradykinin-, Ca
2+ ionophore- and thapsigargin-induced phosphorylation of Ser
1177, on the 
other hand, is mediated by CaMKII (Fleming et al., 2001; Schneider et al., 2003). Recent 
biochemical and crystallography data on the structure of the reductase domain of NOS has 
explained the mechanism involved in the inhibitory effect of Ser
1177. At the end of the C-
terminal-helix, the phosphorylatable Ser
1177 is directed toward negatively charged FMN-
binding domain residues Gln
685 (Gln in eNOS) and Asp
587. This structure thus suggests a 
mechanism for phosphorylation-induced NOS activation by electrostatically- induced 
conformational changes (Garcin et al., 2004). 
Ser
615  
This phosphorylation site is located within the autoinhibitory loop in the FMN binding 
domain. It was identified by phosphopeptide mapping and is reported to be phosphorylated by 
both PKA and Akt. Mimicking phosphorylation
 at Ser
615 significantly increases the Ca
2+-Introduction 
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calmodulin sensitivity of eNOS but is not reported to alter maximal enzyme activity (Michell 
et al., 2002). However, Ser
615 may be important in regulating phosphorylation at other sites as 
well as protein-protein interactions and the assembly of the eNOS signalosome (Bauer et al., 
2003). 
Ser
633  
Ser
633 is located within the auto-inhibitory loop in the FMN binding domain. This loop is 
thought to interact with the CaM binding domain and to interrupt the binding of CaM, thus 
throttling enzyme activity. Although Ser
633 can be phosphorylated in vitro by PKA and PKG 
(Butt et al., 2000), the functional relevance of this observation was unclear and the limited 
experimental studies which initially compared the potential of phosphorylation on Ser
1177 
versus Ser
633 in regulating eNOS activity, concluded that Ser
1177 played a major role in the 
regulation of NO production while either no Ser
633 phosphorylation could be detected or no 
consequence of phosphorylation was evident (Dimmeler et al., 1999; Fulton et al., 1999). 
More recently it has been shown that Ser
633 is most probably phosphorylated in vivo by PKA 
following cell stimulation by fluid shear stress, VEGF, bradykinin and 8-bromo-cAMP albeit 
with a slower time course of phosphorylation than that detected on Ser
1177 and Thr
495 (Boo et 
al., 2002; Michell et al., 2002). 
Ser
114  
This residue is located in the oxygenase domain in close vicinity to Zn (Raman et al., 1998) 
and H4B (Li et al., 1999) binding sites. Although, bradykinin, lysophosphatidic acid (Kou et 
al., 2001) and fluid shear stress (Gallis et al., 1999) were initially reported to enhance Ser
114 
phosphorylation but the consequences of Ser
114  phosphorylation on endothelial NO 
production remains to be elucidated.  
Thr
495  
The Thr
495 was the first residue to be identified, which negatively regulates eNOS. Under 
basal conditions in all of the endothelial cells investigated to-date, Thr
495 is constitutively 
phosphorylated resulting in a decrease in NO production (Fleming et al., 2001; Harris et al., 
2001; Michell et al., 2001). The link between phosphorylation and NO production can be 
explained by interference with the binding of CaM to the CaM-binding domain. Stimulation 
of endothelial cells with agonists, such as bradykinin, histamine or a Ca
2+ ionophore, results 
in a transient dephosphorylation of Thr
495 which facilitates the binding of CaM to eNOS 
(Fleming  et al., 2001). Crystallographic analysis of CaM bound eNOS indicates that the 
phosphorylation of eNOS Thr
495 not only causes electrostatic repulsion of nearby glutamate Introduction 
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residues (Glu
7 and Glu
127) within CaM but may also affect Glu
498 within eNOS and thus 
induce a conformational change within the enzyme itself (Aoyagi et al., 2003). There is a 
good correlation between Thr
495  dephosphorylation, Ser
1177 phosphorylation and NO 
production when bradykinin is used as an agonist for NO production, suggesting that Thr
495 
dephosphorylation is sufficient for eNOS activation(Harris et al., 2001; Michell et al., 2001; 
Michell et al., 2002) (Fig. 10). Recently the dephosphorylation of Thr
495 has been linked to 
the production of O2
- by eNOS (Lin et al., 2003), however it remains to be determined 
whether this occurs in vivo and whether or not the actual cause of the uncoupling is a decrease 
in H4B and/or L-arginine availability as a consequence of prolonged activation of the enzyme.  
The constitutively active kinase which phosphorylates eNOS Thr
495 is most probably PKC 
(Fleming et al., 2001; Matsubara et al., 1996; Michell et al., 2001), a finding which could 
account for the fact that protein kinase inhibitors and the down-regulation of PKC markedly 
increase endothelial NO production (Davda et al., 1994; Hirata et al., 1995). On the other 
hand amlodipine, which inhibits PKC activity in endothelial cells, is able to enhance NO 
production by attenuating eNOS Thr
495 phosphorylation (Lenasi et al., 2003). It is not entirely 
clear which PKC isoform phosphorylates eNOS in native endothelial cells. Clearly the PKC 
in question should form part of the eNOS signalosome in unstimulated cells and be 
constitutively active as the PKC phosphorylation site is phosphorylated in unstimulated 
endothelial cells. To-date, PKC-α (Fleming et al., 2005), PKC-β and PKC-ε (Zhang et al., 
2005) have all been implicated in this process.  
PKC-β has received a lot of attention as the inhibition of this isoform is reported to prevent 
the hyperglycemia-induced attenuation of NO production (Chu & Bohlen, 2004), and to 
reverse endothelial function in animal models of diabetes (Hink et al., 2001) as well as in 
human subjects with type 2 diabetes (Beckman et al., 2002; Guzik et al., 2002). However, it 
remains to be determined whether the beneficial effects of PKC-β inhibition can be attributed 
to a direct effect on eNOS, to the generation of oxygen-derived free radicals or even to the 
generation of a vasoconstrictor compound (Cosentino et al., 2003; Lagaud et al., 2001). Introduction 
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Figure 10. Hypothesis for the activation of eNOS in response to the Ca
2+- elevating agonist 
bradykinin. (A)  eNOS dimer showing electron flux between the two monomers and the phenomenon 
of domain swapping. (B) Under basal (unstimulated) conditions eNOS produces low amounts of NO· 
(see inset) but the binding of CaM to the enzyme is prevented by phosphorylation of Thr
495 in the CaM 
binding domain (CBD). (C) In response to cell stimulation with bradykinin (Bk) there is an increase in 
[Ca²
+]i and PP1 is activated to dephosphorylate Thr
495. (D) CaM can now bind to the CBD and NO· 
production is increased markedly over basal levels. (E) At the same time, CaMKII is activated and 
phosphorylates Ser
1177, which further enhances electron flux through the reductase domain and 
enzyme activity reaches a peak (F). (G) Dephoshorylation of Thr
495 is transient and this residue is 
rapidly rephosphorylated after a decrease in [Ca
2+]i, most probably by PKC. CaM dissociates and 
enzyme activity decreases. PP2A dephosphorylates Ser
1177 and NO· output returns to basal levels (H). 
AL, auto-inhibitory loop, (from Fleming and Busse, Am.J.Physiol.Regul.Integr.Comp.Physiol.2003; 
284: R1–R12). 
 
Elucidating the consequences of eNOS phosphorylation on the sites identified to-date is 
complicated by the fact that “cooperation between multiple phosphorylation events” has been 
described and the mutation of the serine phosphorylation sites 114, 615, and 1177 to alanine 
affects the phosphorylation state of at least one other site (Bauer et al., 2003). 
 
Tyrosine  
Treatment of endothelial cells with inhibitors of tyrosine kinases as well as tyrosine 
phosphatases modulates the tyrosine phosphorylation of eNOS and endothelial NO production 
(Fleming et al., 1996a; Fleming et al., 1998; Takenouchi et al., 2004). There is almost nothing 
is known about the residues which are phosphorylated or the kinases which are involved. 
Elaborating the functional consequences of eNOS tyrosine phosphorylation is complicated by 
the fact that this modification is only evident in primary cultured cells (Garcia-Cardena et al., 
1996a) or in cells that overexpress tyrosine kinases such as Src (Takenouchi et al., 2004) but 
not with passaged endothelial cells (Corson et al., 1996; Michel et al., 1993; Venema et al., 
1996b). The consequences of the tyrosine phosphorylation of eNOS are unknown but are 
perhaps more likely to be related to the docking of associated scaffolding and regulatory 
proteins than to a direct effect on eNOS activity. The use of tyrosine kinase inhibitors 
provides only limited information on the role played by tyrosine phosphorylation in the 
regulation of endothelial NO production as many of these compounds directly affect Ca
2+-
signalling processes (Fleming et al., 1996b; Fleming & Busse, 1997) and/or the activity of 
Akt and the binding of Hsp90 (Papapetropoulos et al., 2004).  Introduction 
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1.7.4  NOS reductase domain regulatory elements 
Recent structural and molecular modeling studies of the NOS reductase domain structure have 
provided novel insight into the molecular mechanisms that control both the intra-module 
electron transfer from NADPH to the flavins and the inter-module electron transfer from 
FMN to heme. 
FMN domain auto-inhibitory insert 
One of the main structural differences between the constitutive and inducible isoforms is an 
auto-inhibitory insert of 40-50 amino acids in the FMN-binding domain of the eNOS and 
nNOS which interfere with CaM binding (Daff, 2003; Salerno et al., 1997). Deletion of the 
inserts results in mutant enzymes which bind CaM at lower Ca
2+ concentrations and which 
retain activity in the absence of CaM (Daff et al., 2001). Two additional roles for the auto-
inhibitory insert in NOS regulation have been hypothesised: (i) that auto-inhibitory insert 
binds CaM and acts as a “mop” that inhibits CaM binding to the CaM- binding linker, (ii) that 
interaction of the auto-inhibitory insert with the FMN and the NADPH binding domains 
contributes to the locked electron-accepting position of the FMN domain (Garcin et al., 
2004). However, at elevated concentration of Ca
2+, CaM would bind to both the auto-
inhibitory insert and CaM-binding regions and release the FMN domain for the inter-module 
electron transfer. 
Regulatory C-terminal tail 
The NOS reductase domain ends in a C-terminal tail. It has a conserved Arg
1165 residue 
(eNOS), and a terminal phosphorylatable Ser
1177 (eNOS) residue. The Ser
1177 at the end of the 
C-terminal  α-helix is directed towards negatively charged FMN-binding domain residues 
Gln
685 and Asp
687 and locks the FMN binding domain in an electron accepting position (Fig. 
11) and prohibits intermodule electron transfer (Craig et al., 2002; Garcin et al., 2004). In the 
absence of CaM, ionic interaction between NADPH and Arg
1165 residue (eNOS) orient the C-
terminal tail in a negatively charged groove at the eNOS reductase domain, further stabilising 
the FMN lock (Daff, 2003). Thus, Ser
1177 phosphorylation, or mutation to Asp to mimic 
phosphoserine would induce a negative charge and repel negatively charged residues thereby 
destabilise and displace the regulatory C-terminal tail to relieve repression of NO synthesis.  Introduction 
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1.8  NOS uncoupling 
All of the NOS isoforms generate O2
- and hydrogen peroxide (H2O2) under specific 
conditions i.e., lower than optimal concentrations of the essential co-factor H4B (Xia et al., 
1998) or the substrate L-arginine (Xia et al., 1996). It is not clear yet whether H2O2 is a 
genuine product of uncoupling NOS catalysis or if H2O2 derives exclusively from the 
dismutation of O2
- (Vasquez-Vivar et al., 1999; Wei et al., 2001). 
The lack of H4B results in the uncoupling of eNOS, which basically means that the transport 
of electrons to ferrous-heme-O2 species generated during the stepwise activation of O2 by 
NOS, does not occur fast enough to prevent their oxidative decay; the result being the 
generation of reactive oxygen species (ROS) (Stuehr et al., 2001; Stuehr et al., 2004). The 
enhanced generation of O2
- is likely to result in the formation of peroxynitrite (ONOO
-), 
which may further enhance O2
- production by oxidation of the zinc thiolate (ZnS4) cluster 
within eNOS and dissociation of the functional dimer (Zou et al., 2002). Although eNOS 
uncoupling has been successfully reversed by enhancing cellular levels of H4B, either by 
using sepiapterin (Tiefenbacher et al., 1996), by preventing the oxidation of H4B (d'Uscio et 
al., 2003), or by endothelial cell-specific overexpression of the GTP-cyclohydrolase I (Alp et 
al., 2003; Alp et al., 2004) circumstantial evidence indicates that the association of Hsp90 
with eNOS,(Pritchard, Jr. et al., 2001) as well as eNOS phosphorylation, in particular on 
eNOS Thr
495 (Lin et al., 2003), can also affect the degree of coupling and the balance of 
NO/O2
- production.  
 
Figure 11. Regulatory action of eNOS 
C-terminal tail. Structure showing the 
interaction of the C-terminal tail of 
eNOS reductase domain with other 
residues leading to the locking of the 
FMN in the electron accepting position 
(see text for details). Modified from 
Garcin et.al, J Biol Chem 
2004;279:37918-37927.  
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1.9  Free radicals in the cardiovascular system 
Reactive oxygen species (ROS), such as O2
-, H2O2, ONOO
-, or lipid peroxides are produced 
by all living cells (Darley-Usmar & Halliwell, 1996). Circulating blood cells, such as 
neutrophils or macrophages, turn into significant sources of free radicals when activated 
(Beckman & Crow, 1993). The generation of free radicals is low under normal conditions and 
compensated by the action of antioxidative enzymes (superoxide dismutase, catalase) and 
biomolecules (ascorbate, glutathione). However, it has been shown that the endothelium can 
generate substantial amount of O2
-  (Britigan  et al., 1992; Rosen & Freeman, 1984), in 
particular following stimulation with cytokines (Bautista et al., 1991; Matsubara & Ziff, 
1986a), the activation of protein kinase C (PKC) (Fleming et al., 2005; Matsubara & Ziff, 
1986b) or an increase in [Ca
2+]i (Gryglewski et al., 2001; Holland et al., 1990). Both 
excessive production and diminished inactivation of O2
-, in combination with secondary 
reactions, are responsible for the development of oxidative stress in vivo and in vitro. The 
uncompensated generation of ROS/reactive nitrogen species causes modifications at various 
levels, including alterations in proteins, lipids, or DNA leading to cells damage and death. 
Thus high levels of free radicals have been connected with a series of degenerative processes, 
while low levels, found under physiological conditions, play key role in a variety of signalling 
cascades. 
1.9.1  Superoxide anion radical (O2
-) 
Superoxide is produced by the one-electron reduction of molecular oxygen. It is formed by 
enzymatic reactions during normal metabolism (as an intermediate of the respiratory chain), 
as a by-product of enzyme activity (xanthine oxidase, cyclooxygenase), or as part of the 
cellular defence mechanism (NADPH oxidase). Lately, eNOS has been identified as a 
potential source of O2
- as a result of the uncoupling of the flow of electrons to form NO under 
conditions of L-arginine (Xia et al., 1996) and/or H4B defiency (Xia et al., 1998). Like NO, 
O2
- is a free radical with a relatively low overall reactivity (compared to 
.OH) however, the 
negative charge of O2
- reduces its diffusion in comparison to NO. As shown for erythrocytes, 
the penetration of O2
- through biological membranes requires the presence of a transport 
mechanism, such as anion channels. 
1.9.2  Peroxynitrite 
Peroxynitrite (ONOO
-) is the product of the reaction between NO
  and O2
-. It is cell-
permeable, as well as being a potent and versatile oxidant that can attack a wide range of Introduction 
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biological molecules. The peroxynitrite anion is relatively stable under basic conditions but is 
protonated at physiological pH.  
Biological effects of ONOO
- 
NO reacts readily with O2
-, at close to diffusion- limited rate to produce ONOO
-. It acts as a 
powerful oxidant, but is sufficiently stable to diffuse through a cell to react with a target. 
Human tissues are continually exposed to a number of damaging ROS. As a strong oxidant 
and nitrating agent ONOO
- is more reactive and harmful than O2
- or H2O2. 
ONOO
- is particularly efficient at oxidizing iron-sulphur clusters, zinc-fingers, and protein 
thiols resulting in cellular energy depletion. ONOO
- also reacts with SOD to form a 
nitronium-like intermediate, which catalyses the 3-nitration of tyrosine residues, particularly 
those in cytoskeletal proteins. Although 3-nitrotyrosine can also be generated by sources other 
than ONOO
-,
 the accumulation of 3-nitrotyrosine-containing proteins, detected with antisera 
to 3-nitrotyrosine, is used as a marker to ONOO
- formation (Beckman & Koppenol, 1996). 
S-Nitrosylation 
In a cellular environment ONOO
- will react preferentially with free thiols because of the fast 
rate of this reaction and the high intracellular thiol concentration. Glutathione, one of the most 
important antioxidants is the predominant source of intracellular thiol, and protect cells 
against ONOO
--induced cytotoxicity. S-glutathiolation by ONOO
- activates the 
sarco/endoplasminc reticulum calcium ATPase to decrease intracellular Ca
2+ concentration 
and relax cardiac, skeletal and vascular smooth muscle (Adachi et al., 2004). NO- mediated 
S-nitrosylation of cysteine residues is reportedly linked to eNOS monomerisation and a 
decrease in enzyme activity (Ravi et al., 2004). 
Tyrosine nitration 
One of the effects of ONOO
- on proteins is nitration of tyrosine residues. Tyrosine 
phosphorylation of enzymes is a common mechanism mediating cellular signalling. In 
endothelial cells tyrosine nitration inhibits tyrosine phosphorylation and causes for example 
accelerated endothelial cell apoptosis via tyrosine nitration of the phosphatidylinositol 3-
kinase (PI 3-kinase), inhibiting activity of Akt-1 kinase and increasing the activity of p38 
MAP kinase (el Remessy et al., 2005). ONOO
- derived nitrated tyrosine has also been found 
in inflammatory cells in the atherosclerotic human artery, macrophages-derived foam cells, 
and human platelets.  Introduction 
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Oxidation of low density lipoprotein 
An increase in oxidized low- density lipoproteins (ox-LDL) is associated with coronary artery 
disease.
  Circulating ox-LDL
  originates from mild oxidation of LDL in the arterial wall. 
Oxidized
 LDL induces atherosclerosis by stimulating monocyte infiltration leading to their 
differentiation into macrophages
  and by stimulating smooth muscle cell migration and 
proliferation. It contributes
 to atherothrombosis by inducing endothelial cell apoptosis, and
 
thus plaque erosion, by impairing the anticoagulant balance
 in endothelium, stimulating tissue 
factor production by smooth
 muscle cells and inducing apoptosis in macrophages (Mertens & 
Holvoet, 2001). 
Peroxynitrite- mediated formation of ox-LDL was demonstrated by treating LDL with SIN-1 
(which simultaneously produces NO and O2
- resulting in ONOO
- formation) which resulted in 
accelerated ox-LDL formation (Darley-Usmar et al., 1992; Patel et al., 2000). Treatment of 
LDL with authentic ONOO
- results in the depletion of antioxidants and the formation of both 
lipid hydroperoxidase- and thiobarbituric acid- reactive substances, indicative of lipid 
peroxidation (Darley-Usmar et al., 1992).  
1.10  Measurement of NO 
The study of NO in biological systems is complicated by the low biologically active 
concentrations of NO (in the nanomolar range) and its short half-life due to the fast 
interaction with ROS or proteins and thiols. While a number of methods have been used to 
assess NO concentrations, most of them are based on the detection of NO metabolites or 
coproducts (Archer, 1993). The consequences are both the loss of specificity and the inability 
to resolve temporal changes in the release of authentic NO. The most commonly used assay is 
the measurement of nitrite and nitrate by Griess reaction (Bender et al., 1999; Ignarro et al., 
1987). Although measurement of nitrite and nitrate offers a simple way to indirectly reflect 
NO formation, the specificity of this assay has been a major concern because nitrite and 
nitrate may arise from a number of sources in biological systems (Archer, 1993). The 
detection of the NO coproduct, L-citrulline, is indeed specific, but it does not afford a direct 
visualization of NO generation by NOS enzymes. 
Spin trapping of free radicals in combination with electron spin resonance (ESR) 
spectroscopy is a well-documented approach to characterize free radicals, including NO and 
O2
-. The spin trapping of NO with a Fe(DETC)2  complex, which has been reported to 
specifically trap NO (Kleschyov et al., 2000; Mülsch et al., 1995) results in the formation of a Introduction 
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paramagnetic NO-Fe
2+ mononitrosyl iron complex (MNIC) which is detected by ESR 
spectroscopy. So far, ESR remains the most unambiguous technique in free radical detection.  
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2  Aim 
 
The objective of this thesis was to identify eNOS residues whose phospho-status would 
regulate the activity of eNOS with emphasis being placed on identifying the phospo-switch 
that would convert eNOS from a NO generating enzyme to a O2
- generating enzyme. 
Identification of the role of eNOS tyrosine phosphorylation and the residue(s) involved on the 
regulation of eNOS activity.  
Work began by assessing serine and threonine phosphorylation and has culminated with a 
reassessment of the role of tyrosine phosphorylation in the regulation of eNOS. 
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3  Materials and methods: 
 
3.1  Bacterial transformation  
3.1.1  Preparation of competent cells by KCM method. 
From a single colony, preculture of the desired E. coli strain(DH5α, JM109, XL-1Blue) in a 5 
mL Luria-Bertani (LB) medium (10 g/L Bactotrypton, 5 g/L Yeast extract, 10g/L NaCl 
pH7.0) without antibiotic was obtained. 1 mL of the overnight culture was added into 100 mL 
of LB medium and incubated in a shaker (250 rpm) at 37°C till a OD600 of 0.5-0.6 was 
obtained. The culture was chilled on ice for 5 min and cell pellet obtained by centrifugation at 
2500g for 15 minutes at 4°C. The bacteria were resuspended in 7.5 mL of TSB (5% v/v 
DMSO, 10 mmol/L MgCl2, 10 mmoL/L MgSO4, 10% w/v PEG 6000 in LB medium) and 
incubated on ice for 1 hour. 100 µL aliquots of competent cells were distributed into pre-
cooled tubes and immediately frozen in liquid nitrogen and stored at –80°C.  
3.1.2  Transformation 
An aliquot of 100 µL was thawed on ice. Transformation mix was prepared with 20 µL 5X 
KCM (500 mmol/L KCl, 150 mmoL/L CaCl2, 250 mmoL/L MgCl2), 80 µL sterile water and 
DNA. The transformation mix was added to the competent cells and incubated on ice for 20 
min, followed by 10 minutes at room temperature. 1 mL of pre warmed LB medium was 
added and incubated at 37°C for 1 hour. The bacteria were collected by centrifugation (2000 
g, 5 minutes at room temperature). The supernatant was partially removed and the pellet was 
resuspended in the residual LB medium and spread on a LB agar plate with appropriate 
antibiotic and incubated overnight at 37°C. 
 
3.2  Isolation of nucleic acids 
3.2.1  Mini plasmid DNA preparation by alkaline lysis method 
Recombinant E. coli were grown in a 3 mL Luria-Bertani (LB) medium (10 g/L bactotrypton, 
5 g/L yeast extract, 10g/L NaCl pH 7.0) containing an appropriate antibiotic overnight (at 
least 16 hrs). The cells were harvested by centrifugation at 10000g for 5 minutes at room 
temperature. The pellet was resuspended in 250 µL of resuspension buffer (50 mmol/L 
Tris/HCl pH 8.0, 10 mmol/L EDTA and 100 µg/mL RNase A) for 5 minutes at room 
temperature followed by lysis with 250 µL freshly prepared lysis buffer (0.2 mol/L NaOH, Materials and methods 
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1%SDS), the contents of the tube were mixed gently and incubated for 5-10 minutes. 300µL 
of neutralization buffer (3.0 mol/L potassium acetate, pH 5.5) was added, mixed gently 
without vortexing and incubated on ice for 15 minutes. The tubes were centrifuged at 10000 g 
for 15 minutes at 4°C. The supernatant containing the plasmid was transferred to a fresh tube 
and the plasmid DNA was precipitated by addition of 600 µL of isopropanol and incubated at 
–20°C for 30 minutes. Precipitated DNA was sedimented by centrifugation at 10000 g for 15 
minutes at 4°C. The DNA sediment was washed with 70% ethanol, air dried and dissolved in 
the 50 µL TE buffer (10 mmol/L Tris/HCl pH 8, 0.1 mmol/L EDTA). 
3.2.2  Maxi plasmid DNA preparation  
Cell culture experiments and sequencing reactions require DNA of high purity. To obtain 
large amount of highly purified plasmid DNA, commercially available kits from QIAGEN 
(Düsseldorf, Germany) were used. The DNA isolation was performed according to the 
manufacturer’s instructions using a 400 mL overnight bacterial culture. 
3.2.3  DNA extraction from agarose gels  
After restriction digestion, the DNA fragment of interest was isolated by agarose gel 
extraction and purification using gel extraction kit from QIAGEN (Düsseldorf, Germany). 
After fractionating the digested DNA on agarose gel, the DNA was stained using ethidium 
bromide solution (0.5 µg/mL) for 20 min. The DNA band was visualized using a UV (315 
nm) transilluminator and the fragment of interest was excised using a scalpel. The DNA was 
then extracted according to the manufacturer’s protocol. 
3.2.4  RNA isolation  
For the isolation of total RNA from cultured cells expressing eNOS, a mixture of guanidine 
thiocyanate and phenol in a mono-phase solution (TRI reagent, Sigma, Germany) was used. 
Cells were lysed with TRI reagent (350 µL per 3.5 cm culture plate). After incubation of the 
lysate for 5 minutes at room temperature, 70 µL of chloroform was added and the mixture 
was vortexed thoroughly and incubated for further 15 minutes at room temperature. For the 
separation of the phenol and aqueous phase the extracts were centrifuged (12000 g, 15 
minutes, 4°C). The upper aqueous phase containing RNA was recovered and was precipitated 
by the addition of 175 µL isopropanol. After vortexing and incubation for 10 minutes at room 
temperature the tubes were centrifuged (12000 g, 15 minutes, 4°C). The RNA sediment was 
washed with 600 µL of 70% ethanol air dried and dissolved in an appropriate volume of 
diethylpyrocarbonate (DEPC) treated water.  Materials and methods 
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3.2.5  Purification of DNA by phenol chloroform isoamyl alcohol extraction and ethanol 
precipitation  
Purification of nucleic acid following restriction digestion was performed by phenol 
chloroform isoamyl alcohol extraction. An equal volume of TE-saturated phenol was added to 
the DNA diluted in water (400 µL). The mixture was vortexed thoroughly, and then 
centrifuged (5 minutes, 10000 g, room temperature) for phase separation. The upper, aqueous 
phase containing the plasmid DNA was transferred into a new microcentrifuge tube and was 
subjected to two rounds of chloroform/isoamyl alcohol (24:1) extraction to remove residual 
phenol. The upper aqueous phase was then collected in a separate tube, and precipitated by 
the addition of 1/10
th volume of sodium acetate solution (3 mol/L pH5.2) and 2.5 volumes of 
100% ethanol. The suspension was mixed by vortexing and then incubated overnight at -20°C 
or at –80°C for 3 hours. Precipitated DNA was collected by centrifugation (15 minutes, 10000 
g, 4°C) and washed with 70% ethanol. The DNA sediment was air dried and dissolved in an 
appropriate volume (25 µL) of TE buffer.  
3.3  Manipulation of nucleic acids 
3.3.1  Restriction digestion 
The cleavage of double-stranded DNA molecules by restriction endonucleases was performed 
by incubating an appropriate amount of DNA with the restriction enzyme in the specific 
buffer and under the conditions recommended by the supplier. A typical digestion reaction 
included one unit of enzyme per µg of DNA and incubation for 1-3 hours (in case of cleavage 
of DNA from a mini-preparation) to overnight (in case of DNA from maxi plasmid 
preparation) at 37°C. 
3.3.2  Dephosphorylation of linearised double-stranded DNA 
To inhibit the self ligation of the vector during cloning, linearised vectors were treated with 
CIP (calf intestinal alkaline phosphatase; Amersham Pharmacia, Freiberg, Germany) to 
remove the 5' phosphate of the double stranded DNA molecules. Reaction mixtures contained 
1µg linearised DNA, in 50 mmol/L Tris/HCl, pH9.0, 10 mmol/L MgCl2, 0.1U/reaction 
diluted CIP in a suitable volume. The above mentioned reaction mixture was incubated at 
37°C for 1 hour, followed by heat inactivation of the alkaline phosphatase (85°C; 15 minutes) 
and phenol chloroform isoamyl alcohol extraction with subsequent ethanol precipitation. The 
DNA sediment was dissolved in sterile water. Materials and methods 
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A control ligation of the dephosphorylated and phosphorylated vectors was performed and 
following transformation checked for the efficiency of dephosphorylation. Few or no colonies 
are indicative of an efficient dephosphorylation reaction.  
3.3.3  Large fragment of the E.coli DNA polymerase I (Klenow fragment):  
The Klenow polymerase was used to modify 3' or 5' overhangs into blunt ends. The Klenow 
fragment possesses a 3' to 5' exonuclease as well as a 5' to 3' polymerase activity. A typical 
reaction mixture contained, 5 µg linearised DNA in 10 mmol/L Tris/HCl, 50 mmol/L NaCl, 
10 mmol/L MgCl2,1 mmol/L dithiothreitol pH 7.9, 0.4 mmol/L dNTPs and 3 U/reaction 
Klenow enzyme (New England Biolabs, Frankfurt am Main, Germany) in a final volume of 
100 µL. After incubation at 37°C for 30 min the reaction was stopped by phenol chloroform 
isoamyl alcohol extraction and the DNA was concentrated by ethanol precipitation. The DNA 
pellet was dissolved in an appropriate amount of sterile water.  
3.3.4  DNA ligation  
Ligation of vector and inserts was performed using T4 DNA ligase. For blunt end ligation, the 
amount of insert was at least five times in molar excess over the vector. A typical reaction 
mixture for blunt end ligation contained the vector and insert in 50 mmol/L Tris/HCl (pH 
7.6), 10 mmol/L MgCl2 , 0.5 mmol/L ATP, 0.5 mmol/L DTT, 5% (w/v) polyethylene glycol-
8000 and 3 units of T4 DNA ligase enzyme (Invitrogen, Karlsruhe, Germany), in a total 
volume of 15 µL. The reaction mixture was incubated at room temperature for 16 to 20 hours. 
5 µL of the ligation mix was used for transformation. 
3.3.5  Site directed mutagenesis 
The eNOS-Ser mutants were produced using polymerase chain reaction-based QuickChange 
XL site directed mutagenesis kit (Stratagene) and the human eNOS wild-type cDNA as 
template. A pair of primers; forward and reverse containing the mutation of Ser
114 to D (GAT) 
or A (GCA) and Ser
633/634 (TCC/AGT) to A (GCC/GCT) were used.  
Forward S114A: 5’ CTA CAG GGC CGG CCC GCA CCC GGC CCC 3’ 
Forward S114D: 5’CTA CAG GGC CGG CCC GAT CCC GGC CCC 3’ 
Reverse S114A: 5’GGG GCC GGG TGC GGG CCG GCC CTG TAG3’ 
Reverse S114D: 5’GGG GCC GGG ATC GGG CCG GCC CTG TAG3’ 
Forward S633/634A: 5’CGG AAG AGG AAG GAG GCC GCT AAC ACA GAC AGT 
GCA GGG 3’ Materials and methods 
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Reverse S633/634A: 5’CCC TGC ACT GTC TGT GTT AGC GGC CTC CTT CCT CTT 
CCG 3’ 
The oligonucleotides were synthesized by Biospring (Frankfurt, Germany) 
The PCR reaction mix contained 1X reaction buffer, dNTP mix (0.2 mmol/L), quick solution 
and 2.5 U Pfu turbo polymerase provided with the kit along with eNOS wild-type cDNA; 50 
ng, primers; forward and reverse-125 ng each in a final volume of 50µL. The PCR was set up 
in a Robo- Cycler (Strategene) with the following cycle conditions. 
Reaction Buffer: 
 1 X Reaction buffer: 10 mmol/L KCl, 10 mmol/L (NH4)2SO4, 20 mmol/L Tris-HCl- pH 8.8, 
2 mM MgSO4, 0.1% Trition X-100 and 10% nuclease-free bovine serum albumine (BSA) 
1 cycle   : 95°C for 1 minute 
18 cycles  : 95°C for 1 minute, 54°C for 1 minute and 68°C 20 minutes 
1 cycle   : 68°C for 10 minutes 
After completion of the reaction, the PCR reaction mix was subjected to Dpn I (10 U) 
restriction digestion at 37°C for 60 minutes, to degrade the methylated of parental plasmid 
DNA. 10 µL of DpnI digested DNA was transformed in XL-10 competent cells and positive 
clones were identified by sequencing of DNA.  
3.3.6  Sequencing of DNA  
To sequence a recombinant vector, the plasmid DNA was column purified and 2 µg DNA in 
20 µl TE was sent to MWG Biotech (Ebersberg, Germany) for sequencing. 
 
3.4  Detection of nucleic acids 
3.4.1  Colony hybridisation using a 
32P-radiolabelled probe 
Colony hybridisation with a 
32P-labelled DNA fragment was used to identify positive 
recombinant clones. Following transformation bacterial colonies grown on an agar plate were 
transferred to a Nytran N nylon transfer membrane, (Schleicher and Schuell GmbH, 
Germany) by spot blotting (i.e. placing the membrane directly onto the plate). The membrane 
was labelled and its orientation on the plate was carefully marked with a needle through the 
filter into the agar. The colonies were lysed by placing the nylon membrane onto filter paper 
soaked with 2% SDS for 2 minutes, followed by denaturation of the DNA double strands, on Materials and methods 
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a filter paper soaked with 0.5 mol/L NaOH and 1.5 mol/L NaCl for 2 minutes, followed by 
neutralization in 0.5 mol/L Tris-HCl pH 8.0 and 1.5 mol/L NaCl for 5 to 10 minutes. The 
DNA was fixed on the membrane by baking for 2 hours at 80°C. The membrane was then 
transferred to hybridisation vials and treated with 15 mL of prehybridization solution 
containing formamide (50% v/v), 5X SSPE (750 mmol/L NaCl, 0.05 mol/L NaH2PO4, 0.05 
mol/L EDTA Ca
2+free); 70 µg/mL denatured herring sperm DNA (which binds to the DNA 
non-specifically and inhibit non-specific signal on autoradiogram after hybridisation), 5X 
Denhardt’s solution (0.5% ficoll, 45 mmol/L polyvinylpyrrolidone, 0.5% BSA) and 0.2% 
SDS on a rotating wheel at 42°C for 2 hours. The prehybridization solution was replaced by 
the hybridisation solution containing heat denatured radiolabelled DNA probe and incubated 
for 16 hours at 42°C. The hybridisation solution was removed and the filters were washed 
twice for 15 minutes at room temperature in Buffer A (6X SSPE, 0.1% SDS) and twice in 
buffer B for 30 minutes at 55°C (1X SSPE, 0.1% SDS). Specifically bound radioactivity was 
detected by autoradiography (FUJIFILM medical X-ray film, Tokyo, Japan). 
3.4.2  Southern blot hybridisation  
Confirmation of the orientation of the gene of interest (insert) in the clones was performed by 
restriction digestion and subsequent Southern blot hydridisation with a specific radiolabelled 
DNA against the insert. The size fractionated double stranded DNA was denatured by soaking 
the gel in a denaturing solution (0.5 mol/L NaOH and 1.5 mol/L NaCl) for 15 to 30 minutes at 
room temperature followed by 15 minutes incubation in the neutralization solution (0.5 mol/L 
Tris/HCl, pH 8.0 and 1.5 mol/L NaCl). The DNA was then transferred onto a positively 
charged nylon membrane (Porablot, Düren, Germany) via upward capillary transfer. The gel 
was placed on a filter paper soaked with 10X SSC (1.5 mol/L NaCl, 0.4 mol/L sodium citrate 
pH 7.0 with 10N NaOH) and the ends of the filter paper were connected to a reservoir of 10X 
SSC. The membrane was placed on top of the gel with 2 sheets of filter paper and a stack of 
paper towels on top of it to facilitate the overnight (16 hours) transfer of DNA to the 
membrane by capillary flow. To immobilise the DNA on the membrane it was cross-linked 
using UV light (215 nm, 2 minutes) and incubated at 80°C for 2 hours. The membrane was 
then placed in the hybridisation vials and the hybridisation as well as the detection of the 
radioactivity was performed as described above. 
3.4.3  Northern blotting and hybridisation  
After isolation of total RNA, 5 µg of RNA was mixed with 5µL RNA pre mix buffer 
containing 20 mmol/L deionised formamide, 40 mmol/L 3-(N-morpholino) propanesulfonic Materials and methods 
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acid (pH 7.0 adjusted with acetic acid), 10 mmol/L sodium acetate and 1 mmol/L EDTA, and 
0.5 µg/mL ethidium bromide. This RNA mixture was heated to 65°C for 10 minutes and 
separated by electrophoresis on denaturing formaldehyde agarose gel containing 1% agarose 
(agarose was dissolved by boiling in DEPC water, the temperature was brought down to 50-
60°C and then 12.3 mol/L formaldehyde was added). Finally 1/10
th volume of running buffer 
MOPS was added and poured in the gel plate. RNA bands were separated in RNA running 
buffer (40 mmol/L MOPS, 10 mmol/L Na-acetate, 1 mmol/L EDTA, pH 7.0). Under a UV-
lamp (at 315nm) 28S, and 18S ribosomal RNA (the ratio of the band intensity of 28S and 18S 
RNA should be 2:1) were visualised. The RNA was then transferred onto a positively charged 
nylon membrane via upward capillary transfer, as described above but with 20X SSC (3 
mol/L NaCl, 250 mmol/L sodium citrate pH 7.0 adjusted with 10 N NaOH) as transfer buffer. 
The hybridisation and the detection of the radioactivity were performed as described above. 
 
3.5  Cell culture and adenoviral methods 
3.5.1  Generation of eNOS adenoviruses 
Construction of recombinant adenoviruses with eNOS mutants was performed as described 
(Fleming et al., 2005).  
Briefly, the full-length, myc/his-tagged eNOS wild-type and mutant cDNA inserts (~ 3.6 kb) 
were excised from pcDNA3.1 myc/his with sequential digestion using HindIII and PmeI in a 
total volume of 50 µg using 5 µg DNA. The DNA fragment of interest was purified by gel 
purification using a gel extraction kit from QIAGEN (Düsseldorf, Germany). The overhangs 
of the inserts were blunted by the large fragment of E. coli DNA polymerase I (Klenow 
fragment) and ligated into linearized and dephosphorylated EcoRV adenoviral shuttle vectors, 
pAd-Track-CMV and pAdShuttle-CMV (kindly provided by Bert Vogelstein, Howard 
Hughes Medical Institute, Baltimore, MD). The plasmids were recombined into the 
adenovirus 5 genome by homologous recombination in E. coli. Briefly, the shuttle vectors 
carrying the eNOS cDNAs were linearized with the restriction endonuclease PmeI, purified 
by phenol/chloroform extraction and ethanol precipitation. These vectors were used to 
transform the recombination positive E. coli strain BJ5183 carrying the plasmid pAdEasy-1. 
The resulting recombinant plasmids conferred resistance to kanamycin (70 µg/mL), and 
plasmids from antibiotic-resistant colonies were isolated and analyzed for eNOS by restriction 
digestion with KpnI/HindIII. Positive plasmids were transformed into E. coli JM109 for large-
scale isolation. Following linearization with PacI and extraction with phenol/chloroform and Materials and methods 
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ethanol precipitation, plasmids were transfected into HEK 293 cells (American Type Culture 
Collection). Transfected cells were incubated for up to 2 weeks and monitored for GFP 
expression (for inserts in pAdTrack-CMV) and plaque appearance. Viruses were obtained 
from these cells and infected into fresh HEK 293 cells for amplification and to confirm 
expression of mRNA and protein. Constructs that expressed eNOS mRNA (detected by 
Northern blotting) were screened for eNOS protein. Only one orientation (sense) resulted in 
increased protein expression. For large scale amplification and purification, five T175 flasks 
of 90% confluent HEK cells were infected with the viruses. The virus particles were purified 
using the BD Adeno-X Virus purification kit (BD Biosciences, Heidelberg, Germany) 
according to the manufacturer’s instructions. The resulting titre of each preparation was 
approximately 10
9 plaque forming unit (PFU)/mL. 
3.5.2  Culturing of cells 
Human umbilical vein endothelial cells (HUVEC) were isolated from fresh umbilical vein 
using dispase as described (Popp et al., 1996) and cultured in growth medium, a 1:1 mixture 
of MCDB 131 (Invitrogen, Karlsruhe, Germany) and M199 (PAA laboratory, Pasching, 
Austria) containing 14% fetal calf serum (FCS), epidermal growth factor (EFG; 0.05 ng/mL), 
basic fibroblast growth factor (bFGF; 0.5 ng/mL), endothelial cell growth supplement (1.5 
mg/mL), heparin (22.5 mg/mL), penicillin (50 U/mL) and streptomycin (50 µg/mL). All 
experiments were performed with cells of passage one.  
Porcine aortic endothelial cells (PAEC) were isolated from fresh porcine aorta using dispase 
and cultured in growth medium, a 1:1 mixture of MCDB 131 (Invitrogen, Karlsruhe, 
Germany) and M199 (PAA laboratory, Pasching, Austria) containing 14% FCS, EGF (0.05 
ng/mL), bFGF(0.5 ng/mL), endothelial cell growth supplement (1.5 mg/mL), heparin (22.5 
mg/mL), penicillin (50 U/mL) and streptomycin (50 µg/mL). 
3.5.3  Transfection with calcium choloride  
HEK 293 cells cultured in 6 cm dishs, were grown in minimal essential medium (MEM) 
supplemented with EARLE’s salts, containing 8% FCS, 50 µg/mL gentamycin, 1% non-
essential amino acids and 1 mmol/L sodium pyruvate. At 70-80% confluence cells were 
incubated with a transfection mix containing the desired plasmid (5µg DNA, 0.126 mol/L 
CaCl2 and 500µL 2X HEPES buffer saline; HBS, in a total volume of 1 mL). After 4 hours 
the transfection mix was removed and subjected to glycerol shock for 60 seconds, with 15% 
glycerol in HBS to facilitate the uptake of DNA. The cells were washed with PBS and 
incubated in fresh growth medium for 48 hours.  Materials and methods 
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3.5.4  Adenoviral infection of COS-7 cells 
COS-7 cells cultured in 6 cm dishes, were grown in MEM supplemented with EARLE’s salts, 
containing 8% FCS, 50 µg/mL gentamycin, 1% non-essential amino acids and 1mmol/L 
sodium pyruvate. At 70-80% confluence, cells were serum-starved (medium containing 0.1% 
BSA) for 4 hours. Infection with recombinant adenoviruses expressing human wild-type 
eNOS or the T495A, T495D, S114A, S114D, S633D or T495A/S1177D eNOS mutants (2 
PFU/cell, in 1 mL medium with 0.1% BSA per 6 cm dish) was for 4 hours followed by 
addition of 2 mL growth medium and further incubated for 48 hours. 
3.5.5  Adenoviral infection of human umbilical vein endothelial cells 
For the infection of endothelial cell, the cells were serum-starved (medium containing 0.1% 
BSA) for 16 hours. Infection with recombinant adenoviruses expressing human eNOS wild-
type or the T495A, T495D, S114A, S114D, S633D or T495A/S1177D eNOS mutants (2 
PFU/cell, in 1 mL medium with 0.1% BSA per 6 cm dish) was for 4 hours followed by 
addition of 2 mL growth medium with 1% FCS and further incubation for 48 hours.  
3.5.6  Ox-LDL treatment 
Confluent cultures of human endothelial cells, were serum-starved (medium containing 0.1% 
BSA) for 24 hours followed by the addition of required concentration of ox-LDL (30 µg/mL, 
unless mentioned otherwise) and incubated for the indicated period of time.  
3.5.7  Stimulation with bradykinin 
Confluent cultures of porcine endothelial cells, were serum-starved (medium containing 0.1% 
BSA) for overnight (~ 16 hours). The cells were then stimulated with bradykinin (1 µmol/L) 
for different time points (10 seconds to 5 minutes). The cells were quickly washed with ice 
cold phosphate buffer saline (PBS) and drained and frozen in liquid nitrogen. 
3.6  Immunohistochemistry 
Human endothelial cells were infected with different eNOS mutants and after 48 hours of 
protein expression used for immunohistochemistry. The cells were fixed in 4% 
paraformaldehyde in PBS for 10 minutes, followed by incubation with glycine (2%) in PBS 
and permeabilized with Triton X-100 (0.05%) in PBS for 10 minutes each. Each step was 
followed by washing the cells 3 times with PBS for 3 minutes. The cells were then blocked 
with 3% BSA in PBS for 60 minutes and followed by incubation with a specific myc 
monoclonal (Santa Cruz Biotech, Heidelberg, Germany) and β-catenin polyclonal (Santa Cruz 
Biotech) antibodies (1:200 dilution) overnight at 4°C. The cells were washed at least 3 times Materials and methods 
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with PBS (with 0.2% Tween) and then incubated with Alexa dye-coupled secondary 
antibodies for 1 hour at room temperature. The cells were again washed with PBS (containing 
0.2% Tween) 3 times and were mounted in antifade (Molecular probes, Karlsruhe, Germany) 
or Dako-Fluoromount (Dako, Hamburg, Germany). Co-localisation studies were carried out 
using a Zeiss laser-scanning confocal microscope LSM 510 META in multi-tracking mode to 
prevent interference of the dyes.  
 
3.7  Methods with protein 
3.7.1  Isolation of protein 
Cells expressing the protein of interest were lysed with Triton X-100 lysis buffer containing 
NaF (100 mmol/L), Na4P2O7 (15 mmol/L), Na3VO4 (2 mmol/L), leupeptin (2 µg/mL), 
pepstatin A (2 µg/mL), trypsin inhibitor (10 µg/mL), PMSF (44 µg/mL) and Triton X-100 
(1% vol/vol). The sample was collected in 1.5 mL tubes and incubated on ice for 10 minutes. 
The lysate was centrifuged at 12,000 g (4°C for 10 minutes) and the supernatant was 
transferred into a fresh tube. The concentration of the proteins was determined at 570 nm 
using Bradford reagent. 
3.7.2  Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blotting 
Proteins were analysis using SDS-PAGE and Western blotting. Protein extracts (20-50 µg) 
per samples were denatured by heating in Laemmli buffer (7.3% w/v SDS, 29.1% v/v 
glycerol, 83.3 mmol/L Tris with bromophenol blue) at 95°C for 5 minutes and separated by 
SDS-PAGE. The proteins were then subjected to electrophoresis (running buffer: 190 mmol 
glycine, 0.1% SDS and 25 mM Tris-HCl) and resolved for about 2 hours with approximately 
35 mA/gel. 
Western blotting was performed using the tank blot technique onto nitrocellulose membranes 
(Bio rad, Munchen, Germany) for 90 minutes, in transfer buffer ( 190 mmol/L glycine, 25 
mmol/L Tris-HCl and 20% methanol) with 250 mA per apparatus (two gels). The 
nitrocellulose membranes were stained with Ponceau S to determine the quality of transfer 
and equal loading of the protein. After destaining with distilled water the membranes were 
blocked in Tris buffer saline(TBS, 150 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.5) 
containing 3% BSA and 0.03% Tween-20 for 1 hour at room temperature. The membranes 
were incubated with the primary antibody (routinely diluted 1:1000) in TBS containing 3% Materials and methods 
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BSA and 0.03% Tween-20 overnight at 4°C. The membranes were then washed in TBS with 
0.03% Tween-20 for 30 minutes at an interval of 5 minutes. The membranes were blocked 
again for 1 hour. The secondary antibody coupled to horse-radish-peroxidase (HRP, 1:20000 
TBS/0.03% Tween-20) was incubated with the membrane for 1 hour at room temperature and 
washed again. The protein were visualised on X-ray film by enhanced chemiluminescence 
solution (ECL, Amersham Pharmacia, Freiberg, Germany).  
3.7.3  Low temperature- polyacrylamide gel electrophoresis (LT-PAGE) 
SDS-resistant eNOS dimers and monomers were assayed using LT-PAGE. Protein extracts 
(20 µg) in Laemmli buffer with or without 2.5% β-mercaptoethanol or heating at 95°C were 
subjected to PAGE at 4°C and with constant current of 30 mA per apparatus. Western blotting 
was performed as described earlier. Fresh protein samples were used exclusively as freeze 
thawing disrupted the eNOS dimer. 
3.7.4  Immunoprecipitation 
Immunoprecipitation (IP) is employed to isolated protein of interest using a specific antibody 
which is subsequently pulled down using protein A/G Sepharose beads.  
Endothelial cells were lysed in 1% Triton lysis buffer, and incubated on ice for 10 minutes. 
The lysate was centrifuged at 12,000 g (4°C for 10 min) and the supernatant was transferred 
into a fresh tube. All subsequent steps were performed at 4°C. Cell extract (50µl) was kept 
aside to check for total expression of the protein of interest and the rest volume was used for 
immunoprecipitation. The cell lysate (300 µg) was subjected to preclearing with 60 µl protein 
A/G Sepharose beads (Santa Cruz Biotechnology,Heidelberg, Germany) without a primary 
antibody and incubated with the sample for 1 hour at 4°C on a rotating wheel. The preclearing 
step, allows the clearing of the lysate of non-specific protein binding to the sepharose. The 
supernatant of the preclearing was used for immunoprecipitation with the specific antibodies. 
For this, 2 µg of the antibody of interest was added to the lysate. The mixture was agitated on 
a spinning wheel in tubes at 4°C, for 2 hours. Then 60 µl of protein A/G Sepharose beads 
were added and incubated with the sample for 1 hour on a rotating wheel at 4°C. The complex 
of antigen, antibody and sepharose was than isolated via multiple centrifugation at 12 000 g 
(4°C for, 10 minutes) and washing with 1% Triton lysis buffer. Finally, 60 µl of Laemmli 
buffer were added and the protein denatured at 95°C for 5 minutes. After centrifugation for 1 
minute in a microfuge at 10 000g, the supernatants were separated by SDS-PAGE and 
Western blotting. Materials and methods 
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3.7.5  Reproducing Western blots 
To strip antibodies from the bolts, stripping buffer (Tris-HCl; 67.5 mmol/L, pH 6.8,and SDS, 
2%) was prewarmed (10 mL per blot) at 50°C. Membranes were added along with 70 µL β- 
mercaptoethanol (0.7% v/v) and incubated for 30 minutes at 50°C under gentle agitation. The 
buffer was decanted and membranes washed thoroughly in TBS with 0.03% Tween-20. The 
membranes were then blocked in TBS containing 3% BSA and 0.03% Tween-20 and 
incubated with specific antibody of interest and processed as described above. 
 
3.8  Assays of eNOS activity, NO and O2
- detection. 
3.8.1  Citrulline assay: 
A standard method for determining the enzymatic activity of NOS is based on determining the 
conversion of radiolabeled L-arginine to L-citrulline. In principle, radiolabelled L-arginine is 
converted by NOS to L-citrulline and separated by trapping the positively charged L-arginine 
on dowex, while the neutral L-citrulline (at pH 5.5), remains in the supernatant. The 
radioactivity in the supernatant gives a direct measure of NOS activity. 
With cell lysate 
The activity of the different eNOS mutants was monitored by conversion of [³H]L-arginine to 
[³H]L-citrulline. HEK 293 cells overexpressing eNOS wild-type or mutants were lysed in 
Triton X-100 lysis buffer and protein extracted as described above. 100 µg of total protein 
was used per assay reaction and was diluted in a total volume of 180 µL of activity assay 
buffer containing (in mmol/L: NADPH 1.0, 6R-H4B 0.015, CaM 0.001, FAD 0.001, HEPES 
50.0 in pH 7.4, DTT 1.0, EDTA 1.0, orthovanadate 2.0, and CaCl2 2.5). All of the reaction 
samples were kept on ice, the reaction was initiated by the addition of 20 µL [³H]L-arginine 
(0.5 µmol/L, 0.5 µCi) and incubation at 37 °C for 30 min. The incubations were terminated by 
the addition of 1000 µL ice-cold HEPES buffer (100 mmol/L, pH 5.5) containing EGTA (10 
mmol/L) and 500 mg Dowex AG 50 W-X8 (counter-ion Na
+ form) cation exchange resin and 
incubated for 5 minutes on ice. The samples were centrifuged (4000 rpm at 4°C). To 5 mL 
scintillation fluid, 500 µL of supernatant was added and [³H]L-citrulline in the supernatant 
was quantified using a liquid scintillation counting. The specific activity of eNOS was 
calculated as the N-nitro-L-arginine sensitive formation of [³H]L-citrulline. Materials and methods 
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With 100000 g pellet 
Transfected HEK 293 cells in 10 cm dishes overexpressing recombinant eNOS protein were 
washed twice with PBS and scrapped in 800 µL sterile double distilled water. The cells were 
subjected to 5 cycles of freeze thawing at 40°C, followed by addition of 1 mL 2X 
homogenization buffer I (homogenization buffer I:Tris-HCl; 50 mmol/L, pH 7.4, KCl; 1.15% 
w/v, EDTA; 1 mmol/L, glucose; 5 mmol/L, DTT;0.1 mmol/L, SOD; 200 U/mL, leupeptin; 2 
µg/mL, pepstatin A; 2 µg/mL, trypsin inhibitor; 10 µg/mL, PMSF; 44 mg/L). The cellular 
debris was pelleted by centrifugation at 4000 rpm for 10 min at 4°C. The supernatant with the 
membrane fraction was subjected to ultra centrifugation at 35000 rpm (100000 g), for 1 hour 
at 4°C. The pellet was resuspended in 200 µL of 1X homogenization buffer II (2X 
homogenization buffer II: Tris-HCl; 50 mmol/L, pH 7.4, glycerin; 10% v/v, 0.1 mmol/L 
EDTA, leupeptin; 2 µg/mL, pepstatin A; 2 µg/mL, trypsin inhibitor; 10 µg/mL, PMSF; 44 
mg/L) and 50 µL was used per reaction and the assay was performed as described above with 
varying concentration of Ca
2+ and calmodulin. 
In vivo on intact cells: 
Transfected HEK 293 cells in 3.5 cm dishes overexpressing recombinant eNOS protein were 
washed 2X with Earle's balanced salt solution (EBSS) and incubated with 1 mL EBSS for 5 
hours to starve cells of L-arginine. To determine eNOS specific activity, cells were incubated 
in the presence or absence of L-NA (500 µmol/L) for 1 hour before incubated with [
14C]L-
arginine (10 µmol/L, 0.05µCi/µL) and further incubated for 15 minutes. A time interval of 3 
minutes between each plate was maintained. The cells were stimulated with ionomycin (100 
nmol/L) for further 5 minutes at 37°C. The reaction was quickly terminated by washing the 
cells twice with ice cold HT and the cells were snap frozen in liquid nitrogen. The cells were 
scraped in 500 µL lysis buffer (Triton X-100 0.2 %, pH 5.2, sodium acetate 20.0 mmol/L, 
citrulline 1.0mmol/L, EGTA 2.0 mmol/L and EDTA 2.0 mmol/L) and transferred to a 2 mL 
eppendorf tube. 10µL was taken to check for total incorporation of [
14C] as a control. 1 mL 
ice-cold HEPES buffer (100 mmol/L, pH 5.5) containing EGTA (10 mmol/L) and 500 mg 
Dowex AG 50 W-X8 (counter-ion Na
+ form) cation exchange resin was added, vortexed and 
incubated for 5 minutes on ice, this was repeated twice. 800 µL of the supernatant was added 
to 5 mL scintillation fluid and [
14C] L-citrulline in the supernatant was quantified by a liquid 
scintillation analyzer.   Materials and methods 
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3.9  Measurement of nitric oxide using Fe(DETC)2  by electron spin resonance 
spectroscopy 
Give the short half life of NO and O2
-, its very difficult to measure it in a biological system. 
This problem has been overcome by trapping NO and O2
-, with other compounds, which can 
then be detected by ESR spectroscopy. 
Preparation of Fe(DETC)2 Colloide: 
10ml Krebs buffer (in mmol/L: NaCl 98.93, KCl 4.69, MgSO4.7H2O 1.2, CaCl2
  2.49, 
NaHCO3 25.0, K2HPO4.3H2O 0.61, glucose 11.1 and HEPES 21.85 pH 7.4) in two 50ml 
falcon tubes was deoxygenated by using argon gas for at least 45 minutes. Parent solutions of 
ferrous sulfate heptahydrate (FeSO4.7H2O) and sodium diethylthiocarbimate (Na DETC) were 
prepared by adding 2.24mg FeSO4.7H2O and 3.6mg Na DETC to each tube and bubbled with 
argon. As soon as the FeSO4.7H2O crystals were dissolved the Na DETC solution was mixed 
with it, giving an almost translucent solution (which is an indication of a good colloid 
preparation). A multi-pipette was deoxygenated by aspirating argon gas. Fe(DETC)2 colloid 
was aspirated in the multi-pipette and use immediately.  
3.9.1  Measurement in cells: 
COS-7 cells (6 cm culture dish) overexpressing recombinant eNOS protein were washed 
twice with Krebs buffer and incubated in 1200 µL for 45 min at 37°C. 400 µL of freshly 
prepared Fe(DETC)2 colloid,(≅ 100 µmol/L Fe
2+) was added and further incubated for 30 min. 
eNOS was inhibited by pre-incubating the cells with L-NAME (300 µmol/L, 45 minutes) and 
activated by stimulating the cells with ionomycin (100 nmol/L, 10 minutes) before stopping 
the reaction by placing the plates on ice. Buffer was aspirated and cells were scraped 
carefully/gently in 100µL Krebs buffer and transferred to a insulin syringe and quickly frozen 
in liquid nitrogen. 
The formation of paramagnetic mono-nitrosyl-iron complex was determined at 77 K in a 
liquid nitrogen cooled dewar using a ESR EMX spectrometer (Bruker, Karlsruhe, Germany). 
The instrument settings were as follows: microwave frequency, 9.487 GHz; power, 20.07 
mW; receiver gain, 1x10
5; modulation amplitude, 5.000G; modulation frequency, 100 KHz; 
conversion time, 81.92ms; time constant, 327.680ms; sweep time, 41.94s; sweep width, 
100G; resolution, 512 points and 3 scans. Materials and methods 
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3.10  Measurement of superoxide anion (O2
-)  
3.10.1  Chemiluminescence 
HUVEC were cultured in 3.5 cm dishes, on attaining confluency the cells were starved of 
serum for 16 hours. The cells were then incubated with nLDL or ox-LDL for 24 hours. To 
determine eNOS-dependent O2
- production, cells were treated with L-NAME (300 µmol/L, 1 
hour). The cells were then washed twice with HEPES-Tyrode solution (in mmol/L: NaCl 
137.0, KCl 2.7, MgCl2 0.5, CaCl2 1.8, NaH2PO4 0.36, glucose 5.0 and HEPES 10.0) scraped 
and gently resuspended in 500 µL. The cell suspension was then transferred to a cuvette and 
the reaction was initiated by the addition of freshly prepared lucigenin (5µmol/L), 15 minutes 
later the cells were stimulated with ionomycin (100 nmol/L), and when the signal reached its 
peak, SOD was added. The concentration of lucigenin used has been shown to accurately 
reflect levels of ambient O2
- and is not subject to redox cycling and the artifactual production 
of O2
- that is observed with higher concentrations of the reagent (Li et al., 1998; Skatchkov et 
al., 1999). Light emission was detected using a Berthold luminometer (LB 9505, Berthold, 
Wildbad, Germany). The mean chemiluminescence observed during a period of 10 minutes 
was used to estimate the production of O2
-.  
3.10.2  Electron spin resonance (ESR) spectroscopy 
O2
- generation in intact cells was assessed using the spin trap 1-hydroxy-3-methoxycarbonyl-
2,2,5,5-tetramethyl-pyrrolidine (CMH, Alexis, Grunberg, Germany) (Dikalov et al., 1997; 
Kuzkaya et al., 2003). 
COS-7 or HEK 293 cells in 6 cm dishes, expressing recombinant eNOS protein were washed 
twice with HEPES-Tyrode (ESR-HT) solution which was pre-treated with chelax-100 (5%, 
overnight, Sigma) and contained diethylenetriamine-pentaacetic acid (DTPA; 100 µmol/L, 
used to decrease the autooxidation of hydroxylamines catalysed by trace transition metal 
ions). To quantify eNOS-dependent formation of O2
- , cells were incubated at 37°C with 1 mL 
ESR-HT in the absence or presence of L-NAME (300 µmol/L) for 1 hour prior to the addition 
of CMH dissolved in argon purged saline (2 mmol/L final concentraiton). After additional 5 
minutes, 400 µL of the solution was withdrawn into an insulin syringe and immediately 
frozen in liquid nitrogen. The formation of the stable spin label 3-methoxycarbonyl-proxyl 
(CM
.
) was determined at 77 K in a liquid nitrogen cooled dewar using an EMX ESR 
spectrometer (Bruker, Karlsruhe, Germany). The instrument settings were as follows: 
microwave frequency, 9.463 GHz; power, 20.02 mW; receiver gain, 1x10
5; modulation Materials and methods 
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amplitude, 2.010G; modulation frequency, 100 KHz; conversion time, 81.92ms; time 
constant, 327.680ms; sweep time, 41.943s; sweep width, 400G; resolution, 512 points and 3 
scans. 
 
3.11  Statistical analysis  
Data are expressed as mean ± SEM, and statistical evaluation
 was performed by using the 
Student’s t test for paired
 or unpaired data, one way ANOVA followed by a Bonferroni t test,
 
or ANOVA for repeated measures, where appropriate. Values of
 P<0.05 were considered 
statistically significant. 
 Results 
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4  Results  
Investigation of the role of eNOS serine, threonine and tyrosine residues on the regulation of 
the enzyme activity provided us with the following data. 
 
4.1  Effects of mimicking phosphorylation at specific serine residues of eNOS  
4.1.1    Effect of Ser
114 or Ser
633  mutations
  on eNOS catalytic activity and Ca²
+-CaM 
dependence 
Potentially phosphorylable serine residues within the eNOS sequence were identified using 
the NetPhos 2.0 program (http://www.cbs.dtu.dk/services/NetPhos). Based on the 
phosphorylation score, with a threshold score for possible phosphorylation being 0.5, two 
serine residues on human eNOS sequence were selected for study; Ser
114  (probability of 
phosphorylation = 0.994) because of its vicinity to H4B and Zn
2+ binding site and Ser
633 
(probability of phosphorylation = 0.987) because of its location within the auto-inhibitory 
loop located with in the FMN binding domain. 
The effect of serine phosphorylation on the activity of the enzyme can be mimicked by the 
mutation of the uncharged serine (S) to a negatively charged aspartate (D) while a non-
phosphorylatable site can be generated by replacing serine with alanine (A). To assess the role 
of phosphorylation of eNOS on Ser
114 and Ser
633 we generated a series of eNOS point 
mutants; S114A, S114D, S633/634A and S633D. As reported previously (Dimmeler et al., 
1999), the activity of the S633D eNOS mutant was comparable to that of the wild-type 
enzyme, it was initially decided to assess the effects of mutating both serines in the Ser
633/634 
doublet to alanine. The activity of eNOS was then determined by monitoring the L-NAME-
sensitive conversion of [³H]L-arginine to [³H]L-citrulline under Vmax conditions using Triton 
X-100 soluble fractions prepared from HEK-293 cells transfected with either the wild-type 
eNOS or one of the eNOS mutants. There was no marked difference in the activity of the 
wild-type eNOS or the S114D or S633/634A mutants. However, there was a significant ~2-
fold increase in the enzymatic activity of the S114A eNOS mutant (196.28 ± 11.82%, 
P<0.001, n=6) over that of the wild-type eNOS or the S114D eNOS mutant, and between the 
S633D eNOS mutant (193.85 ± 13.33%, P<0.001, n=6) and the wild-type eNOS or the 
S633/634A mutant (Fig. 12A). Thus under Vmax conditions, the activity of the non-
phosphorylatable S114A mutant and the phospho-mimetic S633D eNOS mutant were Results 
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significantly higher than that of the wild-type enzyme. As the S633/634A mutant exhibited 
similar activity as the wild-type enzyme, it was excluded from the next assays. 
In intact HEK-293 cells over-expressing either the wild-type eNOS or one of the mutants, 
stimulation with ionomycin slightly increased eNOS activity but there was no significant 
difference between the ionomycin-induced increase in the activity of the wild-type eNOS and 
that of the S633D mutant. This could be explained by the fact that eNOS expressed in 
cultured cell, which may not retain all of the signalling pathways present in native endothelial 
cells is predominantly uncoupled and thus generates a lot of O2
-. Also ionomycin stimulates 
other O2
- generating enzymes. However, the ionomycin-induced increase in the activity of the 
S114A mutant was significantly greater than that of the S114D mutant and ~25% greater than 
either the wild-type enzyme or the S633D eNOS mutant (Fig. 12B).  
 
 Figure 12. Comparison of the activity of wild-type eNOS and Ser
114 and Ser
633 eNOS mutants in 
vitro and in situ. (A) eNOS activity was determined by monitoring the conversion of [³H]L-arginine to 
[³H]L-citrulline under Vmax conditions and using Triton X-100-soluble fractions prepared from HEK-
293 cells transfected with either wild-type (WT) eNOS or one of the S114A, S114D, S633/634A or 
S633D eNOS mutants. eNOS expression was analysed by Western blotting using a specific antibody. 
(B) eNOS activity was assessed in the presence or absence of ionomycin (0.1 µmol/L, 5 minutes) in 
intact HEK-293 cells transfected with wild-type (WT) eNOS or the S114A, S114D and S633D eNOS 
mutants Data are expressed as percent eNOS activity over the activity measured in the absence of 
ionomycin. The bar graphs represent the mean ± SEM of data obtained in four to six independent 
experiments; **P<0.01, ***P<0.001. 
 
Next, the sensitivity of the wild-type eNOS, as well as each of the S114A, S114D and S633D 
eNOS mutants to activation by Ca
2+ and CaM was determined (Fig. 13). In these experiments 
eNOS proteins were expressed in HEK-293 cells and eNOS activity in the 100000g cell pellet 
determined using the citrulline assay. The advantage of using this technique is that it 
facilitates the determination of changes in the sensitivity of the enzyme to Ca
2+/CaM. 
0
50
100
150
e
N
O
S
 
a
c
t
i
v
i
t
y
 
(
%
 
b
a
s
a
l
) ** B
WT S114A S114D S633D
0
50
100
150
e
N
O
S
 
a
c
t
i
v
i
t
y
 
(
%
 
b
a
s
a
l
) ** ** B
WT S114A S114D S633D
A
0
50
100
150
200
250
e
N
O
S
 
a
c
t
i
v
i
t
y
 
(
%
C
T
L
)
***
***
***
WT S114A S114D S633/34A S633D
WT S114A S114D S633/34A S633D
-eNOS A
0
50
100
150
200
250
e
N
O
S
 
a
c
t
i
v
i
t
y
 
(
%
C
T
L
)
***
***
*** ***
***
***
***
***
WT S114A S114D S633/34A S633D WT S114A S114D S633/34A S633D WT S114A S114D S633/34A S633D
WT S114A S114D S633/34A S633D
-eNOSResults 
  51
However, all of the tested eNOS mutants (S114A, S114D and S633D) were concentration-
dependently activated by increasing concentrations of Ca
2+ and CaM. Differences in the 
enzymatic activity of the eNOS mutants could not be attributed to differences in protein 
expression, as determined by Western blotting.  
Figure 13. Effect of the mutation of eNOS Ser
114 and Ser
633 on the Ca
2+ and CaM dependency of the 
enzyme. eNOS activity was determined by monitoring the conversion of [³H]L-arginine to [³H]L-
citrulline in samples prepared from HEK-293 cells transfected with either wild-type eNOS or the 
S114A, S114D and S633D eNOS mutants. The enzymatic reaction was initiated by the addition of 
[³H]L-arginine to a reaction mixture containing different concentrations of Ca
2+, CaM and N
ωnitro-L-
arginine (L-NA; 100 µmol/L; black bar). Data are presented as percent activity with respect to the 
activity of the enzyme at Vmax conditions (1µmol/L CaCl2  and 1µmol/L CaM) and the bar graph 
represents the mean ± SEM of data obtained in three independent experiments.  
 
4.1.2  Effect of shear stress and bradykinin on the phosphorylation of eNOS  
To assess the basal and stimulation-dependent phosphorylation of eNOS, human endothelial 
cells were exposed to either fluid shear stress (12 dynes cm
-2) or bradykinin (10 nmol/L) for 
up to 60 minutes. eNOS was basally phosphorylated on Thr
495 and got dephosphorylated at 
one minute in response to bradykinin and back to basal levels in five minutes. Shear stress 
had no effect on Thr
495 dephosphorylation. eNOS Ser
1177 which was basally not 
phosphorylated showed a transient increase in phosphorylation (at 30 seconds and 1 minute) 
and got back to basal levels at 5 minutes. While Ser
1177 got phosphorylated in response to 
shear at 10 minutes and was maintained as long as the stimuli was applied (up to 60 minutes). 
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eNOS was basally phosphorylated on Ser
114 under basal conditions and there was no change 
in phosphorylation upon application of shear stress or bradykinin (Fig. 14). Interestingly the 
Triton X-100-insoluble fraction showed a decrease in the phosphorylation on Ser
114 in 
response to shear, but the same was not true for bradykinin stimulation. While, under basal 
conditions Ser
633 was not phosphorylated, phosphorylation was detected upon application of 
shear stress for 30 minutes which persisted as long as the cells were exposed to fluid shear 
stress i.e., for up to 60 minutes. The effect was not evident at shorter time points studied i.e. 
five and 10 minutes. However, there was no noticeable change in phosphorylation on Ser
633 
upon bradykinin stimulation (Fig. 14). 
Figure 14. Effect of shear stress and bradykinin on the phosphorylation of eNOS. Confluent 
primary cultures of human endothelial cells were exposed to fluid shear stress (12 dynes cm-²) or 
bradykinin (10 nmol/L) for the time indicated. Thereafter, the cells were harvested and Triton X-100 
soluble and insoluble fractions were analyzed for eNOS phosphorylation on Ser
1177, Thr
495, Ser
114 and 
Ser
633  by Western blotting using phosphospecific antibody. The blots are representative of three 
independent experiments. 
 
4.1.3  Effect of the mutation of eNOS on NO production in intact COS-7 cells as 
measured by ESR spectroscopy  
In vitro activity assays performed in the presence of optimal concentrations of Ca
2+/CaM and 
other essential cofactors cannot accurately reflect the production of NO in living cells since 
phosphorylation, sub cellular localisation and regulated protein-protein interactions can all 
affect eNOS activity (Ghosh et al., 1998; Sessa et al., 1995). Therefore, we compared the 
ability of wild-type eNOS to generate NO in intact COS-7 cells with that of the eNOS 
mutants. Recombinant adenoviruses encoding either the myc-tagged wild-type enzyme or one 
of the T475A/S1177D (TA/SD), S114A, S114D, T495A, T495D, or S633D eNOS mutants 
were used to infect COS-7 cells. The latter cells were chosen because of the need to obtain a 
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high level of protein expression and because the viruses used can replicate in HEK-293 cells, 
leading to cell lyses. In these experiments a non-phosphorylatable mutant of Thr
495 (T495A), 
a phospho-mimetic mutant of Thr
495 (T495D) and a highly active double mutant TA/SD were 
expressed in COS-7 cells as additional positive controls. A colloidal Fe(DETC)2 complex was 
used to trap NO as it has been shown to be specific and appropriate for detection by ESR 
spectroscopy (Kleschyov et al., 2000; Mülsch et al., 1995). NO production was assessed 
under basal conditions as well as following stimulation with ionomycin (0.1 µmol/L, 15 
minutes) by trapping with Fe(DETC)2 at 37°C.  
Figure 15. A typical ESR spectrum of the NO-Fe(DETC)2 complex. A typical ESR spectrum of the 
NO-Fe(DETC)2 complex (+/- L-NAME, 300 µmol/L) obtained by incubating Fe(DETC)2 for 30 min at 
37°C with cells expressing eNOS. The cells were scraped, frozen and measured at 77 K in a liquid 
nitrogen cooled dewar using a ESR EMX spectrometer (Bruker). The arrows indicated the triplet 
signal that is typical for NO. The intensity of the signal marked as h in the figure gives the measure of 
NO detected. 
 
Under basal (unstimulated) conditions, COS-7 cells expressing either the TA/SD, S114A, 
S114D or S633D eNOS mutants generated more NO than cells expressing the wild-type 
eNOS enzyme, or the T495A or T495D mutants (Fig. 16A). Cell stimulation with ionomycin 
(0.1 µmol/L, 15 minutes) elicited a moderate increase in NO production by all of the 
enzymes. Differences in the enzymatic activity of the mutants were not related to differences 
in protein expression, as determined by Western blotting (Fig. 16A; inset).  
As intracellular levels of H4B decrease rapidly in cultured cells (d'Uscio et al., 2003), and can 
lead to eNOS uncoupling (Landmesser et al., 2003; Smith et al., 2002), experiments were 
repeated using cells pre-treated with sepiapterin, a stable precursor of H4B. The presence of 
sepiapterin resulted in a modest increases in NO production from all the samples. However, 
the difference in the amount of NO produced under basal condition between cells expressing 
the wild-type enzyme and either of TA/SD, S114A, S114D or S633D eNOS mutants was 
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significantly enhanced, while the activity of the T495A and T495D eNOS mutants did not 
deviate much from that of the wild-type eNOS (Fig. 16B). Stimulation with ionomycin caused 
a moderate increase in NO production in all the samples. In contrast, stimulation of 
endothelial cells generally results in a 10-20 fold increase in intracellular cGMP levels. This 
discrepancy can most likely be attributed to the fact that cultured cells do not retain all the 
signalling pathways that regulate eNOS in primary cells. 
 
Figure 16. Effect of specific mutation of eNOS on NO production in COS-7 cells. NO production 
from intact COS-7 cells infected with wild-type (WT) eNOS or the TA/SD, T495A, T495D, S114A, 
S114D and S633D eNOS mutants in the absence (open bars) or presence (closed bars) of ionomycin 
(100 nmol/L), was assessed by NO spin trapping with Fe(DETC)2 and measured by electron spin 
resonance (ESR) spectroscopy at 77K. Experiments were performed in cells pre-treated with either 
(A) solvent or (B) sepiapterin (10 µmol/L, 24 hours). eNOS expression was analysed by Western 
blotting using an eNOS-specific antibody. The bar graphs represent the mean ± SEM of data obtained 
in three independent experiments; *P<0.05, **P<0.01, ***P<0.001 vs WT in the absence of 
ionomycin. 
 
4.1.4  Effect of specific mutation on eNOS dimer formation  
Since the treatment of eNOS expressing cells with sepiapterin caused significant increases in 
the production of NO production by the wild-type (WT) eNOS as well as the TA/SD, S114A, 
S114D or S633D eNOS mutants and H4B has been proposed to stabilise the eNOS dimer 
(Franco et al., 2004; List et al., 1997), we next determined whether or not the mutations 
studied affected the ability of eNOS to dimerise.  
Protein extracts (Triton-soluble) from COS-7 cells expressing wild-type eNOS or one of the 
TA/SD, T495A, T495D, S114A, S114D or S633D eNOS mutants were subjected to low 
temperature (LT)-PAGE and Western blot analysis. The gels were run both under reducing 
and non-reducing conditions as the displacement of Zn
2+ from the eNOS dimer leads to the  
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formation of disulphide bridges between the cysteine residues of eNOS are disrupted under 
reducing conditions(List et al., 1997; Zou et al., 2002). We found that most of the eNOS 
expressed in COS-7 cells was dimeric (Fig. 17) and we were unable to detect any difference 
between the ability of the wild-type enzyme and the eNOS mutants studied to dimerise. Any 
differences observed could be attributed to differences in eNOS expression levels.  
 
Figure 17. Effect of specific mutation on eNOS dimer formation. The ability of eNOS to form 
homodimers was analysed using Triton X-100-soluble fractions prepared from COS-7 cells expressing 
either wild-type (WT) eNOS or one of the TA/SD, T495A, T495D, S114A, S114D and S633D eNOS 
mutants by low temperature PAGE (LT-PAGE) and Western blot analysis. Protein extracts (20 µg) 
were subjected to LT-PAGE in the presence (reducing) or absence (non-reducing) of 5% β-2 
mercaptoethanol. The Western blots shown are representative of data obtained in two to three 
additional experiments. 
 
To compare the ability of eNOS to dimerise in the COS-7 over expression model versus 
endothelial cells as well as to determine whether or not cell stimulation was associated with 
any change in the dimer:monomer ratio, we assessed the effects of bradykinin (1 µmol/L, 10 
seconds to 5 minutes) on eNOS dimer levels in porcine aortic endothelial cells.  
In control (unstimulated) endothelial cells, eNOS existed predominantly as a dimer although 
significantly more monomer was detected in the endothelial cells studied than in the COS-7 
cells that over-expressed eNOS. Cell stimulation with bradykinin elicited a rapid and transient 
dephosphorylation of Thr
495 that was maximal at 30 seconds to 1 minute after stimulation but 
was rapidly rephosphorylated within 5 minutes; changes which have previously been linked to 
the activation of eNOS (Fleming et al., 2001). However, the bradykinin-induced activation of 
eNOS did not affect the dimer to monomer ratio in endothelial cells (Fig. 18).  
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Figure 18. Effect of bradykinin stimulation on eNOS dimer formation. To study the effect of 
bradykinin stimulation on eNOS activation and homodimers, porcine endothelial cells were stimulated 
with bradykinin (1 µmol/L) for the times indicated (10 to 300 seconds). Protein extracts (20 µg) were 
subjected to low temperature PAGE (LT-PAGE) and Western blot analysis. The bradykinin-induced 
stimulation of eNOS was evident from the dephosphorylation at Thr
495 as determined by using 
phospho-specific Thr
495 antibody The Western blot shown is representative of data obtained in two 
independent experiments. 
 
4.1.5  Effect of eNOS inhibitors, an NO
.
 donor and radicals on eNOS dimer stability  
Treatment of endothelial cells or purified eNOS with an NO donor, ONOO
- and O2
- have been 
reported to reduce the stability of eNOS dimer (Ravi et al., 2004; Stocker et al., 2004; Zou et 
al., 2002). As dimerisation is an absolute requirement for the catalytic activity of all three 
NOS isoforms (Baek et al., 1993; Klatt et al., 1995; Lee et al., 1995), we ascertained the 
effects of NO, ONOO
- and O2
- on the stability of eNOS dimer in porcine aortic endothelial 
cells using LT-PAGE. Porcine endothelial cells were used for this study as the dimer to 
monomer ratio was higher than that detected in human umbilical vein endothelial cells (data 
not shown). Under control conditions, i.e. cells treated with solvent (HEPES-Tyrode) eNOS 
existed predominantly as a dimer (Fig. 19). The dimer:monomer ratio was not affected by the 
treatment of cells with the ONOO
- donor; 3-morpholino-sydnonimine (SIN-1), while a high 
concentration of ONOO
- (3.75 mmol/L) significantly decreased the dimer levels (34.33 ± 
1.2% vs CTL, P<0.001, n=3). The exogenous O2
--generating system; xanthine/xanthine 
oxidase (X/XO) slightly but non-significantly attenuated dimerisation (Fig. 19). The NOS 
inhibitor L-NAME (300 µmol/L, 1hour), increased basal eNOS dimerisation and under these 
conditions only ONOO
- was able to affect the dimer:monomer ratio (Fig. 19). 
The mutation of eNOS did not interfere with the dimerisation of the enzyme and only a high 
concentration of ONOO
- (3.75 mmol/L) was able to disrupted the eNOS dimer. This 
observation suggests that the eNOS dimer is too stable to be disrupted by the modification of 
a single amino acid.  
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Figure 19. Effect of SIN-1, ONOO
-, O2
- and a NOS inhibitor on the dimerisation of eNOS. Porcine 
aortic endothelial cells were pretreated with solvent, 3-morpholino-sydnonimine (SIN-1, 1 mmol/L, 30 
minutes) xanthine/xanthine oxidase (X/XO,1 mmol/0.1U/mL, 30 minutes) and peroxynitrite (ONOO
-, 
3.75 mmol/L, 10 seconds) in the absence or presence of L-NAME (300 µmol/L). Protein (20 µg extract 
from each sample) was then used to determine the ratio of eNOS dimer to monomers detected by LT-
PAGE. The bar graph summarizes the data from three independent experiments; ***P<0.001 vs. CTL. 
 
4.1.6  Effect of specific eNOS mutation on its intracellular localisation 
Given that the subcellular localisation of eNOS is known to affect its activity (Jiang et al., 
2003; Ortiz & Garvin, 2003; Sessa et al., 1995), one possible explanation for the differences 
in the activity of the eNOS mutants could be an alteration in its subcellular targeting. To 
investigate the consequence of specific mutation of eNOS on its subcellular localisation 
human umbilical vein endothelial cells were infected with recombinant adenovirus carrying 
cDNA encoding myc-tagged wild-type eNOS or one of the TA/SD, TD/SD (Fig. 20), S114A, 
S114D, T495A, T495D, S633/634A or S633D eNOS mutants (Fig. 21) and 
immunohistochemically stained with an antibody directed against myc and an appropriate 
secondary antibody conjugated with the dye Alexia 546. β-catenin was visualised to mark the 
plasma membrane. First passage endothelial cells were used as the culturing of endothelial 
cells results in the loss of certain cellular factors as well as signalling pathways that are 
important for the activation of eNOS. 
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As reported previously by others (Fulton et al., 2002), the wild-type eNOS was localised 
discretely at the plasma membrane and in the peri-nuclear Golgi apparatus (Fig. 20). There 
was no difference in the localisation pattern of eNOS mutants S114A, S114D, T495A T495D 
and S633/634A to that of wild-type eNOS. However, the phospho-mimetic S633D mutant 
showed a distinct and continuous localisation of eNOS at the plasma membrane which was 
not observed with the wild-type enzyme (Fig. 21). The TA/SD double mutant exhibited a 
similar pattern of localisation to the wild-type enzyme, while the TD/SD mutant showed a 
greater degree of eNOS staining at the plasma membrane as well as to the peri-nuclear Golgi 
apparatus to that of wild-type. However, this effect could be due to the higher level of TD/SD 
expression (Fig. 20).  
WT
TD/SD
myc(eNOS) merged β−catenin
TA/SD
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Figure 20. Effect of mutation on Thr
495 and Ser
1177 on the intracellular localisation of eNOS. 
Confocal microscopy of human endothelial cells (first passage) infected with a myc-tagged wild-
type eNOS or either of the T495D/S1177D (TD/SD) or T495A/S1177D (TA/SD) eNOS mutants and 
labelled with antibodies directed against c-myc (red) and β-catenin (green). The results presented 
are representative of data obtained in three independent experiments. Results 
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Figure 21. Effect of specific mutations on the intracellular localisation of eNOS. Confocal 
microscopy of human endothelial cells (first passage) infected with a myc-tagged eNOS mutants 
(S114A, S114D, S633/634A, S633D, T495A and T495D) and stained with antibodies directed against 
myc (red) and β-catenin (green). The results presented are representative of data obtained in three 
independent experiments. 
 
4.1.7  Effect of specific mutation on superoxide anion (O2
-) production by eNOS 
eNOS has been reported to generate O2
- under specific conditions, particularly when the 
concentrations of L-arginine and H4B are limited (Xia et al., 1996; Xia et al., 1998) but it is 
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unclear whether or not phosphorylation-dependent regulatory mechanisms are involved in this 
process. We therefore set out to elucidate the effect of various mutations on eNOS uncoupling 
i.e. the ability of the enzyme to generate O2
-. To this end, the L-NAME (300 µmol/L)-
sensitive generation of O2
- was assessed by monitoring the formation of the stable spin label 
3-methoxycarbonyl-proxyl (CM
•) in HEK-293 cells expressing either of the eNOS mutants 
S114A, S114D, TA/SD, S633D, T495A or T495D. A tracing of a typical ESR spectrum for 
CM
• is shown in figure 22. 
 
Figure 22. A typical ESR spectrum of 3-methoxycarbonyl-proxyl (CM
•).  Representative tracing 
showing the typical ESR spectrum of 3-methoxycarbonyl-proxyl (CM
•) in the presence (dotted line) or 
absence (continuous line) of L-NAME (300 µmol/L), obtained by incubating CMH for 5 minutes at 
37°C with cells expressing eNOS. The supernatant was frozen and measured at 77 K in a liquid 
nitrogen cooled dewar using a EMX ESR spectrometer (Bruker). The arrows indicated the triplet 
signal that is typical for CM
• radicals. 
 
Under basal conditions the TA/SD and T495A eNOS generated more O2
- than the S633D 
S114D S114A or T495D mutants. An increase in O2
- production was observed following the 
application of L-NAME to cells expressing either the S114A or the S114D eNOS mutants a 
finding which can be attributed to the loss of basal NO production which scavenges O2
-. The 
NOS inhibitor did not affect O2
- production by the S633D or the T495D eNOS mutants. 
However, the generation of O2
- by the T495A mutant as well as the TA/SD double mutant 
was attenuated by L-NAME (Fig. 23), indicating that the phosphorylation of these residues 
may affect the ability of eNOS to generate O2
- versus NO.  
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Figure 23. Effect of specific mutation on the L-NAME-sensitive production of superoxide anions 
(O2
-) by eNOS. HEK-293 cells expressing the eNOS mutants; S114A, S114D, TA/SD, S633D, T495A 
or T495D, were treated with either solvent or L-NAME (300 µmol/L), and O2
- generation was 
assessed by monitoring the formation of the stable spin label 3-methoxycarbonyl-proxyl (CM
•) using 
ESR spectroscopy. The bar graph summarizes the mean ± SEM of data obtained in four different 
experiments (each in duplicate). The inset shows a representative Western blot to demonstrate the 
equivalent expression of eNOS. 
 
To get relatively equal amounts of eNOS expressed for all the mutants studied, COS-7 cells 
were infected with recombinant adenoviruses. Significantly more O2
- was generated in cells 
expressing the non-phosphorylatable T495A mutant than in cells expressing the phospho-
mimetic T495D mutant (Fig. 24A). The additional mutation of Ser
1177 to aspartate in order to 
increase electron flow through the reductase domain (McCabe et al., 2000), slightly, but not 
significantly, enhanced O2
- production. The L-NAME sensitive production of radicals by the 
T495A mutant and the wild-type enzyme were comparable; a phenomenon that can be 
accounted for by the fact that, unlike the situation in endothelial cells, eNOS is not basally 
phosphorylated on Thr
495 in COS-7 cells (Fig. 24B).  
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Figure 24. Superoxide anion (O2
-) production by wild-type eNOS and eNOS mutants. (A) COS-7 
cells expressing either wild-type eNOS (WT) or the T495A, T495D or T495A/S114D (TA/SD) eNOS 
mutants were treated with either solvent (CTL) or L-NAME (300 µmol/L) and O2
- generation was 
assessed by monitoring the formation of the stable spin label 3-methoxycarbonyl-proxyl (CM
•) using 
ESR spectroscopy. The bar graph summarizes the L-NAME sensitive production of O2
- measured in six 
independent experiments; *P<0.05, ***P<0.001 vs. WT. (B) Western blots showing the 
phosphorylation status of wild-type eNOS (WT) and the T495A, T495D or TA/SD eNOS mutants in 
COS-7 cells. Positive controls (+ve; unstimulated human endothelial cells in the case of Thr
495 and 
cells stimulated with bradykinin for 2 minutes in the case of Ser
1177) were included to demonstrate the 
sensitivity of the phospho-specific antibodies.  
  
4.2  Effect of ox-LDL on eNOS uncoupling 
Oxidative stress plays a pivotal role in the pathogenesis of
  vascular injury and in the 
progression of atherosclerosis. Oxidized low-density lipoprotein (ox-LDL) is reported to 
increase O2
- production in endothelial cells (Heinloth et al., 2000; Rueckschloss et al., 2001) 
and to decrease the bioavailability of NO via a process involving the lectin-like ox-LDL 
receptor-1 (Cominacini et al., 2001). Since we have previously shown that the 
dephosphorylation of eNOS on Thr
495 is associated with the enhanced production of O2
- (Lin 
et al., 2003) , and animal and clinical studies have revealed a strong correlation between the 
extent of atherosclerosis and titers of auto-antibodies to epitopes of oxLDL (Cyrus et al., 
1999; Palinski et al., 1995; Salonen et al., 1992), we set out to determine whether the ox-
LDL-induced uncoupling of eNOS can be linked to changes in its phosphorylation. 
The bioavailability of eNOS-derived NO from human umbilical vein endothelial cells was 
assessed by monitoring the basal and bradykinin-induced increase in cyclic GMP. Under 
basal conditions, ox-LDL attenuated cyclic GMP production by approximately 25% while the 
bradykinin-induced increase in cyclic GMP levels was reduced by 45% (Fig. 25A). In cells 
pre-treated with SOD, basal cyclic GMP levels were significantly (2.8 ± 0.1-fold, P<0.01, 
n=8) elevated such that there was no longer a difference between the control and ox-LDL-
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treated groups. SOD however failed to completely normalize the response to bradykinin in 
cells exposed to ox-LDL (Fig. 25A).  
A low level of O2
- could be detected using lucigenin-enhanced chemiluminescence in human 
endothelial cells treated with either solvent or native LDL. Superoxide anion levels were 
however markedly increased in cells treated with ox-LDL for 24 hours (Fig. 25B). L-NAME 
attenuated O2
- production in ox-LDL-treated cells but did not significantly affect radical 
production in either solvent- or native LDL-treated cells. Similar results were obtained in cells 
stimulated with ionomycin. Superoxide dismutase (200 U/mL) attenuated the 
chemiluminescence signal in all samples indicating specificity of lucigenin to O2
- (Fig. 25C). 
As H4B is reported to influence eNOS coupling (d'Uscio et al., 2003; Tiefenbacher et al., 
1996), we assessed cellular H4B levels in the absence and presence of native-LDL or ox-LDL 
(Fig. 25D). Ox-LDL (30 µg/mL) failed to significantly attenuate H4B levels. 
Figure 25. Effect of ox-LDL on the generation of NO and O2
- by human endothelial cells. Human 
endothelial cells were pretreated with either solvent (culture medium) native LDL (nLDL) or ox-LDL 
(30 µg/mL) for 24 hours. Thereafter, the production of (A) cyclic GMP, (B and C) O2
- (lucigenin-
enhanced chemiluminescence) were assessed and (D) tetrahydrobiopterin (H4B) levels were 
determined. Experiments were performed in the absence and presence of bradykinin (10 nmol/L, 5 
minutes), superoxide dismutase (SOD, 150 U/mL), ionomycin (100 nmol/L) and N
ωnitro-L-arginine 
methyl ester (L-NAME, 300 µmol/L). The bar graphs summarize the data obtained in three to eight 
independent experiments; *P<0.05, **P<0.005 vs. CTL. 
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4.2.1  Time course of the LDL-induced changes in eNOS phosphorylation 
In cultured human endothelial cells eNOS was phosphorylated on Thr
495 but only weakly on 
Ser
1177, as reported previously (Fleming et al., 2001). Incubation of endothelial cells with 
native LDL did not affect the phosphorylation of eNOS, while ox-LDL resulted in the time-
dependent dephosphorylation of eNOS on Thr
495  (Fig. 26A). Ox-LDL concentration-
dependently dephosphorylated eNOS on Thr
495, with an approximately 50% decrease in 
phosphorylation being observed using concentrations of 5 and 10 µg/mL and almost complete 
dephosphorylation occurring after 24 hours treatment with 30 µg/mL (Fig. 26B).  
  
Figure 26. Time- and concentration-dependent effects of nLDL and ox-LDL on the 
phosphorylation of eNOS. Human endothelial cells were incubated with native LDL (nLDL; 30 
µg/mL) or ox-LDL (5 to 30 µg/mL) for 2 to 48 hours and (A) the phosphorylation of eNOS on Thr
495 
and Ser
1177 and the phosphorylation of Akt were assessed by Western blotting with phospho-specific 
antibodies. The data were quantified relative to (B) total eNOS and the graph summarizes data 
obtained in nine to 12 independent experiments; *P<0.05, **P<0.005 vs. native LDL. (C) 
Comparison of the effects of the dephosphorylation of eNOS Thr
495 by histamine (0.1 µmol/L; 30 
seconds to 5 minutes) and by ox-LDL (30 µg/mL, 24 hours) on the association of eNOS with 
calmodulin (CaM). The upper Western blot (WB) shows the stimulus-induced changes in Thr
495 
phosphorylation in the same lysates used to immunoprecipitate (IP) eNOS. Identical results were 
obtained in three additional experiments. 
 
Oxidized-LDL did not alter eNOS protein expression. However there was a time-dependent 
increase in Akt phosphorylation, which was not associated with the phosphorylation of eNOS 
on Ser
1177 (Fig. 26A). 
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Since dephosphorylation of eNOS on Thr
495 lead to an increase in CaM binding, which in turn 
increase the turnover of NO from NOS (Fleming et al., 2001), we compared the effects of 
histamine and long-term (24 hours) stimulation of ox-LDL on the ability of CaM to bind to 
eNOS by co-immunoprecipitation. In cells maintained under control conditions, histamine 
induced the transient dephosphorylation of eNOS Thr
495, which was temporally correlated 
with the association of CaM. Interestingly, although ox-LDL elicited the dephosphorylation 
of eNOS on Thr
495, CaM did not associate with the enzyme (Fig. 26C).  
To determine whether or not ox-LDL interfered with agonist-mediated activation of eNOS, 
we stimulated human endothelial cells with bradykinin (100 nmol/L). In contrast to the cells 
treated with native LDL, stimulation of ox-LDL-treated cells with bradykinin did not further 
affect Thr
495 phosphorylation (Fig. 27A), but it did increase the phosphorylation of eNOS on 
Ser
1177. Ox-LDL-treatment also attenuated the PMA (300 nmol/L)-induced phosphorylation 
of eNOS Thr
495 while slightly increasing that of Ser
1177 (Fig. 27B). The ox-LDL-induced 
changes in eNOS phosphorylation were not associated with the activation of PKA or the 
AMP-activated protein kinase (data not shown).  
Loss of phosphorylation on Thr
495; kinase or phosphatase involved? 
The loss of phosphorylation can be attributed to either inhibition of the activity or expression 
of a kinase or an increase in the expression or activity of a protein phosphatase. The protein 
phosphatase 1 (PP1) specifically dephosphorylates eNOS on Thr
495 (Fleming et al., 2001) 
and, the PP1 inhibitor calyculin A (300 nmol/L) increased the phosphorylation of eNOS 
Thr
495 in ox-LDL-treated cells (Fig. 27C). However, the dephosphorylation of eNOS was not 
associated with an increase in the expression of the phosphatases PP1 or PP2A (Fig. 27D), 
indicating the involvement of a kinase for the loss of phosphorylation on Thr
495. 
Role of PKC in the ox-LDL-induced dephosphorylation of eNOS 
Since PKC phosphorylates Thr
495  (Michell  et al., 2001), and the response to PMA was 
attenuated in ox-LDL-treated cells, we assessed the effects of ox-LDL on PKC 
phosphorylation and activity. The PKC-pan antibody used detects PKCα, βI, βII, ζ, ε and δ 
isoforms only when phosphorylated at a carboxy terminal residue (Tyszkiewicz et al., 2004; 
Walker & Plows, 2003). 
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Figure 27. Effect of endothelial cell activation on the phosphorylation of eNOS in ox-LDL-treated 
cells. Human endothelial cells were incubated with either solvent or ox-LDL (30 µg/mL) for the time 
indicated prior to stimulation with either (A) bradykinin (10 nmol/L, 30 seconds to 5 minutes), (B) 
PMA (300 nmol/L, 5 to 30 minutes) or (C) calyculin A (CA, 10 nmol/L for 10 minutes). (D) The effect 
of ox-LDL (30 µg/mL, 24 hours) on the expression of PP1 and PP2. The Western blots shown are 
representative of data obtained in three to five additional experiments and the bar graph summarizes 
data obtained in three independent experiments. 
 
Upon activation PKC translocates from the cytosol to the plasma membrane fraction. The 
basal phosphorylation of a PKC isoform (approximately 77 kDa) was detected in the Triton 
X-100-insoluble fraction of unstimulated endothelial cells. Native-LDL failed to affect the 
phosphorylation of this enzyme while ox-LDL induced a time-dependent decrease in the 
phospho-PKC pan signal (Fig. 28A and B). A similar phenomenon was observed using an 
antibody that selectively recognizes the phosphorylated forms of PKCα/β. Although a basal 
phosphorylation of PKC was detected in the Triton X-100-soluble cell fraction, ox-LDL 
affected neither the signal obtained with the PKCpan antibody nor the selective phospho 
PKCα/β antibody (Fig. 28C). PKCα was detected in the Triton X-100-insoluble fraction from 
unstimulated endothelial cells and the signal was time-dependently decreased by ox-LDL 
(Fig. 28A). Since the molecular mass of PKCα and the signal given by the phospho-PKC 
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antibodies used were identical, PKCα appears to be the isoform that phosphorylates eNOS 
Thr
495 and is targeted by ox-LDL.  
Global PKC activity was assessed by monitoring the phosphorylation of acetylated myelin 
basic protein  (Ac-MBP). Ox-LDL, but not nLDL, induced a time- and concentration-
dependent decrease in PKC activity (Fig. 28D). 
 
 
Figure 28. Effect of nLDL and ox-LDL on the phosphorylation and activity of PKC in endothelial 
cells. Human endothelial cells were pretreated with either solvent (culture medium), native LDL 
(nLDL) or ox-LDL (30 µg/mL) for 8 to 24 hours. The phosphorylation of PKC was determined by 
Western blotting with phospho-specific specific antibodies (A) and quantified densitometrically (B). 
(C) Comparison of the effect of ox-LDL (30 µg/mL, 18 hours) on the phosphorylation of PKC in the 
Triton X-100-insoluble (Tx-insol) and soluble (Tx-sol) cell fractions. (D) Time- and concentration-
dependent effect of ox-LDL pre-treatment on the activity of PKC in endothelial cell lysates, as 
determined by the phosphorylation of myelin basic protein. Cells treated with PMA (1 µmol/L, 10 
minutes) served as a positive control. The graphs summarize data obtained in three to 10 independent 
experiments; *P<0.05, **P<0.005, ***P<0.001 vs. time 0 or CTL. 
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Effect of LPC on the phosphorylation of eNOS 
Lysophosphatidylcholine (LPC) a major lipid constituent of ox-LDL, can mimic the effect of 
ox-LDL on endothelial cells (Wu et al., 1998). LPC-treatment time- and concentration-
dependently decreased PKC activity and led to the dephosphorylation of eNOS Thr
495. 
However, in contrast to the effects of ox-LDL, LPC also elicited the phosphorylation of Akt 
and eNOS Ser
1177 (Fig. 29A). Moreover, 24 hours after application of the highest 
concentration of LPC used (100 µmol/L) eNOS expression was attenuated (data not shown).  
 
Figure 29. Time- and concentration-dependent effect of lysophosphatidyl choline (LPC) on the 
phosphorylation of eNOS. Human endothelial cells were incubated with LPC (10 to 100 µmol/L) for 
4 to 24 hours. (A) The phosphorylation of eNOS on Thr
495, Ser
633 and Ser
1177 and Akt on Ser
473 was 
assessed by Western blotting with phosphospecific antibodies. (B) Changes in the phosphorylation of 
eNOS Thr
495 were quantified relative to total eNOS levels and the graph summarizes data obtained in 
six independent experiments; **P<0.005, ***P<0.001 vs CTL.  
 
Effect of ox-LDL on the eNOS dimer 
To determine whether or not the ox-LDL-induced uncoupling of eNOS was linked to an 
alteration in the stability of the eNOS dimer we assessed the effect of ox-LDL on the eNOS 
dimer to monomer ratio by LT-PAGE. Cells were pretreated for 24 hours in the absence or 
presence of ox-LDL and vitamin C. Treatment of endothelial cells with vitamin C increases 
intracellular H4B content (Huang et al., 2000) which in turn might influence the dimer to 
monomer ratio. Neither ox-LDL nor vitamin C treatment altered the levels of eNOS dimer. 
However, inhibition of eNOS with L-NAME resulted in a maximal restoration of eNOS dimer 
in human (Fig. 30), as well as in porcine endothelial cells (Fig. 31). The gels were run both 
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under reducing as well as non-reducing conditions as the displacement of Zn
2+ from the eNOS 
dimer leads to the formation of disulphide bridges between the cysteine residues of eNOS 
which gets disrupted under reducing conditions (Zou et al., 2002). However, no detectable 
differences were observed under the two conditions (Fig. 31). 
 
Figure 30. Effect of ox-LDL on eNOS dimerisation in endothelial cells. Human endothelial cells 
were pretreated in the presence or absence of ox-LDL (30 µg/mL, 24 hours) in the presence or 
absence of L-NAME (300 µmol/L). Protein extracts (20 µg) from each sample were used to determine 
eNOS dimerisation by LT-PAGE under reducing (5% β-2 mercaptaethanol) conditions. The Western 
blot shown is representative of data obtained in two separate experiments performed with different 
batches of ox-LDL and in duplicate.  
 
Figure 31. Effect of ox-LDL on eNOS dimerisation in endothelial cells. Porcine aortic endothelial 
cells were pretreated in the presence or absence of ox-LDL (30 µg/mL) for 24 hours in the presence or 
absence of vitamin C (100 µmol/L) and L-NAME (300 µmol/L). Protein extracts (20 µg) from each 
sample were used to determine eNOS dimerisation by LT-PAGE under reducing or non-reducing 
conditions. The Western blots shown are representative of data obtained in three separate 
experiments.  
 
Effect of ox-LDL on the eNOS localisation 
In endothelial cells treated with either solvent (CTL) or native LDL, eNOS was localised to 
the plasma membrane as well as to the peri-nuclear Golgi apparatus. Ox-LDL (30 µg/mL, 24 
hours) resulted in the redistribution of the enzyme within the cytosol, and the Golgi 
disintegrated and was no longer detectable at the cell membrane (Fig. 32). These observations 
are consistent with previous studies, which reported the displacement of eNOS from caveolae 
upon ox-LDL treatment, by binding to endothelial cell CD36 receptors (Shaul, 2003) 
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Figure 32. Effects of nLDL and ox-LDL on the intracellular localisation of eNOS. 
Immunohistochemical staining of eNOS (red) and β-catenin (green) in human endothelial cells 
pretreated with either solvent (CTL), native LDL (n LDL; 30 µg/mL) or ox-LDL (30 µg/mL) for 24 
hours. The results presented are representative of data obtained in three independent experiments.  
 
4.3  The role of tyrosine phosphorylation in the regulation of eNOS activity 
Although eNOS can be tyrosine phosphorylated and endothelial NO production can be 
modulated by inhibitors of tyrosine kinases as well as tyrosine phosphatases (Fleming et al., 
1996a; Fleming et al., 1998; Takenouchi et al., 2004), almost nothing is known about the 
residues which are phosphorylated or the kinases which are involved. The consequences of 
the tyrosine phosphorylation of eNOS are unknown but are perhaps more likely to be related 
to the docking of associated scaffolding and regulatory proteins than to alterations in eNOS 
activity directly. As preliminary data indicated that both fluid shear stress (which increases 
eNOS activity) and insulin (which generally has no effect on NO production) elicit the 
tyrosine phosphorylation of eNOS (Fisslthaler, unpublished observations), we decided to 
determine the role of tyrosine phosphorylation on the regulation of eNOS. Since two different 
software programmes the NetPhos 2.0 (4 potentially phosphorylatable tyrosine residue) and 
DISPHOS (http://www.ist.temple. edu/DISPHOS, no phosphorylatable tyrosine residue) 
program gave contradicting results we decided to study tyrosine residues based on their 
location (Fig. 33). 
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Figure 33. Scheme showing the organisation of eNOS (human sequence) and tyrosine residues. The 
following tyrosine residues Tyr
210, Tyr
217, Tyr
357, Tyr
467, Tyr
534, Tyr
556, Tyr
597, Tyr
657, Tyr
900 and Tyr
939 
based on there location in the eNOS Tyr
357 in the arginine binding region, Tyr
556 and Tyr
657 in FMN 
binding domain and Tyr
939 in FAD binding domain, which can potentially be phosphorylated and play 
a role in eNOS regulation.  
 
A number of tyrosine kinases e.g., Src (Cheng et al., 2002; Okuda et al., 1999) and Src-family 
kinases (Davis et al., 2001; Davis et al., 2004), focal adhesion kinase (FAK) (Li et al., 1997; 
Takahashi et al., 1997) and PYK2 (Cheng et al., 2002; Tai et al., 2002) are reported to be 
activated in response to the application of fluid shear stress and/or cyclic stretch to endothelial 
cells. Fluid shear stress is reported to induce the tyrosine phosphorylation of eNOS as well as 
that of PECAM and as a Src or Src-family kinase-dependent has been implicated in the 
tyrosine phosphorylation of PECAM (Cao et al., 1998; Osawa et al., 1997) we next 
determined the time course of Src activation in primary cultures of endothelial cells.  
Effect of fluid shear stress on the tyrosine phosphorylation of Src and PYK2 
The effect of shear stress on the activity of the tyrosine kinase Src, or rather on the 
dephosphorylation of the inhibitory tyrosine residue Tyr
527, was assessed in primary cultures 
of porcine aortic endothelial cells. We observed a time-dependent dephosphorylation of Tyr
527 
that was significant 5 minutes after the application of shear stress and increased over 
experimental period studied (up to 30 minutes) indicating an increase in the activity of Src 
Fig. 34). 
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Figure 34. Effect of fluid shear stress on the tyrosine phosphorylation of Src. Confluent primary 
cultures of porcine aortic endothelial cells were exposed to fluid shear stress (12 dynes cm-²) for the 
time indicated. Thereafter, the cells were harvested and Src phosphorylation on Tyr
527 was analyzed 
by Western blotting with a specific antibody. The same blot was then stripped and reprobed for Src. 
The bar graph summarizes data obtained in four independent experiments; *P<0.05, **P<0.005 
versus static condition. 
 
The application of hemodynamic stimuli to endothelial cells is reported to activate Src which 
in turn activates PYK2 (Cheng et al., 2002), we determined the effect of shear stress on PYK2 
activation. Shear stress was also associated with a slight increase in the phosphorylation of 
PYK2, however a significant effect was only detected after approximately 60 minutes (Fig. 
35).  
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Figure 36. Effect of fluid shear stress on the phosphorylation of PYK2. Confluent primary cultures 
of human umbilical vein endothelial cells were exposed to fluid shear stress (12 dynes cm-²) for up to 
2 hours. Thereafter, the cells were harvested, PYK2 was immunoprecipitated and its tyrosine 
phosphorylation determined using a phospho-specific antibody. The bar graph summarizes the data 
obtained in three independent experiments; *P<0.05 versus static condition. 
 
In contrast to the weak effect observed on the tyrosine phosphorylation of total cellular 
PYK2, we observed a pronounced shear stress-induced association of PYK2 with eNOS. 
While only low levels of PYK2 co-precipitated with eNOS from cells maintained under static 
conditions there was an increase in the physical association of the two proteins that remained 
intact as long as cells were exposed to fluid shear stress i.e., for up to 2 hours (Fig. 36).  
 
Figure 36. Effect of fluid shear stress on the association of eNOS with the tyrosine kinase PYK2. 
Confluent primary cultures of porcine aortic endothelial cells were either maintained under static 
conditions or exposed to fluid shear stress (12 dynes cm
-²) for up to 2 hours. eNOS was 
immunoprecipitated and the association of PYK2 determined by Western blotting. The bar graph 
summarizes the data obtained in four to 10 independent experiments; *P<0.05, **P<0.01 versus 
static condition. 
 
Phosphorylation of eNOS by the tyrosine kinase PYK2 and Src 
To determine whether or not PYK2 and Src were able to tyrosine phosphorylate eNOS in 
intact cells, HEK-293 cells were co-transfected with eNOS and either PYK2 or Src. 
Immunoprecipitation of either eNOS (Fig. 37A) or phosphotyrosine (Fig. 37B) revealed that 
both kinases are able to phosphorylate eNOS in intact cells. To directly
 identify the tyrosine 
residues phosphorylated, eNOS recovered from PYK2-overexpressing HEK-293 cells, was 
Static 10 30 60 120 Static 10 30
-
-
83 -
175 -
IP: eNOS
WB: PYK2
minutes
IP: eNOS
WB: eNOS
Shear Shear
Static 10 30 60 120
0
50
100
150
200
250
300
350
P
Y
K
2
/
e
N
O
S
 
(
%
 
S
t
a
t
i
c
)
**
** **
Shear stress
min
KDa Static 10 30 60 120 Static 10 30
-
-
83 -
175 -
IP: eNOS
WB: PYK2
minutes
IP: eNOS
WB: eNOS
Shear Shear
Static 10 30 60 120 Static 10 30
-
-
83 -
175 -
IP: eNOS
WB: PYK2
minutes
IP: eNOS
WB: eNOS
Shear Shear Shear Shear
Static 10 30 60 120
0
50
100
150
200
250
300
350
P
Y
K
2
/
e
N
O
S
 
(
%
 
S
t
a
t
i
c
)
**
** **
Shear stress Shear stress
min
KDaResults 
  74
digested with trypsin, and subjected to MALDI-Mass spectroscopic (Toplab, Martinsried, 
Germany) analysis which revealed the phosphorylation of eNOS on Tyr
657 which is located in 
the FMN binding region in the reductase domain of eNOS. 
 
 
Figure 37. Phosphorylation of eNOS by the tyrosine kinases PYK2 and Src. HEK-293 cells were 
transfected with eNOS alone (CTL) or in combination with either PYK2 or Src. After 48 hours the 
cells were lysed and either (A) eNOS or (B) tyrosine phosphorylated (P-Tyr) proteins were 
immunoprecipitated. Blots were then probed with either anti-P-Tyr or anti-eNOS antibodies to 
determine the tyrosine phosphorylation of eNOS. Similar results were obtained in three independent 
experiments.  
 
Effect of the mutation of Tyr
657 residues on the activity of eNOS and dimer formation 
The consequences of tyrosine phosphorylation on eNOS activity and subcellular localisation 
where then studied using eNOS mutants in which Tyr
657 was mutated to the phosphomimetic 
amino acids aspartate (D) or glutamate (E) or the non-phosphorylatable phenylalanine (F). 
The sensitivity of the wild-type eNOS, Y657D, Y657E and Y657F eNOS to Ca
2+/CaM was 
then determined by monitoring the L-NAME sensitive conversion of [³H]L-arginine to [³H]L-
citrulline. While the wild-type eNOS and the Y657F mutant demonstrated a similar 
dependency on Ca
2+  and CaM, the Y657D and Y657E eNOS mutants were completely 
inactive at all concentrations (Fig. 38).  
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Figure 38. Effect of the mutation of Tyr
657 on the activity of eNOS. eNOS activity was determined by 
monitoring the N
ω-nitro-L-arginine sensitive conversion of [³H]L-arginine to [³H]L-citrulline in 
samples prepared from HEK-293 cells transfected with eNOS wild-type (WT) or the Y657D, Y657E 
and Y657F eNOS mutants. The bar graph summarizes data obtained in two experiments.  
 
Using NO spin trapping and ESR spectroscopy, the same phenomenon was observed in intact 
HEK-293 cells expressing wild-type eNOS, or either one of the Y657D, Y657E or Y657F 
eNOS mutants. A slight decrease in NO production was detected in cells expressing the 
Y657F mutant compared to that of wild-type eNOS which was correlated with a consistently 
lower recovery of the Y657F eNOS mutant in Triton X-100 lysis buffer. The Y657D and 
Y657E eNOS mutants were completely inactive (Fig. 39) and stimulation with ionomycin 
failed to affect NO production. 
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Figure 39. Effect of the mutation of Tyr 
657 on NO production. NO. production from intact HEK-293 
cells transfected with the eNOS WT or the Y657D, Y657E and Y657F eNOS mutants was determined 
by NO. spin trapping with Fe(DETC)2 and measured by ESR spectroscopy at 77K. Experiments were 
performed in cells pretreated with sepiapterin (10 µmol/L). eNOS expression was analysed by Western 
blotting using an eNOS-specific antibody. The bar graph summarizes data obtained in three 
independent experiments.  
 
To determine whether the lack of activity of the Y657D and Y657E eNOS mutants was 
related to the inability of the enzyme to dimerise we performed LT-PAGE. No consistent 
difference in the ability of the wild-type eNOS and Y657D or Y657F eNOS mutants to 
dimerise was detected, although the Y657E eNOS mutant showed a tendency towards a 
greater degree of dimer disruption (Fig. 40), this effect can most probably be attributed to a 
difference in protein expression. The recovery of eNOS mutants in Triton X-100 lysis buffer 
or SDS-PAGE sample buffer showed Y657E was more resistant to Triton X-100 lysis buffer, 
than the wild-type or the Y657D and Y657F eNOS mutants. Upon preparing the protein 
extract with SDS-PAGE sample buffer relatively more protein was detected for Y657E, 
indicating that this eNOS mutant get localised in the Triton X-100 insoluble fraction (Fig. 41). 
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Figure 40. Effect of the mutation of Tyr
657 on 
eNOS and dimer formation. Western blot 
showing the effect of the Tyr
657 mutation on eNOS 
dimer formation as determined by LT-PAGE. The 
data shown are representative of two 
independent experiments. 
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Intracellular localisation of wild-type eNOS and the Y657D and Y657E mutants 
To determine whether or not the wild-type and Tyr
657 eNOS mutants localised to the same 
intracellular compartments, immunohistochemical analysis was performed. Human umbilical 
vein endothelial cells were infected with recombinant adenovirus carrying cDNA encoding 
myc-tagged wild-type eNOS or one of the Y657D, Y657E or Y657F eNOS mutants (Fig. 42) 
and immunohistochemically stained with an antibody directed against myc and an appropriate 
secondary antibody conjugated with the dye Alexia 546. β-catenin was visualized to mark the 
plasma membrane. The wild-type eNOS was localised discretely at the plasma membrane and 
in the peri-nuclear Golgi apparatus. Of the two phosphomimitic mutants Y657D and Y657E, 
the latter showed a greater degree of eNOS localisation in the cytoskeletal compartments. 
This would well explain the low levels of Y657E detection by Western blotting using Triton-
X 100 soluble fraction from cells overexpressing this eNOS mutant. The Y657F mutant 
localised in a much diffused pattern in the Golgi apparatus and around the nucleus. 
Effect of the mutation on additional tyrosine residues on the activity of eNOS  
As mentioned earlier, two different stimuli, shear stress (which results in an increase in eNOS 
activity) and insulin (which has no effect on NO production) elicit the tyrosine 
phosphorylation of eNOS but with opposite effects, indicating the possible involvement of 
more than one tyrosine residue. We screened other tyrosine residues which would be involved 
in the regulation of eNOS. Additional tyrosine residues, which could regulate eNOS activity, 
were determined by citrulline assay. Mutation of either of theTyr
357, Tyr
534, Tyr
556 and Tyr
939 
tyrosine residue of eNOS to Ala proved to be lethal to the activity of the enzyme, while eNOS 
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Figure 41. Effect of the mutation of Tyr 
657 on the 
Triton solubility of eNOS. Protein extracts (20 µg) 
from HEK-293 cells transfected with eNOS WT or 
the Y657D, Y657E and Y657F eNOS mutants, were 
used to determine the effect of the eNOS tyrosine 
mutation on the Triton X-100 solubility of the 
enzyme. Total eNOS expression was determined by 
treating the samples with Laemmli buffer (7.3% w/v 
SDS) and analyzed by Western blotting using eNOS 
specific antibody. The blot is representative of four 
independent experiments. 
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Figure 42. Comparision of the intracellular localisation of wild-type eNOS and the Y657D, Y657E 
and Y657F mutants. Immunohistochemical staining of myc (red) and β-catenin (green) in human 
endothelial cells (first passage) infected with a myc-tagged wild-type eNOS (WT) or the Y657D, 
Y657E and Y657F eNOS mutants for 48 hours. The results presented are representative of data 
obtained in three independent experiments.tyrosine residue Tyr
210, Tyr
217, Tyr
597 and Tyr
900 
mutated to Ala were at least 100% more active than the wild-type, with Tyr
900 Ala mutants 
showing a maximum increase of approximately 400% (Fig. 43).  Results 
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Figure 43. Effect of the mutation of specific tyrosine residues on eNOS activity. HEK-293 cells were 
transfected with wild-type eNOS (WT) or one of the Y210A, 217A, Y357A, Y467A, Y534A, Y556A, 
Y597A, Y900A and Y939A tyrosine to alanine mutants. Thereafter eNOS activity was assessed by 
monitoring the conversion of [³H]L-arginine to [³H]L- citrulline under Vmax conditions (1 µmol/L 
CaCl2 and 1 µmol/L CaM. The bar graph summarizes data obtained in three experiments and 
corrected to the protein expressed. nt: non-transfected control. 
 
The work done with the eNOS tyrosine residues (40% of the total tyrosine residues were 
studied) have provided evidence for the involvement of the putative tyrosine residues whose 
phosphostatus could modulate the activity of eNOS. Since some of the alanine mutants 
completely inhibited the activity of the enzyme, and while some others increased the activity 
by at least 100%, it is possible that more than two tyrosine residues might regulate the activity 
of eNOS with opposing effects. Clearly much further work needs to be done to establish the 
physiological relevance of these tyrosine residues, and the signalling pathway involved for 
their phosphorylation and/or dephosphorylation.  
Conclusion: The data with tyrosine mutants clearly indicate the potential importance of Tyr
657 
for the regulation of eNOS activity, as Tyr
657 mutated to a phosphomimetic aspartate or 
glutamate completely inactivated the enzyme. Recent published data (Garcin et al., 2004) on 
the structure of reductase domain of eNOS goes a long way to explaining why this residue is 
critical, given its involvement in the correct positioning or “stacking” of the FMN on FAD so 
that electron transfer can take place.  
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5  Discussion 
The findings of this study highlight the central role of phosphorylation in the regulation of the 
function of eNOS. We have demonstrated the consequences of phosphorylation on the 
activity of eNOS and identified the amino acid residues which can modulate eNOS activity to 
either produce NO, or lead to eNOS uncoupling i.e. the flow of electrons in the eNOS dimer 
does not result in the formation of NO but reactive oxygen species (ROS) which reacts with 
NO to generate RNS.  
In unstimulated endothelial cells eNOS is phosphorylated on Thr
495 and no phosphorylation is 
detected on Ser
1177. The role of Ser
1177 and Thr
495 in the regulation of eNOS has been well 
documented. Upon activation by various stimuli such as bradykinin, VEGF etc, Thr
495 is 
rapidly dephosphorylated while there is a concomitant increase in Ser
1177 phosphorylation. 
Not much is known about the other phosphoryatable residues on eNOS which can regulate the 
enzyme activity. We have identified two phosphorylation sites; Ser
114, within the vicinity of 
Zn
2+ and H4B binding sites and Ser
633 in the putative CaM autoinhibitory sequence (586–641) 
within the FMN binding domain of eNOS, whose phospho-status influenced the enzyme 
activity.  
Previous reports suggest that eNOS stimulation with fluid shear stress resulted in an increase 
in serine and tyrosine phosphorylation as evident from 2D gel analysis (Dimmeler et al., 
1999) (Fissithaler et al., 2000) as well as mass spectroscopic analysis, which revealed the 
existence of at least two serine residues which gets phosphorylated (Gallis et al., 1999). Based 
on the location and the probability of phosphorylation as predicted by NetPhos 2.0 
programme, we identified serine residues Ser
114 and Ser
633 for our study. 
Gallis et al (Gallis et al., 1999) reported that fluid shear stress stimulates the phosphorylation 
of Ser
1177as well as that at Ser
114 but that these events were mediated by two different kinases, 
Akt/PKB and a proline- directed protein kinase respectively. The regulatory consequences of 
Ser
114 phosphorylation are almost entirely unknown. Our preliminary experimental data on 
the enzyme activity using the citrulline assay revealed that the activity of wild-type eNOS and 
the S114D mutant was almost the same, while the S114A mutant showed a two-fold increase 
in its activity, compared to the S114D mutant or wild-type enzymes. This gave us the first 
indication of the involvement of this site in enzyme activity. Since it is proposed that multiple 
sites of phosphorylation contribute to NO formation and activity assays performed with 
protein extracts may be misleading until the mutants are examined in an appropriate cellular 
environment, we performed the activity assay and direct NO measurement by ESR Discussion 
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spectroscopy at either basal or elevated [Ca
2+]i concentrations in intact HEK-293 cells and 
COS-7 cells overexpressing the protein in study. Under basal conditions there was no 
difference in the activity of wild-type eNOS, S114A and the S114D mutants, but upon 
stimulation with ionomycin, the S114A mutant exhibited a higher activity than either the 
wild-type eNOS or the S114D mutant as measured with citrulline assay. Surprisingly, cells 
expressing the S114A and S114D eNOS mutants released almost equal amounts of NO and 
were twice as active as the wild-type enzyme when NO was assessed by ESR spectroscopy. 
These findings regarding the S114A eNOS mutant were independently confirmed by Kou et 
al (Kou et al., 2002), who reported that the activity of wild-type eNOS was similar to that of 
the S114A mutant under basal conditions, and was significantly enhanced upon stimulation 
with a calcium ionophore. However, their study lacked the S114D mutants, which would have 
been ideal in studying the consequence of phosphorylation on this serine residue. On the basis 
of the data obtained with this mutant on direct NO production, surprisingly both S114A and 
S114D made similar amounts of NO. Also both the mutants produce higher amounts of NO 
than the wild-type enzyme or an active double mutant TA/SD. The inhibition of the S114A 
and S114D mutants with L-NAME resulted in an increase in O2
- production as measured by 
spin labelling with CMH, due to the loss of the scavenging effect of NO on O2
-. Also no 
changes in phosphorylation on Ser
114 were observed on stimulating the cells with shear stress 
or bradykinin.  
It is presently not clear whether the importance of Ser
114 is actually conferred by changes in 
its phosphorylation status as evident from the same amount of NO released from both the 
S114A and S114D mutants. It may be possible that Ser
114 will determine the phospho-status 
of other amino acids. Recent reports have suggested that S114A promoted a greater 
interaction with Hsp-90 and Akt and an enhanced Ser
1177 phosphorylation (Bauer et al., 
2003). 
The mechanisms whereby Ser
114 modulates eNOS enzyme activity remain to be determined. 
Some clues may be derived from inspecting the crystal structure of eNOS in the vicinity of 
Ser
114; which is the region that includes sites for Zn
2+ ligation and H4B binding, both of which 
stabilizes the dimer. The Zn
2+ is tetrahedrally coordinated by four cysteine residues, two from 
each subunit (Cys94-Cys99) forming a zinc tetrathiolate (ZnS4) cluster, (Fischmann et al., 
1999; Li et al., 1999; Raman et al., 1998) (Fig. 43). The residue Ser
102 helps in the binding of 
H4B (Li et al., 1999). Disruption of ZnS4 cluster by S-nitrosylation (Ravi et al., 2004) or by 
ONOO
- (Zou et al., 2002), and also depletion of H4B (List et al., 1997) result in an unstable 
eNOS dimer . This eNOS dimer monomerises under reducing condition due to the disruption Discussion 
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of the disulphide bridges. However, Ser
114 mutated to Ala or Asp did not interfere with the 
dimerisation of eNOS, suggesting that Ser
114 may not critically interfere with Zn
2+ or H4B 
binding. 
 
Our findings on Ser
114 contradict findings by other groups (Kou et al., 2002) attributing a role 
for Ser
114 phosphorylation in the regulation of eNOS which we dispute and conclude that this 
residue might not be directly relevant in the regulation of eNOS by phosphorylation. 
Ser
633 is situated in the autoinhibitory loop which impart part of the Ca
2+ dependency of the 
constitutively expressed NOS isoforms. The putative auto-inhibitory loop which has been 
speculated to interfere with binding of CaM with the CaM binding peptide is present only in 
nNOS and eNOS and, interestingly, Ser
633 is conserved only in human, mouse, and bovine 
eNOS, but not
 in nNOS (Butt et al., 2000; Garcin et al., 2004; Salerno et al., 1997). Deletion 
of the auto-inhibitory loop increased the activity of the Ca
2+-dependent enzyme. In previous 
studies it was reported that the activity of S633D eNOS mutant was similar to that of wild-
type enzyme when determined with the citrulline assay in lysates from transfected cells as 
well as by assessing nitrate accumulation (Dimmeler et al., 1999; Fulton et al., 1999). Ser
633 
has been reported to be phosphorylated in vitro by PKA and PKG (Butt et al., 2000), but the 
functional relevance of Ser
633 in regulating eNOS activity in intact cell system has not been 
addressed so far. Keeping this in mind, we decided to reassess the role of this residue in 
regulating eNOS activity in intact cell system. 
 
Figure 43. Zinc thiolate cluster of 
eNOS.  Crystal strcuture of eNOS 
showing the zinc thiolate cluster (C94 
and C99) and the interaction with heme 
and tetrahydrobiopterin (H4B). Modified 
from Raman et al, Cell 1998; 95: 939-
950. 
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Using three different methods we examined the effects of the mutation of Ser
633 to aspartate 
(S633D) on eNOS activity by performing citrulline assays using cell lysates, in intact cells 
overexpressing the wild-type and mutant eNOS enzymes and by directly measuring NO 
production from intact cells with the aid of ESR spectroscopy. Studies using cell lysates 
obtained from transfected cells showed that the abilities of the S633D mutant and wild-type 
eNOS to convert L-arginine to L-citrulline were similar (Bauer et al., 2003; Dimmeler et al., 
1999). In contrast, with the aid of the citrulline assay and ESR spectroscopy we observed that 
in intact cells under basal conditions the S633D eNOS mutant was twice as active as the wild-
type enzyme. These apparent differences can most probably be attributed to the experimental 
conditions employed. The other groups employed nitrate accumulation over a period of 24 
hours to determine the enzymatic activity and nitrate in the cells cannot be solely attributed to 
eNOS activity. However, we were careful in selecting NO spin trapping using Fe-DETC for 
determining NO release from the cells, which gives a direct measure of NO release. In intact 
cells or in broken cell lysates, eNOS interacts with many regulatory proteins such as caveolin, 
Hsp90, and numerous other factors (Boo & Jo, 2003; Fleming et al., 2001; Fulton et al., 2001) 
which could play a role in the activity of the enzyme. We did not see any change in the Ca
2+ 
sensitivity for S633D mutant using 100,000 g pellet and citrulline assay but Boo et al have 
reported Ser
633 to be Ca
2+ insensitive (Boo et al., 2002; Boo et al., 2003) which they observed 
by determining the total nitrate content from intact cells. It could also be due to the fact that 
phosphorylation of Ser
633 by PKA and PKG enhanced the Vmax of eNOS activity in the 
presence of Ca
2+/CaM, which would explain our result as we determined the enzyme activity 
over a period of 30 minutes, which would have been too long to detect small differences 
between the eNOS wild-type and the S633D mutant. 
Stimulation of human endothelial cells with shear stress resulted in an increase in the 
phosphorylation on Ser
633 at 30 minutes and remained phosphorylated as long as shear was 
applied up to 60 minutes which suggest the physiological relevance of this residue in the 
regulation of the eNOS enzyme.  
Based on our finding and other work reported during our study, the physiological implication 
of eNOS phosphorylated at Ser
633 can be as follows. Shear stress elicits the biphasic 
production of NO so that responses generally consist of an initial short NO burst phase 
followed by a maintained phase where the levels of NO are maintained at levels two to three 
times higher than the basal levels (Fleming et al., 1997; Kuchan & Frangos, 1994). The initial 
NO burst phase is characterised by a transient increase in the levels of intracellular Ca
2+ 
(Ayajiki et al., 1996; Corson et al., 1996) leading to a Ca/CaM dependent activation of eNOS, Discussion 
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which is associated with the transient dephosphorylation of Thr
495 and phosphorylation of 
Ser
1177 by CaMKII (Fleming et al., 2001) or Akt (Dimmeler et al., 1998; Fulton et al., 1999; 
Michell et al., 1999). As a result the levels of NO are maintained at levels much higher than 
basal over a period of time. Ser
633 has been reported to become phosphorylated in a PKA-
dependent manner upon exposing endothelial cells to shear stress for 30 minutes (Boo et al., 
2002), roughly corresponding to the beginning of the second phase of NO production in 
response to shear (Frangos et al., 1996). Therefore it can be suggested that the Ser
633 
phosphorylation may be responsible for the long-term potentiation of eNOS activation that 
persists at basal Ca
2+ levels beyond peak activation, resulting in a low level of NO production 
which may play a critical role in the atheroprotective role of chronic shear stress. 
Many studies have demonstrated a link between the localisation and activity of eNOS. We 
studied the influence of eNOS mutants on this link. There was no marked difference between 
the mutants studied, wild-type eNOS and TA/SD, TD/SD, S114A, S114D, or S633/634A, all 
of them localising at the plasma membrane and at the perinuclear Golgi apparatus. However, 
S633D showed a greater localisation at the plasma membrane.  
With respect to the possible molecular mechanism underlying Ser
633 phosphorylation-
dependent activation of eNOS, studies by Salerno et al (Salerno et al., 1997) presented 
evidence for an auto-inhibitory
 control element, a 45-amino acid insert located near the CaM-
binding
  region of only constitutive NOS forms (eNOS and nNOS), not iNOS. The 
autoinhibitory region is postulated to stabilise
 an inhibited NOS conformation. Binding of 
CaM could cause displacement
  of the auto-inhibitory element, thereby evoking a 
conformational
 change of eNOS to support activation. The auto-inhibitory
 domain is notably 
rich in positively charged amino acid residues,
 especially in the case of eNOS which contains 
the sequence
 RRKRK (Lane & Gross, 2000) immediately before Ser
633. Phosphorylation
 of 
Ser
633 would increase the negative charge in the autoinhibitory
 domain, and could thereby 
facilitate displacement of this domain
 from the site with which it interacts, thus partially 
activating
 NOS in the absence of Ca
2+/CaM, as well as facilitating Ca
2+/CaM binding and 
enhancing maximal NOS
 activity. Based on CaM binding and displacement of auto-inhibitory 
element its tempting to propose a cooperation between Ser
633 and Thr
495. This scenario is 
however unlikely as the dephosphorylation on Thr
495 is transient and rapid which is evident 
within the first 3 minutes of stimuli application, the phosphorylation on Ser
633 is evident only 
at 30 minutes. Although eNOS uncoupling has received a lot of interest, the mechanisms 
involved are not entirely clear and very little is known about the role of phosphorylation in 
regulating eNOS uncoupling. Here we report the identification of Thr
495, as a potential Discussion 
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“phospho switch” for eNOS uncoupling. Oxidized-LDL was identified as a 
pathophysiological stimuli and PKCα as the kinase responsible for the phosphorylation of 
Thr
495. Stimulation of eNOS with ox-LDL led to a decrease in the basal phosphorylation on 
Thr
495 with a consequential increase in O2
- production as a result of eNOS uncoupling. The 
importance of this residue in the ability of eNOS to generate O2
- was evident from the fact 
that a non-phosphorylatable T495A eNOS mutant generated more O2
- than the phospho-
mimetic T495D eNOS mutant does. 
As eNOS has been reported to uncouple and produce O2
- during endothelial dysfunction, we 
were interested in elucidating if there was any eNOS residue involved whose phosphostatus 
determined whether eNOS makes NO or O2
-. Lin el al (Lin et al., 2003) had previously 
reported that dephosphorylation of eNOS on The
495  is associated with the enhanced 
production of O2
-. It has also been shown by other investigators that exposure of endothelial 
cells to ox-LDL results in the formation of ROS, although the source of these species remains 
an area of uncertainty (Cominacini et al., 2001). Our study with the eNOS mutants expressed 
in COS-7 cells indicated the involvement of Thr
495 in O2
- production. 
Based on previous reports and on our findings it is tempting to postulate that the 
dephosphorylation of Thr
495 leads to eNOS uncoupling. We initially observed that the 
dephosphorylation of Thr
495 elicited by down regulating of PKC by long-term treatment with 
PMA was previously found to enhance rather than attenuate NO production by eNOS 
(Fleming et al., 2001). This gave us a hint for the involvement of other factors involved in the 
regulation of eNOS activity. While dephosphorylation of Thr
495 i s  a s s o c i a t e d  w i t h  a  
concomitant increase in the binding of CaM to eNOS (Fleming et al., 2001), surprisingly 
eNOS dephosphorylated by ox-LDL at Thr
495  failed to associate CaM, but histamine 
stimulation of eNOS led to transient binding of CaM to eNOS which was very short-lived as 
the level of CaM returned to levels as observed in ox-LDL treated eNOS with in 1 minute. 
However, this would make a good argument for eNOS-dependent O2
- generation. As CaM 
binding results in an increased flow of electrons from the reductase domain to the oxygenase 
domain(Abu-Soud & Stuehr, 1993; Matsuda & Iyanagi, 1999), this loss in the ability of eNOS 
to bind to CaM could possible result in a state where the electrons are flowing through the 
reductase domain but are not able to cross over to the oxygenase domain for the effective 
generation of NO. Under such conditions the electron is accepted by O2 leading to radical 
formation (Stuehr et al., 2001), which was exactly what was observed with ox-LDL treated 
endothelial cells. Discussion 
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There has been a lot of discrepancy in the reports on the effect of ox-LDL on Ser
1177 
phosphorylation as well as on the kinases involved. This can be attributed to the diverse 
concentration of ox-LDL employed in such studies, ranging from 5 to 250 µg/ml and the 
duration of the stimulation. In our study we used a maximal concentration of 30 µg/mL. A 
transient enhanced phosphorylation of Ser
1177 has been reported in endothelial cells exposed 
to higher concentration of ox-LDL (150 µg/mL), we failed to see the same with 30 µg/mL, 
while similar levels of ox-LDL levels were found to attenuate eNOS Ser
1177 phosphorylation 
in VEGF-stimulated endothelial cells and, thus, to inhibit cell migration (Chavakis et al., 
2001). However, we found no significant attenuation of the bradykinin-induced 
phosphorylation of Ser
1177 in cells pre-treated with ox-LDL. This latter discrepancy may be 
explained by the fact that the kinases activated by the two stimuli that mediate the 
phosphorylation of eNOS on Ser
1177 are distinct; VEGF-induced phosphorylation is Akt-
dependent, while the phosphorylation induced by bradykinin is CaM kinase II-dependent 
(Fleming et al., 2001). While such observations indicate that ox-LDL differentially affects 
Akt-mediated cell signalling, we found that ox-LDL treatment resulted in modest, but 
significant, time- and concentration-dependent activation of this kinase without a concomitant 
increase in eNOS Ser1177 phosphorylation, rather than the dephosphorylation and 
inactivation of Akt reported previously (Chavakis et al., 2001). 
The loss of phosphorylation of eNOS Thr
495 as a result of ox-LDL stimulation can be the 
consequence of either the down-regulation/inhibition of a kinase or an up-
regulation/activation of a phosphatase. The phosphatase involved in the dephosphorylation of 
Thr
495 is thought to be PP1 (Fleming et al., 2001; Michell et al., 2001), but although the PP1 
inhibitor, calyculin A , was able to increase Thr
495 phosphorylation in ox-LDL treated cells, 
we found no evidence to suggest that its activity or expression was increased by ox-LDL. 
Harris et al have reported that the serine/threonine phosphatase, calcineurin (PP2B) can also 
dephosphorylate eNOS Thr
495 (Harris et al., 2001), but this is not a universally observed 
phenomenon (Fleming et al., 2001; Michell et al., 2001). Moreover, since this phosphatase is 
sensitive to inhibition by O2
- (Namgaladze et al., 2002), ox-LDL would be expected to result 
in a decrease rather than an increase in its activity. Therefore, our data indicate that ox-LDL-
induced dephosphorylation of eNOS Thr
495 can be attributed to the down- 
regulation/inactivation of a kinase. 
eNOS is reported to be basally phosphorylated on Thr
495 by a constitutively active kinase 
most probably PKC (Fleming et al., 2001; Matsubara et al., 1996; Michell et al., 2001), a 
finding that can account for the fact that protein kinase inhibitors and the down-regulation of Discussion 
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PKC attenuate the phosphorylation of this residue. The inhibition and down-regulation of 
PKC were also associated with a marked increase in endothelial NO production, which is 
consistent with a negative regulatory role of Thr
495 on CaM binding and eNOS activity 
(Davda  et al., 1994; Hirata et al., 1995). Mukherjee et al (Mukherjee et al., 2001) have 
reported that ox-LDL stimulates PKC activity, in contrast, our data clearly demonstrate that a 
constitutively active isoform of PKC is targeted by ox-LDL and that this effect underlies the 
ox-LDL-stimulated Thr
495 dephosphorylation of eNOS. Indeed, the dephosphorylation of 
Thr
495 was temporally correlated with a decrease in the phosphorylation and activity of PKC 
in ox-LDL-treated endothelial cells. The PKC isoform targeted by ox-LDL was tentatively 
identified as PKCα on the basis of its molecular mass and the fact that the same signal was 
obtained using three different antibodies. So far there has not been any report on the PKC 
isoform involved, ours is the first study which has identified the PKC isoform involved in 
Thr
495 phosphorylation. Whether PKCα forms part of the eNOS signalosome remains to be 
determined, as this analysis is hampered by the fact that the activated PKC is detergent-
insoluble. However, eNOS can also be detected in the Triton-insoluble cell fraction and the 
bradykinin- as well as the fluid shear stress- induced increase in NO production has been 
linked to a change in the solubility of eNOS (McCabe et al., 2000; Venema et al., 1996b). 
Oxidized-LDL has previously been reported to acutely increase (within 15 minutes) the 
activity of PKCα in coronary artery smooth muscle cells (Giardina et al., 2001) and to 
increase global PKC activity (over 24 hours) in coronary endothelial cells by activating the 
LOX-1 receptor (Li et al., 2003). Clearly, our results are in direct contrast with the results of 
this study. The reasons for this apparent contradiction can most likely be attributed to the 
differences in the concentration and time of incubation with ox-LDL, as well as the cells used. 
However, it is important to note that, in the present study, we were careful to use cells after 
only one passage to avoid artefacts related to the gradual loss of cell signalling pathways in 
multi-passaged cultured cells. 
Intracellular localisation of eNOS plays an important role in the activity of the enzyme 
(Sakoda et al., 1995; Sessa et al., 1995). Oxidized-LDL and hypochlorite-modified LDL have 
been previously reported to alter the intracellular localisation of eNOS (Blair et al., 1999; 
Nuszkowski et al., 2001). Oxidized-LDL causes displacement of eNOS from caveolae by 
binding to endothelial cell CD36 receptors and by depleting caveolae cholesterol content 
(Shaul, 2003; Uittenbogaard et al., 2000), resulting in the disruption of eNOS signalling 
complex and activation. Oxidized-LDL is also reported to interfere with the association of 
eNOS with Hsp90 (Stepp et al., 2002). The association of eNOS with Hsp90 is necessary to Discussion 
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mediate the balance of NO and O2
- release from eNOS (Pritchard, Jr. et al., 2001). Thus, it 
appears that ox-LDL has diverse effects on eNOS regulatory mechanisms which includes 
inactivation of a kinase leading to dephosphorylation and loss of interaction with regulatory 
protein and intracellular localisation of the enzyme. 
It has been suggested that oxidative stress results in the disruption of the eNOS dimer by 
disrupting the ZnS4 cluster (Zou et al., 2002) and oxidizing H4B (List et al., 1997), while our 
study has showed that eNOS dimer is relatively stable. These conflicting results can be due to 
difference in the methodologies and experimental conditions employed. In the previous study, 
the experiments were carried out using purified eNOS, where the eNOS dimer is in direct 
contact with the oxidants without any interference in their action on the eNOS dimer. While 
we were not able to detect the same in endothelial cells, where ONOO
- can be rapidly 
degraded, we did not detect any difference in levels of eNOS dimer upon treatment with ox-
LDL, or SIN-1 or X/XO. Only when cells were stimulated with high concentration of ONOO
- 
(3.75 mmol/L) was the dimer completely disrupted. However, recent reports indicate that the 
NOS dimer once formed is relatively stable, indicating that the uncoupling of eNOS has not 
necessarily to be associated, if at all, with the disruption of the dimer. 
There are numerous reports of the restoration of endothelial dysfunction by treating the cells 
with H4B (Tiefenbacher et al., 1996) or vitamin C (d'Uscio et al., 2003) which is know to 
restore the H4B content (Baker et al., 2001; Heller et al., 2001). Levels of this essential 
cofactor are reported to be decreased by oxidative stimuli, in particular, by ONOO
- (Kuzkaya 
et al., 2003), which oxidizes H4B (Milstien & Katusic, 1999), as well as by ox-LDL (Dulak et 
al., 1997; Frank et al., 1998). The H4B oxidation hypothesis also implies that eNOS 
uncoupling is preceded by the activation of other endothelial O2
- generating enzymes. 
Arguing against such a central role of H4B in the uncoupling of eNOS, in the present study, 
ox-LDL did not significantly affect endothelial H4B levels, and the mutation of eNOS Thr
495 
to alanine was sufficient to increase O2
- production. Since Thr
495 is upstream of H4B, it 
deserves attention in itself as a key player in eNOS uncoupling or which act as a phospho-
switch, determining whether the eNOS makes NO or O2
- upon experiencing 
pathophysiological stimuli.  
Experiments performed on endothelial cells using inhibitors of tyrosine kinases as well as 
tyrosine phosphatases (Fleming et al., 1996a; Fleming et al., 1998; Takenouchi et al., 2004) 
have been reported to modulate the NO production. But there is nothing much known about 
the residues which are phosphorylated or the kinases which are involved. Elaborating the Discussion 
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functional consequences of eNOS tyrosine phosphorylation is complicated by the fact that this 
modification is only evident in primary cultured cells (Fleming et al., 1998; Garcia-Cardena 
et al., 1996a) or in cells that overexpress tyrosine kinases such as Src (Takenouchi et al., 
2004). The consequences of the tyrosine phosphorylation of eNOS are unknown but are 
perhaps more likely to be related to the docking of associated scaffolding and regulatory 
proteins than to affect eNOS activity directly. 
Studies using tyrosine kinase inhibitors provide only limited information on the role played 
by tyrosine phosphorylation in the regulation of endothelial NO production as many of these 
compounds directly affect Ca
2+-signalling processes (Fleming et al., 1996b; Fleming & 
Busse, 1997) and/or the activity of Akt and the binding of Hsp90 (Fleming et al., 1996b). 
Since preliminary data from our group indicated that both fluid shear stress (which increases 
eNOS activity) and insulin (which generally has no effect on NO production) elicit the 
tyrosine phosphorylation of eNOS (Fisslthaler, unpublished observations) we decided to 
determine the role of tyrosine phosphorylation in the regulation of eNOS.  
Shear stress has been previously reported to activate Src in endothelial cells (Jalali et al., 
1998). We found that application of shear stress on endothelial cells resulted in the activation 
of Src by the displacement of phospho Tyr
527 from the Src SH2 domain and mediated its 
dephosphorylation. The dephosphorylation was significant within 5 minutes of shear stress 
application, which increased over a period of 30 minutes, indicating an increase in the activity 
of Src. The activation time followed by Src correlates with the activity pattern exhibited by 
eNOS in response to shear stress. This clearly indicated the possible involvement of a Src 
tyrosine kinase in the shear mediated activation of eNOS (Fig 35). 
Proline-rich tyrosine kinase 2 (PYK2) is a non-receptor
 tyrosine kinase, structurally related to 
focal adhesion kinase, and has been shown to play a role in signaling cascades (Litvak et al., 
2000; Nakamura et al., 2001). Src has been reported to associate and activate PYK2 by 
tyrosine phosphorylation in response to cyclic stress (Cheng et al., 2002). So we looked for 
the effect of shear stress on PYK2 activation. We found that upon application of shear stress 
on endothelial cells there was a time-dependent increase in the phosphorylation of PYK2 
which results in the activation of the kinase. The increase in phosphorylation was evident in 
10 minutes and increased over the experimental period studied (up to 120 minutes) which 
reached significantly highest levels at 60 minutes. So having witnessed the activation of Src 
and PYK2 upon shear stress we determined whether or not a tyrosine kinase is associated 
with eNOS. Discussion 
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In contrast to the slow tyrosine phosphorylation of PYK2 which was maximum at 60 minutes 
of shear, the association of PYK2 with eNOS in response to shear was rapid. While only low 
levels of PYK2 co-precipitated with eNOS from cells maintained under static conditions there 
was a time-dependent increase in the association of the two proteins. The increase in 
association was at least 2-fold more within the first 10 minutes of shear, and remained intact 
as long as cells were exposed to fluid shear stress i.e., for up to 2 hours.  
We next determined the tyrosine phosphorylation of eNOS overexpressed in HEK-293 cells 
along with either PYK2 or Src. Immunoprecipitation of eNOS and Western blotting using 
phosphotyrosine antibody revealed both PYK2 and Src were able to tyrosine phosphorylate 
eNOS. However the level of phosphorylation in PYK2 cotransfected cells was lower than that 
observed in Src expressing cells. This probably could be due to the fact that PYK2 is 
activated by Src, which HEK-293 lack. The phosphorylation of eNOS tyrosine residue(s) by 
Src and PYK2 was also confirmed by immunoprecipitating phosphotyrosine and Western 
blotting using eNOS antibody. This data helps us to suggest that both kinases are able to 
phosphorylate eNOS in intact cells.  
Garcia-Cardena et al (Garcia-Cardena et al., 1996a) had reported that tyrosine 
phosphorylation of eNOS observed following the stimulation of endothelial cells with H2O2 
resulted in the loss of eNOS activity by 50% compared to non-treated cells. However the 
residues involved were not determined in the latter study. Mass spectroscopic analysis for 
tyrosine residues on the eNOS recovered from PYK2-overexpressing HEK-293 cells revealed 
the phosphorylation of eNOS on Tyr
657 which is located in the FMN binding region in the 
reductase domain of eNOS. We mutated this residue to a phosphomimetic aspartate (D) or 
glutamate (E) or the non-phosphorylatable phenylalanine (F). The data obtained using the 
citrulline assay performed on the membrane fraction of the HEK-293 cells overexpressing 
eNOS mutants and NO measurement by ESR spectroscopy clearly indicated that the eNOS 
mutants Y657D and Y657E were completely inactive, while the Y657F mutant was slightly 
less active compared to wild-type eNOS. The slight decrease in the activity of Y657F can be 
accounted for by a consistently lower level of transfection rather than an effect on enzyme 
activity. Recent biochemical and crystallographic study has revealed the importance of this 
residue, which is situated in the FMN binding domain, and is suggested to stack the ring plane 
of the FMN almost parallel to the ring plane of another aromatic residue Phe
574 (Garcin et al., 
2004) (Fig. 44). This conformation is necessary for the transfer of electrons from FAD to 
FMN. This data clearly demonstrate the significance Tyr
657 can play in eNOS regulation. Discussion 
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Further, to determine whether the lack of activity of the phosphomimetic eNOS mutants 
Y657D and Y657E was related to the inability of the enzyme to dimerise we performed LT-
PAGE and did not find any consistent difference in the ability of the wild-type eNOS and 
Y657D, Y657E or Y657F eNOS mutants to dimerise, which further suggests that the 
inactivation of the enzyme is due to the disruption of the flow of electrons at the FMN 
binding domain. 
Bradykinin and H2O2 stimulation of endothelial cells resulted in an enhanced tyrosine 
phosphorylation of eNOS, an effect which has been implicated to the localisation of eNOS to 
the cytoskeleton (Venema et al., 1996b) or caveolae (Garcia-Cardena et al., 1996a). Also the 
intact cytoskeleton is required for LPC-stimulated PYK2 phosphorylation (Rikitake et al., 
2001). The tyrosine mutants studied gave a distint localisation pattern. The wild-type eNOS is 
localised mainly in the perinuclear Golgi apparatus and at the plasma membrane. The 
phosphomimetic mutants Y657D and Y657E localised markedly in the cytoskeleton, with 
Y657E showing a greater degree of localisation in the cytoskeleton, while the Y657F 
exhibited a very diffused distribution of eNOS in the cytosol, giving an impression that the 
enzyme is stuck in the endoplasmic reticulum. Further experiments need to be performed with 
specific endoplasmic reticulum markers to confirm this claim.  
However, previous studies have shown that enhanced tyrosine phosphorylation resulting in an 
increased NO production (Fleming et al., 1996a; Takahashi et al., 1997; Takenouchi et al., 
2004) and studies in our group, have observed that two different stimuli, shear stress 
(activated eNOS) and insulin (which does not have any effect on NO production) culminated 
Figure 44. Stacking of FMN by Tyr657 
residue. Structure showing the interaction of 
tyrosin residue Y657 and FMN with FAD and 
NADPH respectively. Tyr657 is proposed to 
stack FMN in the conformation required to 
accept electron from the FAD. Modified from 
Garcin et al, JBC 2004; 279: 37918-37927. 
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in the tyrosine phosphorylation of eNOS but with opposing effects, indicating the possible 
involvement of more than one tyrosine residue which can be phosphorylated. Additional 
eNOS tyrosine residues Y210, Y357, Y534, and Y556 mutated to Ala proved to be lethal to 
the activity of the enzyme, while eNOS mutants Y217A, Y467A, Y597A and Y900A showed 
an enhanced activity of at least 2-fold more than the wild-type enzyme, with Y900 showing a 
maximum increase of 4.5 fold.  
So far no post-translation modification has been know to knock out the activity of eNOS 
completely, it is still premature to speculate the physiological effect of these tyrosine residues 
on the enzyme activity. However, preliminary data suggest a role of Tyr
657 in the translocation 
of the enzyme into the cytoskeletal fraction. However it would be interesting to study the 
effect of phosphorylation of Tyr
657 on eNOS uncoupling, and if it generates O2
-, then it could 
be the strongest candidate in contention for the phospho-switch which uncouples eNOS. The 
determination of the phospho-switch of eNOS would help us in developing strategies by 
targeting the kinase or phosphatase involved to treat endothelial dysfunction.  
 Summary 
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6  Summary 
Since its recognition as an endothelium-derived relaxing factor, the control and consequences 
of nitric oxide (NO) production have been investigated intensely. We know now that NO is 
not simply a vasodilator or regulator of smooth muscle tone but is a potent anti-platelet agent, 
neuromodulator and regulator of gene expression. NO is synthesized from the amino acid L-
arginine by a family of enzymes termed NO synthases (NOS). The ‘endothelial’ (eNOS or 
NOS III) and ‘neuronal’ (nNOS, NOS I or bNOS) NOS isoforms, which were named after the 
tissues in which they were first identified, are expressed constitutively and are generally 
regulated by Ca
2+/calmodulin (CaM). Endothelium-derived NO is thought to be responsible 
for maintaining the vasculature in an anti-atherosclerotic state and a decrease in the 
bioavailability of NO (a state generally referred to as endothelial dysfunction) results in “pro-
atherosclerotic” alterations in vascular gene expression. Recently it has become clear that the 
activity of eNOS is largely determined by its association with regulatory proteins as well as 
by the phosphorylation of the enzyme on serine, threonine and possibly tyrosine residues. 
Moreover, the enzyme can be “uncoupled” i.e. transformed from a NO generating to a 
superoxide (O2
-)-generating enzyme, which would be expected to attenuate vasodilator 
responses and enhance vascular inflammation. The aim of this thesis was to study the 
consequences of phosphorylation on specific serine, threonine and tyrosine residues on the 
activity and intracellular localisation of eNOS and in particular to determine whether a 
phospho-switch for eNOS uncoupling exists. 
 
eNOS is phosphorylated under basal conditions and its serine phosphorylation can be 
enhanced following cell stimulation with hemodynamic stimuli such as cyclic stretch and 
fluid shear stress as well as by hormonal stimuli such as histamine and bradykinin. Our group 
has previously demonstrated the importance of Ser
1177 in the activation of eNOS and here I set 
out to determine the relative importance of phosphorylation on Ser
633 and Ser
114. By 
generating point mutants in which serine was replaced by either alanine (non-
phosphorylatable mutants) or aspartate (phosphomimetic mutants) it was observed that the 
activity of the S633D and S114A eNOS mutants exhibited an 2-fold increase over the activity 
of the wild-type enzyme or either of the S633/634A or S114D eNOS mutants as determined 
by monitoring the conversion of L-arginine to L-citrulline.  
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eNOS is basally phosphorylated on Thr
495 and stimulation of endothelial cells with Ca
2+-
elevating agonists generally results in the transient dephosphorylation of this residue. The 
latter is essential to allow the binding of calmodulin to the enzyme and is the actually 
initiating step in the generation of NO. Correspondingly, the T495A eNOS mutant can be 
activated at lower Ca
2+ and calmodulin concentrations than the T495D mutant. However, 
some eNOS mutants (T494A/S1177D and T495A) showed an enhanced ability to generate 
O2
- in a NOS inhibitor-sensitive manner suggesting that the phosphorylation of the enzyme 
may also play a role in the uncoupling process. To determine the physiological relevance of 
eNOS dephosphorylation on Thr
495 we assessed the consequences of treating cells with 
oxidised low-density lipoprotein (ox-LDL) on eNOS phosphorylation as well as on the eNOS-
dependent generation of NO and O2
-. Oxidised LDL concentration- and time-dependently 
decreased phosphorylation of eNOS on Thr
495 and led to a concomitant decrease in cellular 
levels of cyclic GMP and an enhanced production of O2
- compared to cells treated with native 
LDL. Alterations in the activity of protein kinase C (PKC) were related to the change in 
eNOS Thr
495 phosphorylation. There was not only the basal activity of PKCα inhibited by ox-
LDL but the PKC activator phorbol-12-myristate-13-acetate also failed to elicit the 
phosphorylation of Thr
495 in ox-LDL-treated endothelial cells. The dephosphorylation of 
eNOS on Thr
495 in response to the addition of ox-LDL was not associated with an increase in 
the binding of calmodulin to eNOS, an association usually necessary for the activation of 
eNOS. Moreover, following treatment with ox-LDL for 24 hours eNOS was no longer 
detected at the plasma membrane but was redistributed to the cytosol indicating that ox-LDL 
may disrupt the eNOS signalling complex or signalosome.  
 
To date the role played by the tyrosine phosphorylation of eNOS in the regulation of its 
activity or intracellular association is controversial. However, during the preparation of this 
thesis we have been able to demonstrate a link between the tyrosine phosphorylation of eNOS 
and the activation of the tyrosine kinases Src and PYK2. The application of fluid shear stress 
to endothelial cells resulted in the activation of Src and PYK2 as well as in the association of 
PYK2 with eNOS. Co-expression of eNOS and PYK2 led to the putative identification of 
Tyr
657 as a potential modulatory site. Mutating eNOS at Tyr
657 to Asp or Glu resulted in the 
localisation of the mutant eNOS predominantly in the cytoskeleton and also in a complete 
inactivation of the enzyme. The Y657F mutants, on the other hand, did not demonstrate any 
marked alteration in the activity when compared with the wild-type eNOS. However, the Summary 
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intracellular localisation pattern was very diffuse in the cytoplasm, giving the impression that 
this mutant may be stuck in the endoplasmic reticulum. 
 
In conclusion, the results describe in this thesis indicate that eNOS is regulated by 
phosphorylation at multiple sites. Depending on the phosphorylation site involved 
phosphorylation can inhibit or activate NO production or even uncouple the enzyme so that it 
generates O2
-. While the phosphor-status of eNOS on Ser
114 and Ser
633 influenced NO release 
they did not contribute to O2
- production and the dephosphorylation of Thr
495 seems sufficient 
to uncouple eNOS. Cell treatment with ox-LDL, which is known to increase eNOS-derived 
O2
- output was correlated with a dephosphorylation of Thr
495 as well as a decrease in the 
activity of the kinase that phosphorylates this site i.e., PKCα. The phosphorylation status of 
all the eNOS serine and threonine residues studied however did not influence the ability of the 
enzyme to dimerise, indicating that contrary to previously published reports the eNOS dimer 
is highly stable in endothelial cells. The tyrosine phosphorylation of eNOS was not initially 
expected to play a determinant role in the regulation but rather to facilitate the docking of 
associated regulatory proteins. However, Tyr
657 seems to play a critical role in the generation 
of NO as its mutation resulted in the generation of a completely inactive enzyme as well as in 
an apparent intracellular mislocalisation of the protein. The physiological relevance of these 
findings remain to be further elucidated. 
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7  Zusammenfassung 
 
Seit der Identifizierung des endothel-abhängigen, relaxierenden Faktors als Stickstoffmonoxid 
(NO) durch R. F. Furchgott und L. Ignarro im Jahre 1986 sind die Regulation und die 
funktionellen Konsequenzen der endothelialen NO-Produktion Gegenstand intensiver 
Forschung. Heute ist NO nicht nur als relaxierender Faktor für Gefäße bekannt, sondern auch 
als potenter Hemmer der Thrombozytenaggregation, als Neuromodulator sowie Regulator der 
Genexpression. Die Enzyme der Familie der NO-Synthasen bilden aus der Aminosäure L-
Arginin, NO und L-Citrullin. Die endotheliale und neuronale NO-Synthase, die nach den 
Geweben, in welchen sie zuerst gefunden wurden, benannt sind, sind konstitutiv exprimiert 
und werden vor allem über Ca
2+/Calmodulin aktiviert. Als wichtigste Funktion von 
endothelial gebildetem NO wird derzeit angesehen, dass es eine protektive, anti-
atherosklerotische Wirkung auf die Gefäßwand ausübt. Eine Verminderung der 
Bioverfügbarkeit von NO (allgemein als endotheliale Dysfunktion bezeichnet) führt zur 
Expression von pro-atherosklerotischen Genen. Es wurde gezeigt, dass die Aktivität der NO-
Synthasen von der Interaktion mit regulatorischen Proteinen und von der Phosphorylierung 
des Enzyms an Serin-, Threonin- und möglicherweise auch Tyrosinresten abhängt. Außerdem 
kann das Enzym entkoppelt werden, was bedeutet, dass nicht NO sondern Superoxidanionen 
(O2
-) gebildet werden, welche dann die vasodilatierende Wirkung von NO einschränken und 
inflammatorische Antworten verstärken.  
 
Das Ziel dieser Dissertation war es, die Konsequenzen der Phosphorylierung der 
endothelialen NOS (eNOS) an Serin-, Threonin- und auch Tyrosinresten auf die Aktivität und 
intrazelluläre Lokalisation zu untersuchen, vor allem mit der Frage, inwieweit eine 
Phosphorylierung für die Entkopplung des Enzyms mitverantwortlich ist.  
 
Die schon unter basalen Bedingungen beobachtbare Phosphorylierung der eNOS an 
Serinresten kann durch hämodynamische Stimuli wie Schubspannung oder rhythmische 
Dehnung der Gefäßwand bzw. der Endothelzellen sowie durch agonisten-vermittelte 
Stimulation mit Histamin oder Bradykinin erhöht werden. Unsere Gruppe hat vor kurzem die 
Bedeutung der Phosphorylierung von Ser
1177 für die Ca
2+-unabhängige Aktivierung der eNOS 
gezeigt. In der vorliegenden Arbeit wurde die Relevanz der Phosphorylierungen von Ser
633 
und Ser
114 untersucht. Durch gerichtete Punktmutagenese („site-directed mutagenesis“) 
wurden Mutanten erstellt, in denen die entsprechenden Serinreste zu Alanin (nicht Zusammenfassung 
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phosphorylierbare Mutante, A) bzw. zu Aspartat (phosphomimetische Mutante, D) mutiert 
sind. Die Aktivität der überexprimierten eNOS-Mutanten wurde in-vivo und in-vitro durch 
die Bildung von L-Citrullin aus L-Arginin bestimmt, die Menge an gebildetem NO oder O2
- 
durch Elektron-Spin Resonanz (ESR) Analysen ermittelt. Hierbei wurde gefunden, dass die 
Aktivität der S114A- bzw. der S633D-Mutanten um das zweifache gegenüber der Aktivität 
des Wildtyps oder der S114D- bzw. der S633/634A-Mutanten erhöht waren, die Bildung von 
O2
- dieser Mutanten jedoch gleich war wie beim Wildtype 
 
In nicht-stimulierten Zellen ist die eNOS auch am Thr
495 phosphoryliert und die Stimulation 
mit Ca
2+-erhöhenden Agonisten führt zu einer transienten Dephosphorylierung dieses 
Aminosäurerestes. Dies ermöglicht erst die Bindung von Calmodulin beim initialen Schritt 
der NO-Bildung. Dementsprechend kann die T495A-Mutante im Vergleich zur T495D-
Mutante bei niedrigeren Ca
2+-Konzentrationen aktiviert werden. Bei den Mutanten, bei denen 
Thr
495 nicht phosphorylierbar ist (T495A und T495A/S1177D), wurde eine Erhöhung der O2
--
Bildung beobachtet, die sensitiv gegenüber NOS-Inhibitoren war, was auf eine Funktion der 
Thr
495-Phosphorylierung auch für die Entkopplung der eNOS deutet. Die Stimulation von 
Endothelzellen mit oxidiertem „low-density lipoprotein“ (ox-LDL) führt bekanntermaßen zur 
eNOS-vermittelten Radikalbildung. Die Bedeutung der Thr
495-Phosphorylierung für diese 
Beobachtung wurde mittels Western-Blot-Analysen sowie Bestimmung der NO- und O2
--
Bildung ermittelt. Die Behandlung von Endothelzellen mit ox-LDL führte zu einer 
konzentrations- und zeitabhängigen Erniedrigung der Thr
495-Phosphorylierung, die mit einer 
verringerten intrazellulären cGMP-Konzentration einherging. Zugleich war die O2
--
Produktion gesteigert im Vergleich zu Zellen, die mit nativem LDL inkubiert wurden. Vor 
allem die Proteinkinase C (PKC) ist für die Thr
495-Phosphorylierung verantwortlich und die 
Verringerung der eNOS Phosphorylierung am Thr
495 korrelierte nicht nur mit der Hemmung 
der basalen PKCα Aktivität durch ox-LDL, sondern auch der PKC-Aktivator 12-Myristat-13-
Acetat konnte in ox-LDL-behandelten Endothelzellen keine Phosphorylierung am Thr
495 
vermitteln. Allerdings führte die Dephosphorylierung des Thr
495-Restes nicht zur erhöhten 
Bindung von Calmodulin an die eNOS, was bei Agonisten-Stimulation zu beobachten ist und 
hier den initialen Schritt zur NO-Bildung darstellt. Außerdem konnte mittels 
Immunhistochemie gezeigt werden, dass in Endothelzellen, die über 24 Stunden mit ox-LDL 
inkubiert worden waren, die eNOS nicht mehr an der Plasmamembran lokalisiert war, 
sondern ins Zytosol translozierte. Dies deutet auf eine Zerstörung des „eNOS Signalosoms“ 
durch ox-LDL hin.  Zusammenfassung 
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Derzeit wird die Rolle der Tyrosinphosphorylierung der eNOS für die Aktivätsregulation und 
intrazellulären Lokalisation kontrovers diskutiert. Während der Arbeit an dieser Dissertation 
konnte ein Zusammenhang zwischen der eNOS-Tyrosinphosphorylierung und der 
Aktivierung der Tyrosinkinasen PYK2 und Src gefunden werden. In Endothelzellen führt die 
Stimulation mit Schubspannung zur Aktivierung von PYK2 und Src sowie zur Assoziation 
von PYK2 mit der eNOS. Die Überexpression der eNOS und PYK2 in COS-7 Zellen führte 
zur Identifizierung des Tyr
657-Restes als phosphoryliertes Tyrosin der eNOS. In 
Endothelzellen, welche die phosphomimetischen eNOS-Mutanten Y657D bzw. Y657E (Y = 
Tyrosin; E = Glutamat) überexprimierten, zeigte die eNOS in immunhistochemischen 
Untersuchungen eine Assoziation mit dem Zytoskelett und sowohl in ESR-Untersuchungen 
als auch in Citrullin-Assays war keinerlei NO-Bildung nachzuweisen. Die nicht-
phosphorylierbare Y657F-Mutante (F = Phenylalanin) zeigte keine Veränderung der Aktivität 
im Vergleich zum Wildtyp. Die intrazelluläre Lokalisation dieses Proteins war allerdings sehr 
diffus über das gesamte Cytoplasma und vermittelte den Eindruck, dass eine Hemmung des 
Transports vom endoplasmatischen Retikulum zum Golgi-Apparat vorliegt.  
 
Zusammenfassend beschreiben die Ergebnisse dieser Arbeit, dass die eNOS an 
verschiedensten Aminosäureresten phosphoryliert werden kann. Abhängig von der 
Lokalisation dieser Phosphorylierung kann die NO-Produktion gesteigert oder gehemmt 
werden bzw. das Enzym kann entkoppelt werden und O2
- bilden. Während der 
Phosphorylierungszustand von Ser
114 und Ser
633 die NO-Synthese moduliert, haben diese 
Aminosäurereste keinen Einfluss auf die O2
--Bildung. Die Dephosphospoylierung von Thr
495 
scheint für eine Entkopplung des Enzyms ausreichend zu sein. Die Inkubation von 
Endothelzellen mit ox-LDL führte zu einer Dephosphorylierung der eNOS am Thr
495 sowie 
zu einer Inaktivierung der PKCα, die diesen Aminosäurerest phosphoryliert. Der 
Phosphorylierungsstatus keiner der untersuchten eNOS-, Serin- und Threonin-Reste hatte 
einen Einfluss auf die Dimerisierung des Enzyms, was darauf hindeutet, dass im Gegensatz zu 
bislang publizierten Untersuchungen das Dimer der eNOS in Endothelzellen sehr stabil ist. 
Funktionell wird von der eNOS-Tyrosinphosphorylierung zunächst eine veränderte 
Interaktion mit regulatorischen Proteinen erwartet, mit einer möglichen Modulation der 
Aktivität. In dieser Arbeit wurde gezeigt, dass die Phosphorylierung von Tyr
657 eine kritische 
Rolle sowohl für die Bildung von NO als auch für die Interaktion mit anderen Proteinen hat, 
da eine phosphomimetische Tyrosin-Mutante vollständig inaktiv ist und außerdem keine Zusammenfassung 
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korrekte intrazelluläre Lokalisation zeigt. Die physiologische Relevanz dieser 
Tyrosinphosphorylierung muss noch weiter untersucht werden.  
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